Manual for the Pharmacokinetics Program PCModfit (with Several Examples)

Version 7.8

Graham D. Allen



Update history is detailed further, as version summaries which are shown in Section 8, p. 126.

Latest

Version 7.8 (1st September 2023)

The Non-Compartmental module (NCA) has been further updated in V7.8. There was a minor anomaly in earlier versions, which was noticed by a very astute user, in the NCA graphs only (Dr Tony Jarman from Category 1 Pharma Consulting Pty Ltd Australia) wherein; the λ_z value was shown as a minus value when it should have been positive. None of the numerical results were affected but just the sign of λ_z values on the graphs! The numerical examples in all sections (including NCA) of the manual have been re-analysed using V7.8 and yield the correct results.

Version 7.7 (1st March 2023)

Compartmental modelling has been further updated. Using option 'Mixed models', profiles containing no i.v. models but oral models only (mixing with and without lag-time dosing) can now be analysed. This may be useful when for example, when oral doses are administered alternately, with and without a lag-time. There are example data sets on p. 105 and p. 108 to demonstrate that this option is working and yields the correct answer. As long as the number of compartments remain the same, this will work for 1, 2 and 3-compartment oral models. The λ_n values are also calculated as for the other possible Mixed models. The subtitles for each profile can now contain spaces as previous versions sometimes got muddled with these. They have also been expanded to 30 characters/profile whereas previous versions only allowed for 20. All of the examples in the Modelling sections of the manual have been re-analysed using V7.7 and yield the correct results.

Version 7.6 (1st February 2023)

Compartmental modelling has been further upgraded. In the results summary Excel file, the lambda values $(\lambda_1, \lambda_2 \text{ and } \lambda_3 \text{ for relevant compartmental models})$ are now calculated, being generated from the rate constants k_{12} , k_{21} etc., as this was requested by several users (example on p.102). This applies to Single, Repeat and Mixed model dosing. Further testing for all fitting options (Single, Repeat and Mixed) has been expedited and some minor bugs when clicking the 'Keywords' button have been corrected. A couple of users experienced an 'out of memory' message when the Modelling summary file was generated in V7.5. In the 'Fitting Options Selected' details, which was added as a helpful reminder for the settings used in a particular run, the size of picture was apparently the culprit. This has now been fixed by using a different and more efficient method. It has been tested on several computers with no further warning or error

messages. The Modelling Summary output file now has the file names of the pictures generated from a run which are detailed at the top of the Excel file at the request of several users. The same addition is also added to the NCA module as a complete record. The 'Stats' spreadsheet for CI's etc. has been expanded to allow for up to 100 values (previous versions only allowed for 50).

Version 7.5 (1st January 2023)

Compartmental modelling has been significantly upgraded as described in Section 4 of this new manual. This is a new option, and examples are included to demonstrate its validity. The program now permits data to be fitted from a combination of i.v. bolus, infusion, and oral dosing regimens in any sequence and with varying doses and intervals. Several users have requested this facility wherein; a repeat dose profile may comprise, for example, a bolus and infusion followed by oral maintenance dosing with different doses and intervals. This can now be accomplished easily as help is given, in more detail, within the Modelling spreadsheet and the setup procedure has been completely reworked to make life easier for all modelling options. The new Fitting Options section, shown below for information, with more explanation in Section 4. Note that the user must enter the number of profiles and the number of doses prior to clicking 'Keywords' to setup the layout. The new option for 'Mixed models' is shown under 'Profile type' if required.

	<u>Algorithm</u>	W	eighting	Pr	ofile type	No. of Profiles	No. poin	ts for fitted line
	DFP (WLS)		1/Conc		Single dose	5 -		200
~	Marquardt (IRWLS)	~	1/Conc ²		Repeat dose			500
	Simplex (WLS)		Unweighted	Ľ	Repeat dose	No. of Doses	~	1000
	Simplex (IRWLS)			~	Mixed models	5 -		5000
								10000
	Parameters	<u>Co</u>	<u>nstraints</u>		<u>Data layout</u>	-	Useful for	profiles with
	Computer estimates	~	Yes		Time conc time	e conc	long times	s (500 to 1000
~	User estimates		No	~	Time conc conc	с	is usual bu	ut is dependent
							on profile	time and shape).
	Plotting	Mod	<u>el number</u>	<u>Graph</u>	<u>n axis titles (upd</u>	<u>ated at Run time)</u>	RD bolus	may need 5000
~	Yes		9 🔻	X-axis	Time (h)		or more.	
	No	Only use Repeat do	ed for Single or ose (not Mixed)	Y-axis	Conc. (µg/mL)		Select bef	fore running.

In addition to the upgrades above, the modelling output, which is automatically generated as an Excel file, now has more information added including the 'Fitting Options' choices used, and the cells where Doses, Parameters, Titles etc. are added as a complete record should the user wish to access these as a reminder. Also, after completion of a Fitting run (when the 'Next' button is clicked) the names of the Plot files are sent to the end of the Summary file as well, for completeness. It is no longer necessary to highlight the cells in the Keywords area for the setup section or for the time-concentration data. The parameter labels that were previously erased ('User estimates' selected) when 'Activate' was clicked are now retained in the Sheet and sent to the Summary file, at the request of several users.

Version 7.4 (1st October 2022)

PCModfit V7.4 with updates from previous versions is now released (still runs on 32 or 64-bit PC computers). The NCA module has been upgraded so the user can now have up to 100 profiles with 1000 points in each (previously 100) as some users requested this update. There is now a red 'Cancel' button in the NCA spreadsheet to stop a run at any point during analysis (also a request from a couple of users) which is useful if there are many profiles, and the user decides to abort the run for whatever the reason. Modelling has been updated so that the Summary Excel file that now opens automatically after a completed run now specifies the parameter names instead of just numbers e.g., Parameters 1, 2, 3, 4 etc. becomes Parameters V₁, k_{12} , k_{21} , k_{10} etc. In addition, the Summary file now contains individual profile data and the fitted data at the same time points with %Differences so users don't have to manipulate text files (this was often bothersome for some users). The fitted parameters and errors together with brief statistics, if more than one profile is analysed, are still displayed. The summary file is often used as a tracking mechanism as it shows the date, time and records the fitting information (algorithm, weighting etc.) used for a particular run.

Program PCModfit Copyright © GD Allen 1990-2023

Original publication reference: GD Allen 'Modfit: a pharmacokinetics computer program', Biopharm. & Drug Disp., Vol. 11, 477-498, 1990.

Secure Website: <u>https://www.pcmodfit.co.uk/</u> Forum; <u>https://www.pcmodfit.co.uk/forum/index.php</u> Author E-mail: graham.allen@pcmodfit.co.uk

Contents

1.	Copyright notices (program, documentation etc.)	6
2.	Brief overview	7
	Figure 1: PCModfit available spreadsheet tabs	7
3.	Available facilities (detailed)	
	3.1 Non-compartmental analysis (NCA)	
-	Figure 2: Options for NCA.	8
	Figure 3: Data layout options in Excel [®] NCA spreadsheet	8
	Figure 4: Data layout options in Excel [®] NCA spreadsheet	9
	Figure 5: Points selected in the 1 st profile for NCA	9
	Figure 6: Points selected in the 1 st profile for NCA (note extra values chosen).	
	Figure /: Example NCA results in the created Excel file and the NCA spreadsheet	
	3.2 NCA from V6.9 onwards (bolus intercept and handling zero values)	
	Figure 8: Bolus i.v. profile (first 3-points) to estimate C ₀ value.	
	Figure 9: Use of zero concentration values in oral dosing profiles.	
	Figure 10: 'Stats' spreadsheet containing data (left) and example output (right).	14
	3.3 Single Dose (SD) Simulator	
	3.3.1 Using built in explicit models.	
	Figure 11: Example SD simulation input/output (4 profiles, 1-compt oral, 1 with lag-time)	15
	Figure 12: Example SD simulation graphic output from Figure 11 data	
	Figure 13: Example SD simulation (4 profiles, 3-compt infusions over 5 to 20 h)	
	Figure 14. Example 5D simulation graphic output from Figure 15 data	
	3.3.2 User defined 'Differential Equation' models (SD simulations)	
	Figure 16: Pictorial example of a 3-compartment infusion model	
	Figure 17: Example setup using a 3-compartment infusion model	19
	Figure 18: Output from a 3-compartment infusion model simulation	19
	Figure 19: Graphics output from a 3-compartment infusion model simulation	
	Figure 20: Run time Window displaying the user's equations and variables	20
	3.4 Repeat Dose (RD) Simulator	
	3.4.1 Using built in explicit models	
	Figure 21: Simulation RD (10 doses 1-compt oral) 2 Subjects: 1 same dose and different dose	
	Figure 22: Example RD simulation concentration output	
	Figure 25: Example KD simulation graphic output	
	Figure 25: Simulation (2-compt. model: bolus+infusion then oral) for 2 Subjects (mput)	
	Figure 26: Simulation (2-compt. model; bolus+infusion then oral) for 2 Subjects (output graphics)	
	3.4.2 User defined 'Differential Equation' models (RD simulations)	
	Figure 27: Symbols used in the 2-compartment model equations (bolus, infusion and oral)	25
	Figure 28: Pictorial example of a 2-compartment bolus model	
	Figure 29: Equations for a 2-compartment bolus model	
	Figure 30: Fictorial example of a 2-compartment infusion model	
	Figure 32: Pictorial example of a 2-compartment oral model	
	Figure 33: Equations for a 2-compartment oral model	
	Figure 34: Spreadsheet information required for Step 1 of the simulation	27
	Figure 35: Screen clip from spreadsheet detailing some values for the current simulation	27
	Figure 36: Screen clip from spreadsheet detailing parameter values for the current simulation	
	Figure 37: Screen clip from spreadsheet detailing CO values for the current simulation	
	Figure 39: Message showing no errors were found after Initialisation	
	Figure 40: Screen clip from spreadsheet showing 'Initialise' and 'Run' buttons	
	Figure 41: Simulation result graphic for compartment 1	
	Figure 42: Simulation result graphic for all 3-compartments	
	Figure 43: Numerical results from the bolus + infusion followed by oral maintenance simulation	
2	8.5 Superposition option	
•	Figure 44: Example 1 - input data (time, concentrations, intervals and no. of doses etc.)	
	Figure 45: Output graphics from Example 1 simulation (10 doses)	
	Figure 46: Results showing C_{min} and C_{max} in addition to AUC _{0-τ} for all doses (Example 1)	
	Page 3 of 136 Version 7.8	01-Sept-2023

	Figure	47: Example 2 setup parameters showing different doses and intervals	
	Figure	48: Output graphics from Example 2 simulation (different doses and intervals)	36
3	.6 De	convolution	
U	Figure	49: Example profiles of oral data for Deconvolution analysis (parameters included)	
	Figure	50: PCModfit input for a 2-compt. model data set (with NCA results for estimating $AUC_{0-\infty}$)	
	Figure	51: Example LR analysis (input and options).	40
	Figure	52: Example graphic output (% Absorbed) for 2-compartment oral data	40
	Figure	53: Both types of Deconvoluted results from 1, 2 and 3-compartment oral data (1 % cut off)	41
	Figure	54: Deconvoluted graphic results from 1, 2 and 3-compartment oral data (1 % cut off)	41
	Figure	55: Results of ka estimates from %Absorbed and %Remaining data	42
3	7 Ti	ne above an MIC ontion	43
U	Figure	56: Example time-concentration data ($n\sigma/mL$) sets used for analysis ($n=7$)	43
	Figure	57: Time and exposure results and graph	
_			
3	.8 Co	mpartmental analysis (principles and modelling data)	45
	3.8.1	Control data set up and initialisation	
	Figure	58: Keyword information for Control parameters (user options)	47
	Figure	59: Examples of Control layout for various models using single a dose	
	Figure	60: Examples of Control layout for repeat dose scenarios	
	3.8.2	Concentration-time data layout for modelling	
	Figure	61: Concentration-time data layout for modelling (two options)	
	Figure	62: Data layout for analysing more than 1 profile in a single run.	
3	.9 Co	mpartmental analysis (Example data and results)	52
	3.9.1	3-exponential i.v. bolus repeat dose (Model 6)	
	3.9.2	1-Compt. bolus (Model 11)	
	3.9.3	2-Compt. bolus (Model 12)	
	3.9.4	3-Compt. bolus (Model 13)	
	3.9.5	1-Compt. infusion (Model 15)	
	3.9.6	2-Compt. infusion (Model 17)	
	3.9.7	3-Compt. infusion (Model 19, using V7.6 onwards)	64
	3.9.8	1-Compt. infusion + bolus (Model 14)	
	3.9.9	2-Compt. infusion + bolus (Model 16)	
	3.9.10	3-Compt. infusion + bolus (Model 18)	
	3.9.11	1-Compt. oral (Model 8)	
	3.9.12	1-Compt. oral with lag-time (Model 7)	
	3.9.13	2-Compt. oral (Model 10)	
	3.9.14	2-Compt. oral with lag-time (Model 9)	
	3.9.15	3-Compt. oral (Model 43)	80
	3.9.16	3-Compt. oral with lag-time (Model 42)	82
	3.9.17	Repeat dose infusion, varving rate, time, & interval (Model 17: 2-Compt., V7.7)	
	3.9.18	Repeat dose infusion, varying rate, time, & interval (with constraints, V7.7)	
	3.9.19	Repeat dose oral, varying dose and interval (Model 10: 2-Compt.)	88
	3920	IVIVC using nublished data RD i v varving dose and interval	90
	0.7.20		
Δ	Comp	artmontal analysis using Miyod innuts (i.v. and oral)	92
т.	comp	ar unchtar anarysis using wixed inputs (i.v. and or ar)	
4	.1 Int	roduction	92
4	• •		03
4	.2 Ex	amples	
	4.2.1	2-compartment bolus + infusion followed by oral maintenance (varying doses and interva	als) 93
	4.2.2	1-compartment bolus + infusion, oral (lag), bolus, oral (lag) then bolus + infusion (V7.6).	
	4.2.3	3-compartment bolus + infusion followed by oral maintenance (varying doses and interva	als) 99
	4.2.4	2-compt. bolus + infusion followed by oral maintenance V7.6, varying dose, and interval.	
	4.2.5	2-compt. Oral, varying with and without lag-time models and doses and intervals	
	4.2.6	3-compartment oral with and without lag-time (varying doses and intervals, V7.7)	108
_			
5.	Mode	s and symbols	111
6	Apper	dix 1 (Modelling Approaches)	113
	I I [*]		
7	Apper	ndix 2 (creating differential equations from models)	124
	1.1		

8	Brief history updates 1	126
9	A few words about the author1	130
10	Brief list of publications referencing PCModfit1	130
11	Symbols used throughout document 1	136

1. Copyright notices (program, documentation etc.)

PCModfit

Technical Documentation, System Design, Equation Derivation and Programming: Created by Graham D. Allen

Please read the manual carefully before using PCModfit.

Information in this document is subject to change without notice. Companies, names and data used in examples are fictitious unless otherwise stated.

All rights are reserved. No part of this publication, either the whole or any part of the program or documentation, may be reproduced, transmitted, transcribed, stored in a retrieval system or translated into any language or computer language in any form or by any means. These include electronic, mechanical, optical, chemical, manual or otherwise, for any purpose, without the prior express written permission of the author.

GD Allen provides the program PCModfit and associated modules under the laws of copyright and licences its use to the user. This licence means that, unless you have GD Allen's permission to the contrary: you may use the downloaded program on a single computer or move the program and use it on another computer, but you may not use the program on more than one computer at a time; you may make one copy only of the program for backup purposes.

If the user/company wishes to use the program on several computers then each computer should use a fresh downloaded version from the PCModfit website.

You may not make any copy of the documentation without prior permission from GD Allen.

There is no charge for the program but small donations can be made on the Website (download page) to help maintain the program and documentation.

Acknowledgement

The picture of the 'confused modelling man' shown on the Webpages, Forum and in this documentation (front cover) should not be used without acknowledgement or reference to GD Allen and PCModfit. The talented artist who drew the original cartoon, at the request of GD Allen, was Ms E. Ginn (at that time) and her name has been retained on the amusing sketch ever since it was originally hand drawn in black ink (> 30 years ago!).

Disclaimer

No warranty is made with respect to the program, its quality or performance, its merchantability or fitness for any particular purpose. The program is provided 'as is'. You, the user, assume responsibility for the selection of the program to achieve your intended results, and for installation, use and results obtained from the program.

Copyrights

PCModfit Copyright © 1990-2023 GD Allen. PCModfit Manual Copyright © 1990-2023 GD Allen. Equations and Coding © 1990-2023 GD Allen (all programming code rewritten since original publication). Website for PCModfit Copyright © 2017-2023 GD Allen.

All trademarks and other proprietary rights are acknowledged, where known.

2. Brief overview

PCModfit has several options open to the user and this section gives a brief overview of the facilities. Parameters and/or data are all entered through Excel[®] within a PCModfit spreadsheet. The spreadsheet 'tabs' in PCModfit are shown below in Figure 1 which allows the user to select the appropriate option e.g., Modelling, Simulations, Superposition, NCA etc. when the Excel[®] PCModfit file is opened. Users must allow macros and Firewalls to run all modules (thoroughly tested for viruses using up-to-date software). The program runs under Microsoft[®] Windows[®] 7 and upwards with Office[®] 2013 onwards, including 365. Earlier versions of Windows[®] and Office[®] may be compatible but the user will just have to try it! The PCModfit website location, <u>https://www.pcmodfit.co.uk/</u> has a download link for the installation file which will install the program in directory C:\PCModfit Vx.x\ which is the default option and required (x.x is the version number). Do not install it in any other directory as it will not work! There is a detailed manual, this document, for using the program which can also be downloaded separately.

Figure 1: PCModfit available spreadsheet tabs.

NCA Superposition Modelling Stats SD Simulator RD Simulator LR Deconvolution Time above Diff. Eqn. Simulator (SD) Diff. Eqn. Simulator(RD)

Briefly, drug concentration-time can be numerically analysed using a variety of models or simulations generated on a single or repeated dose basis (with different doses, parameters, and dosing intervals). For fitting data, many of the models have parameter starting estimate routines available to save a significant amount of time. The available models and whether they include starting estimate routines together with many of the equations are detailed in later chapters and within each spreadsheet.

In addition to 'Modelling' data and generating 'Simulations', there are additional options for 'Deconvolution Analysis' (Wagner's modification of the Loo-Riegelman method) requiring intravenous parameters. 'Time and Exposure' above a user defined concentration (e.g., MIC) for a profile is also available. 'Superposition' (major upgrades in V7.1 onwards) for repeated doses (when only a half-life is calculable) and a 'Stats' spreadsheet which calculates arithmetic and geometric means and Confidence Intervals etc. for a quick estimate of these and other descriptive statistics.

In V6.8 onwards, there is now a facility for conducting single dose <u>and</u> repeated dose simulations using differential equations which can be entered in the 'Diff. Eqn. Simulator (SD or RD)' tab. The program will parse the equations into the PCModfit code automatically from Excel[®] without having to re-compile the program. This step is very quick as the equations are Tokenised in high memory for repetitive access and rapid solution in real time. There are detailed instructions on the spreadsheet with further examples in Section 3.3.2 of this manual and but does require the user to be comfortable with defining such differential equations from models. This option will also be made available for modelling repeat dose data (still being worked on).

There is a non-compartmental option (NCA) which has been completely revamped to generate those parameters which are commonly used in reports etc. all within the NCA PCModfit spreadsheet. The assignment of half-life is interactive to ensure that a visual plot in addition to the numbers generated, are representative of the data. This module has been tested independently and gives the same results as some commercial programs. The author would like to thank Angus McLean, Ph.D., from the USA and Dr med. Christian de Mey from ACPS in Germany, for their valuable suggestions and help with verification of some aspects of the program over the past few years.

The Excel[®] front-end has numerous lines of VBA code for ease of use but the main number crunching routines are written in 32/64-bit optimised Fortran compiler (FTN95 from Silverfrost; free version is available but not required for running) and modelling is surprisingly fast using computers with Intel i5 and i7 processors. As an example, 100 data sets for a 3-compartment infusion model were analysed on a computer with an i7 processor and the whole process took less than 3 seconds in real time including generation of starting estimates for the 6-parameters followed by the complete minimisation procedure.

Finally, the program is free to use but there is a facility on the Website Download page for making a donation to help the author to maintain the program and manual should the user feel generous!

3. Available facilities (detailed)

3.1 Non-compartmental analysis (NCA)

The technique of NCA is certainly one of the most common approaches for calculating and then comparing and contrasting pharmacokinetic parameters from both clinical and non-clinical studies. Parameters such as a concentration maximum (C_{max}) and various areas under curve (trapezoidal AUC as linear, logarithmic, or linear up logarithmic down) in addition to half-life (t¹/₂) and AUMC (linear trapezoidal moment area) are the usual parameters and can easily be estimated using the program. In version 7.1 onwards, additional parameters such as CL, MRT, V_d and V_{ss} are also calculated with all results displayed in an Excel[®] spreadsheet which is saved in directory /Results/ as NCA*.xls or .xlsx files, which opens automatically after the data set(s) are analysed, and in the NCA spreadsheet. The graphs are also stored in the /Results/ directory as NCA*.png files as a graphical record of the points chosen for t¹/₂ determination in addition to these points being listed in the NCA* Excel[®] results file. There are a couple of 'Row n' buttons to help moving around the spreadsheet more conveniently.

To setup a NCA run, the following example should help the user conduct such an analysis without too many problems. Although most of the following is obvious, it is probably worth taking the time to follow the example below, at least to begin with.

Initially, in the spreadsheet there is an Options region (shown in Figure 2 below and Row 15 in the spreadsheet) and this should be populated before adding data, doses etc. Select the appropriate Checkboxes e.g., 'tl/2 and AUC infinity', 'Last actual (usual)' or 'Predicted point' and the concentration-time layout for the data. When the 'Data layout' Checkboxes are activated, Row 74 will show yellow shaded cells to help with Dose entry and a dropdown ComboBox for the Dose units. The correct choice of 'Data layout' is essential, otherwise the user could end up with wrong results! There are 2-options available as some studies require the same nominal time points across all profiles or, for many others, different time points are required for each profile (e.g., in clinical studies). Once the selections are chosen, the titles for both axes on the Chart(s) can be entered (Row 26/27 in the spreadsheet and in Figure 3 below) and these will be updated on all graphs at run-time. Once this is completed, click the 'Go' button to move down to Row 72 to select the concentration units, infusion times (if relevant) and the doses/units in the yellow highlighted cells.

Finally, the concentration-time data can be entered (either typed or copied from another source, Figure 4) together with a profile title for each data set which will be shown at run-time on the graph and in the results summary (an Excel[®] file which automatically opens) at the end of the analysis as a record.

Note: deleting cell contents in the data region and pasting data is ok but <u>don't</u> drag or move/remove cells as it will corrupt the spreadsheet! If a conc. value is absent, just leave the cell blank as shown in this example (96 h).

Figure 2: Options for NCA.

Area Options	Select		<u>Select</u>
t ¹ /2 and AUC to infinity	~	Data layout	
		Time, Conc., Conc., Conc. etc.	
Oral profiles with lag time	~		
		OF .	
Extrapolation to infinity		Time, Conc., Time, Conc., etc.	~
Last actual point (usual)	~		
Last predicted point		Data entry (Row 72) Go	

Figure 3: Data layout options in Excel[®] NCA spreadsheet.

Enter axis titles	Time (min)	<u>for X-axis</u>
(Graph updated at runtime)	Conc. (µg/mL)	<u>for Y-axis</u>

Figure 4: Data layout options in Excel® NCA spreadsheet.

Concentration units	µg/mL ↓		Data entere	ed? Go to 'R	un' section	Go
Infusion? If Yes, enter Inf. Times in Yellow cells.	No -					
Dose units. Enter Doses in Yellow cells.	mg 🗸	2		2		

<u>Time-Conc. Data</u>	Time	Vol.1	Time	Vol.2
	0	0	0	0
	1	1.26	1	0.623
	2	2.02	2	1.18
	3	2.54	3	1.44
	4	4.09	4	2.72
	4.25	4.77	4.25	2.27
	4.5	4.29	4.5	2.25
	5	2.76	5	1.44
	5.5	1.54	5.5	1.19
	6	1.27	6	1.1
	7	0.87	7	0.786
	8	0.99	8	0.733
	10	0.639	10	0.506
	12	1.05	12	0.465
	24	0.43	24	0.201
	36	0.376	36	0.12
	48	0.355	48	0.0531
	72	0.196	72	0.0213
	96	0.124	96	

Once the data have been entered, click the 'Go' button to return to the section of the spreadsheet for running the NCA module. In this example, the PCModfit 'NCA' spreadsheet contains two separate profiles (for missing conc. values, if not sure then leave blank). To initiate the NCA, click the 'Run' then 'Update' in the sheet which will produce a layout similar to that shown in Figure 5. PCModfit V7.4 has an additional button 'Cancel' which will terminate the run at any stage should the user wish to do so (a message box will appear informing the user).





The default is 3 points but if more points are required, then single click on the additional ones in the 'Current Data Set' box which will highlight or deactivate; then click 'Update' and 'Continue' to produce Figure 6.



Figure 6: Points selected in the 1st profile for NCA (note extra values chosen).

V7.8 onwards will now show λ_z as a positive number on the graphs. All other numbers are unaffected by this change.

If a further change is required, then select or deselect values in the 'Current Data Set' box and single click the 'Update' button followed by the 'Continue'.

If all is well, click 'Continue' again and the next profile will be displayed.

As the process continues, the parameter values will update, together with the picture in the NCA sheet reflecting the changes in $t^{1/2}$ (with λ_z) and R^2 , for an estimate of fit, interactively.

The final user accepted pictures from the NCA will be stored as NCA*.png files of high quality in directory C:\PCModfit Vx.x\Results\ (x.x being the version number) with names such as NCA08.png or NCA128.png with corresponding Excel[®] files (PCModfit V7.1 onwards) as a record (worth mentioning that these files will need cleaning up from time to time to stop so many files being produced).

Once both profiles have been analysed, the sheet will display all of the results starting at Row 50 onwards and in the created $\text{Excel}^{\text{@}}$ file which will automatically open at the end of the analysis. In this example, the results file will look very similar to the one shown in the following Figure 7. It's worth mentioning that the time and date is shown in the file together with the results and the points selected for t¹/₂ determination for each profile as a record of the users' selections (useful as a paper trail). Obviously, for a single profile the descriptive statistics will be absent, but the NCA results will still be shown.

Figure 7: Example NCA results in the created Excel file and the NCA spreadsheet.

<u>21/04/2021 15:43</u>	V7.6 will show the p	lotting file names	s here.							
Results	Profile	Vol.1	Vol.2							
	AUC time range	0 to 96	0 to 72	Min.	Max.	Mean	GMean	Median	SD	CV
Comments	Tmax	4.25	4	4	4.25			4.125		
	Cmax	4.8	2.7	2.7	4.8	3.7	3.6	3.7	1.4	38.7
(Usual)	Lin AUCt	47.5	19.7	19.7	47.5	33.6	30.6	33.6	19.7	58.5
	Log AUCt	46.5	19.2	19.2	46.5	32.8	29.9	32.8	19.3	58.7
	Lin/Log AUCt	46.6	19.3	19.3	46.6	33.0	30.0	33.0	19.3	58.6
	Lin AUMCt	1245.8	269.6	269.6	1245.8	757.7	579.6	757.7	690.2	91.1
	Lin AUMC∞	2030.0	311.3	311.3	2030.0	1170.6	794.9	1170.6	1215.3	103.8
	λz	0.0223	0.0476	0.0223	0.0476	0.0349	0.0326	0.0349	0.0179	51.2
$(Ln(2) / \lambda z)$	t ¹ /2	31.1	14.6	14.6	31.1	22.8	21.3	22.8	11.7	51.2
(Usual)	Lin AUC∞	53.1	20.2	20.2	53.1	36.6	32.7	36.6	23.3	63.6
	Log AUC∞	52.0	19.6	19.6	52.0	35.8	32.0	35.8	22.9	63.9
	Lin/Log AUC∞	52.2	19.7	19.7	52.2	36.0	32.1	36.0	22.9	63.8
	R ²	0.914	0.987	0.914	0.987	0.950	0.950	0.950	0.052	5.4
	No. pts. for t ¹ / ₂	6	4	4	6					
	No. pts. (total)	19	18	18	19					
	Intercept	1.0	0.6	0.6	1.0	0.8	0.8	0.8	0.3	32.5
(Dose/AUC∞)	CL /F	37.7	99.2	37.7	99.2	68.4	61.1	68.4	43.5	63.6
(AUMC∞/AUC∞)	MRT	38.2	15.4	15.4	38.2	26.8	24.3	26.8	16.1	60.1
$(CL/\lambda z)$	Vd /F	1691.2	2085.1	1691.2	2085.1	1888.2	1877.9	1888.2	278.5	14.8
(CL x MRT)	Vss /F	1440.8	1532.0	1440.8	1532.0	1486.4	1485.7	1486.4	64.5	4.3
Concentration units	sug/mL									
Infusion?	No									
Dose units	mg	2		2						
Time-Conc. Data	Time	Vol.1	Time	Vol.2						
	0.0000	0.0000	0.0000	0.0000						
	1.0000	1.2600	1.0000	0.6230						
	2.0000	2.0200	2.0000	1.1800						
	3,0000	2 5400	3 0000	1 4400						
	4 0000	4 0900	4 0000	2,7200						
	4 2500	4 7700	4 2500	2 2700						
	4 5000	4 2900	4 5000	2.2700						
	5,0000	2 7600	5 0000	1 4400						
	5.5000	1.5400	5.0000	1 1 1 9 0 0						
	6,0000	1.3400	6,0000	1 1000						
	7,0000	0.8700	7,0000	0.7860						
	8.0000	0.0700	8.0000	0.7800						
	10,0000	0.5500	10,0000	0.7550						
	12,0000	0.0390	12,0000	0.3000						
	24,0000	0.4200	12.0000	0.4030						
	24.0000	0.4300	24.0000 36.0000	0.2010						
	30.0000 48.0000	0.3700	30.0000	0.1200						
	48.0000	0.5550	48.0000	0.0351						
	72.0000	0.1960	72.0000	0.0215						
A street and musik	90.0000	0.1240	96.0000							
Actual and predic	cted points selected for han-	me assignment(s)	2							
Vol 1	Time	Cone (setual)	Cone (prod)						
V UI.1	12	1 05	0 7515)						
	24	0.43	0.7513							
	2 4 26	0.43	0.3732							
	30 40	0.3/0	0.4403							
	40 70	0.555	0.3370							
	12	0.190	0.19/4							
17-1.0	90 Tr'	0.124	0.115/	`						
v 01.2	Time	Conc.(actual)	Conc.(pred.)						
	24	0.201	0.1963							
	36	0.12	0.1109							
	48	0.0531	0.0627							
	72	0.0213	0.0200							

3.2 NCA from V6.9 onwards (bolus intercept and handling zero values)

PCModfit V6.9 and later versions will now display the Y-intercept value (C_0) which can be useful in calculations and often assists with estimating bolus C_0 values (at time 0) but for the terminal t¹/₂ of course, this would only be for the λ_z line. The correct method to use for a C_0 estimate is very debatable as some people prefer to conduct modelling of a complete profile (unweighted) to extrapolate back to the Y-axis (can overestimate C_0) and others who just use the first few points within NCA to achieve the desired result. Whichever method is selected, it will always be approximate, and inspection of each individual profile should be examined to see if the C_0 value generated, is reasonable. The data will usually dictate which method is most appropriate but in the author's experience, either approach can be used. Alternatively, a bolus dose has a time delay before a 'true' value of concentration can be established because, for example, if a human volunteer is dosed into a peripheral vein in the left arm, there will be a delay before levels of drug can be detected in the right arm. On this basis, one could argue that the model defining the dosing/distribution may be exhibiting an infusion situation (albeit very short) and perhaps a concentration at time zero is in fact zero. So now there are 3-approaches, all of which are approximate, and it's left to the reader to decide which option is 'best'.

As a simple example, the early part of a bolus profile is shown (Figure 8) and the intercept value estimated by NCA (using the 3-points) yielded a value of 99.902 which is close to the theoretical value of 100.0 for these data. The intercept will be shown on the NCA graph, in the results .txt file and in the spreadsheet results and can then be used to estimate AUC_{0-t} and $AUC_{0-\infty}$ values for the complete profile by inserting the intercept concentration value at time zero (shown in blue).

Figure 8: Bolus i.v. profile (first 3-points) to estimate C₀ value.

Time	Vol.1
0	99.902
0.05	96.22
0.1	92.61
0.2	85.91

It is important to understand how zero values are handled by programs (often quite different) when for example, calculating AUC estimates for oral profiles. There has, and still is, debate on the correct approach. The approach used in PCModfit can be demonstrated using a specific example (Figure 9) but can be briefly described as follows:

- Zero values at the end of a profile should not be used as the real value would be unknown and should be left blank or use a hyphen.
- Zero values in the middle of a profile again should not be used, particularly if there are positive values either side of the zero. Leave the cell blank or use a hyphen.
- At the beginning of a profile e.g., oral data, care needs to be taken as the wrong approach will yield incorrect values for AUC etc. The example data sets with their associated results, shown in Figure 9, should help to explain this in more detail.

The same 5-data sets were used from 0.5 h to 10 h for simplicity but labelled Vol.1 to Vol.5 to help with the discussion. The concentration-time values used for half-life determinations were the same for all profiles and utilised the last 4 values for consistency. However, the zero values at the beginning of the profiles are shown differently to demonstrate how the program handles these data sets and what impact it has on the results.

The AUC values for sets Vol.1, Vol.2 and Vol.3 are the same as would be expected and show the data layout using zero and - values for concentrations. For these, the first non-zero data point is at 0.25 h and all values before this time are either absent or zero so the AUC would be expected to be equal. For profiles Vol.4 and Vol.5 however, they both have zero values at time zero but no value at 0.25 h so the AUC will be calculated from time zero to 10 h. Both of these are equal but different from Vol.1 to Vol.3 due to the extra area calculated from time zero to 0.5 h.

So, in summary, Vol.1 to Vol.3 profiles all start contributing to the AUC from 0.25 h onwards but Vol.4 and Vol.5 start from zero, hence the increase in AUC for the latter two. At the end of Figure 9 there is a picture of a NCA plot, for information, to show the reader what one of the profiles looks like.

Figure 9	9: Us	e of	zero	concentration	values	in	oral	dosing	profiles.
----------	-------	------	------	---------------	--------	----	------	--------	-----------



If the user has several profile results and would like further descriptive statistics, there is an additional spreadsheet in PCModfit titled 'Stats'. This sheet will allow up to 15 different parameters (up to 100 of each from V7.6 onwards) and after the values are entered (typed or pasted) the sheet will automatically update itself to produce further information such as geometric means etc. using log-transformed data together with CI's (90 and 95 % intervals) such as the example output shown in Figure 10.

Figure 10: 'Stats' spreadsheet containing data (left) and example output (right).

Data Set	P1	P2	P3	Untransfo	rmed resu	lts			
1	914.9	35.40	1.53	n	22	11	11		
2	44.1	18.92	1.26	Min	38.40	14.556	0.783		
3	905.6	28.61	1.72	Max	1568.30	48.645	2.120		
4	390.8	14.56	0.783	Median	138.70	28.605	1.530		
5	60.3	36.13	1.58	SD	379.23	11.253	0.417		
6	1568.3	29.35	1.78	Mean	307.16	28.006	1.441		
7	331.7	24.01	1.71	CV (%)	123.5	40.2	29.0		
8	155.4	17.66	1.14	Log trans	formed re	sults			
9	483.5	48.65	1.44	Summary					
10	506.9			Min.		38.40	14.5	6	0.78
11	50.5	40.26	2.12	Max.	Max.		48.65		2.12
12	139.3			Med	Med		28.61		1.53
13	138.1	14.56	0.783	SD (Arith	metic)	379.23	11.25		0.42
14	62.6			Mean (Ari	thmetic)	307.16	28.01		1.44
15	221.8			CV (%, A)	rithmetic)	123.5	40.1	8	28.98
16	94.1			Geom. Me	an	176.37	25.9	4	1.38
17	115.6			Geom. SD		2.84	1.52	2	1.39
18	95.2			Geom. CV	(%)	140.1	43.6	- i	33.5
19	128.5			CI (90%)	Lower	120.33	20.6	5	1.15
20	112.5			CI (90%)	Upper	258.52	32.5	8	1.65
21	199.5			CI (95%)	Lower	111 10	19.6	0	1 11
22	38.4			CI (95%)	Unner	279.98	34.3	3	1.72
23				n	C PPCI	279.90	11	-	11
24				CT (90%)		(120 33 258 52)	(20.65.3	2 58)	(1.15, 1.65)
25				CI (95%)		(111.10, 279.98)	(19.60, 3	34.33)	(1.11, 1.72)

A more detailed example is shown in Figure 9 that includes different ways of how the program will calculate the AUC values when data have zero values during the early part of profiles.

3.3 Single Dose (SD) Simulator

3.3.1 Using built in explicit models.

The SD simulator allows for 10 regimens comprising different models, doses and parameters in a single run over a user defined time period. Select the 'SD Simulator' spreadsheet and enter the appropriate values. The models are shown in Row 24, Column N which includes intravenous, infusion and oral functions with the sequence of parameters that need to be entered into the sheet at Row 13 onwards. Other parameters that need user input are dose, model, infusion details if selected, and the profile time. For example, if the profile time is 30 h and the number of points per plot is 30, then the concentrations generated (Row 25) will be every hour. If the number of points per plot is 60, then concentrations every 0.5 h will be produced. Ensure that the no of points per plot is a multiple of the simulation time or some erroneous values may be generated. User specific time points are now permitted from V7.1 onwards and explained within the spreadsheet.

As a specific example (Figure 11 for input and output values and Figure 12 for graphics) a simulation was conducted for 4-different regimens using dissimilar parameters, doses and models (4x 1-compartment oral, one with a lag-time). If a model is chosen has a lag-time and it is omitted, the program will assume a lag-time of zero as shown in Figure 11. After entering the parameters and clicking the 'Run' button, the picture in the spreadsheet (containing the 4-profiles) will update automatically at the end of the run and a high-quality graphic file will appear in directory C:\PCModfit Vx.x\Results\ with names like SDSim3.PNG or SDSim156.PNG which can be used in other documents.

Model	7 1-co	ompartment	t p.o. with o	or without l	ag-time (V
User selections	No. pts./plot	60			
	No. Simulations	4			
	Profile time	30			
	Simul. No.	1	2	3	4
	Dose	1000	900	1100	800
	Model	7	7	7	7
	Inftime	/	/	7	1
	Infrata				
	Dui, Dusc Daram 1	100.00	80.00	75.00	70.00
	Param 2	0.5	0.45	0.52	/0.00
	Taraille 4	0.5	0.45	0.52	0.5
	Faran A	0.20	5	0.19	0.22
Concentration	Timo	1	י ר	2	Δ
utnut		0.000	2	0.000	4
ութու	0	0.000	0.000	0.000	0.000
	0.5	2.1006	0.0000	3.1968	2.3884
	1	3.5367	0.0000	5.3719	3.9998
	1.5	4.4742	0.0000	6.7856	5.0318
	2	5.0407	0.0000	7.6361	5.6359
	2.5	5.3338	0.0000	8.0739	5.9274
	3	5.4280	0.0000	8.2134	5.9943
	3.5	5.3802	0.0000	8.1408	5.9028
	4	5.2332	0.0000	7.9210	5.7030
	4.5	5.0195	0.0000	7.6025	5.4322
	5	4.7632	0.0000	7.2215	5.1181
	5.5	4.4824	2.1640	6.8044	4.7810
	6	4.1901	3.7058	6.3709	4.4357
	6.5	3.8960	4.7667	5.9346	4.0925
	7	3.6067	5.4582	5.5056	3.7589
	7.5	3.3269	5.8683	5.0906	3.4394
	8	3.0597	6.0658	4.6940	3.1373
			Etc		
	29.5	0.0457	0.2276	0.0850	0.0310
	30	0.0413	0 2080	0.0773	0.0278

Figure 11: Exam	ole SD simulation	input/output (4	4 profiles, 1	-compt oral, 1	with lag-time)
- Bar o TTA Tanani		- mpan ourput (· p. o		······································

Figure 12: Example SD simulation graphic output from Figure 11 data



As a further example (Figure 13 for input and output values and Figure 14 for graphics) a simulation was conducted for 4-different infusion regimens (3-compartment model) using the same parameters and doses but with different infusion times (dose = Rate x Infusion time). After entering the parameters and infusion information and clicking the 'Run' button, the picture in the spreadsheet (containing the 4-profiles) will update automatically at the end of the run and a high-quality graphic file will be produced in directory C:\PCModfit Vx.x\Results\ (x.x being the version number) with names such as SDSim3.PNG or SDSim156.PNG which can be used in other documents.

Model	6	3-com	partment i.	v. infusion	+ optional	bolus (V, l	$k_{12}, k_{21}, k_{13}, k_{31}, k_{10}$
User selections	No. pts./p	lot	500				
	No. Simu	ations	4				
	Profile time		50				
	Simul. No		1	2	3	4	
	Dose		0	0	0	0	
	Model		6	6	6	6	
	Inftime		20.0	16.0	8.0	5.0	
	Infrate		100.00	125.00	250.00	400.00	
	Bol. Dose		0	0	0	0	
	Param. 1		10.00	10.00	10.00	10.00	
	Param. 2		1.0	1.0	1.0	1.0	
	Param. 3		0.20	0.20	0.20	0.20	
	Param. 4		0.3	0.3	0.3	0.3	
	Param. 5		0.05	0.05	0.05	0.05	
	Param. 6		3.00	3.00	3.00	3.00	

Figura 13, Evampla SD	cimulation (A nraf	iles 3-compt infusions	(avor 5 to 20 h)
rigure 15. Example SD	⁷ simulation (4 prof	nes, s-compt musions	0 VCI 5 10 40 II)

Concentration	Time	1	2	3	4
output	0	0.000	0.000	0.000	0.000
	0.1	0.8131	1.0163	2.033	3.252234
	0.2	1.3434	1.6792	3.358	5.373458
	0.3	1.6906	2.1133	4.227	6.762514
	0.4	1.9194	2.3992	4.798	7.677519
	0.5	2.0714	2.5892	5.178	8.285520
	0.6	2.1737	2.7171	5.434	8.694623
	0.7	2.2437	2.8046	5.609	8.974795
	0.8	2.2928	2.8660	5.732	9.171319
	0.9	2.3284	2.9105	5.821	9.313502
	1	2.3551	2.9438	5.888	9.420313
				Etc.	
	49.5	0.066	0.058	0.046	0.042
	49.6	0.066	0.057	0.046	0.042
	49.7	0.065	0.057	0.045	0.042
	49.8	0.065	0.057	0.045	0.042
	49.9	0.064	0.057	0.045	0.041
	50.0	0.064	0.056	0.045	0.041

Figure 14: Example SD simulation graphic output from Figure 13 data



An additional note: in most spreadsheets there is a facility for calculating λ_n values together with their respective half-lives from the $k_{i,j}$ values as shown in the examples below. If the user enters the $k_{i,j}$ values into the cells (blue characters) in the PCModfit spreadsheet (example shown in Figure 15) then the λ values will automatically update (red characters). The reverse can also be calculated in V7.3 onwards.

Figure 15: Calculator for getting λ_n values from $k_{12}.\,k_{21}$ etc. and the reverse

Useful para	meters: ent	er values i	n blue to ca	alculate re	ed values a	utomatical	ly				
Compts.	k ₁₂	k 21	k 10	λ1	λ2	$t_{1/2} \lambda_1$	$t_{1/2} \lambda_2$				
2	0.09194	0.14312	0.03494	0.2500	0.0200	2.77	34.65				
3	k ₁₂	k 21	k 13	k 31	k 10	λ1	λ2	λ3	$t_{1/2} \lambda_1$	$t_{1/2} \lambda_2$	$t_{1/2} \lambda_3$
	0.49013	0.26821	0.11753	0.03579	0.20833	1.00000	0.10000	0.02000	0.693	6.931	34.657
OR (for bo	lus and infu	sion mode	ls)								
Compts.	C ₁	λ_1	C_2	λ_2	k ₁₂	k ₂₁	k ₁₀				
2	70.00186	1.00002	24.99996	0.02000	0.670155	0.277895	0.071971				
3	C 1	λ_1	C ₂	λ_2	C ₃	λ3	k ₁₂	k 21	k 13	k 31	k 10
	80.0000	1.0000	15.0000	0.1000	5.0000	0.0200	0.49013	0.26821	0.11753	0.03579	0.20833

3.3.2 User defined 'Differential Equation' models (SD simulations)

There are often times when models cannot, or they would be very difficult to solve algebraically and, in these situations, it is much simpler to set up a series of differential equations and let the program do the hard work to solve them. With this in mind, PCModfit V7.1 now has a facility for conducting single dose simulations using differential equations which can be entered in the 'Diff. Eqn. Simulator (SD)' tab.

The program will parse the user entered equations into the PCModfit code automatically from Excel[®] without having to re-compile the program. This step is very quick even though the code is highly complicated as the typed in equations are essentially Tokenised in high memory at the start of the process for later repetitive access and rapid solution in real time.

There are detailed instructions on the spreadsheet with further examples in Section 7 of this manual and but does require the user to be comfortable with defining such differential equations from models. The author is currently working on a repeat dose differential equation simulator (about 75% complete) which should hopefully be available in the next couple of versions. This option will also be made available for modelling single and repeat dose data using differential equations which is currently being coded.

On the 'Diff. Eqn. Simulator (SD)' spreadsheet (starting on Column U) there are examples of how to set up a desired model showing the user what parameters are required. These include an accuracy level, equations, model parameters, volumes, doses (or infusions) and amounts in each compartment at time zero; a necessary requirement.

As a specific example, a 3-compartment single dose infusion model was defined (pictorially represented in Figure 16) and analysed using the differential equation simulator. The data shown in Figure 17 indicates the 3 equations and the other required parameters. Please don't change any of the blue cells but just enter the required numbers in those marked black.

The figure below shows the rate parameters (p_1 to p_5) and the labelling of the 3-compartments for information so the reader can relate these to the spreadsheet in Figure 16.

Specifically, p_1 is k_{12} , p_2 is k_{21} , p_3 is k_{13} , p_4 is k_{31} and p_5 is k_{10} where the $k_{i,j}$ parameters are ones often quoted in the literature. T is the infusion time and the cn values correspond to the amount of drug in each of the compartments at time t.

Figure 16: Pictorial example of a 3-compartment infusion model



The data shown in Figure 17 sets up the required variables (and constants) for a 3-compartment infusion simulation. The 3-equations are shown together with the 5-parameters and the compartmental volumes. Assuming the volume of compartment 1 is known (V₁) the volumes for the other two can be calculated as $V_2 = V_1 x k_{12}/k_{21}$ and $V_3 = V_1 x k_{13}/k_{31}$. For the profile time, a value of 24 h was required and the No. of points set at 24. This generated concentrations every hour but if the No. of points were set at 48 (a multiple of the time; recommended) then concentrations every 0.5 h would have been produced. The output of the simulation is initiated by clicking the 'Run' button and the results for each compartment appear in Row 60 onwards; for this example, the results are shown in Figure 18.

	Set a minimum value for concentration	ons	1.00E-03	(If too small,	log axis might be wide. Recommend 1.0E-03			
No. of	3	No. of	5	Accuracy	1.00E-06	(Recommended	d)	
equations		parameters						
Profile time	24.0	No. of points	24	(e.g. prof. time	= 24 h and no.	pts = 48 will yie	ld conc every 0.5	h).
				(Maximum 1000	0).			
Equation		Equations	Compt.	Amount at	Parameter	Parameter	Volume	
No.		(user defined)	ref.	time 0 (C0)	ref.	value	compt.	
1	D/T-c1*p1+p2*c2-c1*p3+p	p4*c3-c1*p5	c1	0.0	pl	1.0	10.0	
2	(p1*c1-p2*c2)		c2	0.0	p2	0.10	100.0	
3	(p3*c1-p4*c3)		c3	0.0	p3	0.5	100.0	
4			c4	0.0	p4	0.05	1.0	
5			c5	0.0	p5	1.20	1.0	
6			c6	0.0	p 6	0.0	1.0	
7			c7	0.0	p7	0.0	1.0	
8			c8	0.0	p8	0.0	1.0	
9			c9	0.0	p9	0.0	1.0	
10			c10	0.0	p10	0.0	1.0	
11			c11	0.0	p11	0.0	1.0	
12			c12	0.0	p12	0.0	1.0	
13			c13	0.0	p13	0.0	1.0	
14			c14	0.0	p14	0.0	1.0	
15			c15	0.0	p15	0.0	1.0	
16			c16	0.0	p16	0.0	1.0	
17			c17	0.0	p17	0.0	1.0	
18			c18	0.0	p18	0.0	1.0	
If infusion mod	el, define the rate in an equ	ation as D/T (Example 3 in Column U	IJ .					
Set both values	(Time and Dose below) to a	zero if not an infusion.						
Infusion		Infusion Dose		Infusion I	Rate (informa	tion Only)		
time (T)	4.0	(D)	400.0	(D	/ T)	100.0		

Figure 17: Example setup using a 3-compartment infusion model

Figure 18: Output from a 3-compartment infusion model simulation

Results			
Time	Compt. 1	Compt. 2	Compt. 3
0.000			
1.000	3.518	0.235	0.120
2.000	3.896	0.570	0.297
3.000	4.066	0.895	0.477
4.000	4.217	1.204	0.656
5.000	0.843	1.263	0.713
6.000	0.603	1.207	0.711
7.000	0.565	1.147	0.705
8.000	0.541	1.091	0.698
9.000	0.520	1.037	0.689
10.000	0.499	0.987	0.681
11.000	0.479	0.940	0.671
12.000	0.461	0.895	0.661
13.000	0.443	0.853	0.651
14.000	0.426	0.813	0.641
15.000	0.410	0.775	0.630
16.000	0.394	0.740	0.619
17.000	0.379	0.706	0.607
18.000	0.365	0.674	0.596
19.000	0.352	0.644	0.584
20.000	0.339	0.616	0.573
21.000	0.326	0.589	0.561
22.000	0.315	0.563	0.549
23.000	0.303	0.539	0.537
24.000	0.292	0.516	0.526

In addition to the numerical output, the graph in the spreadsheet is automatically updated and can be copied or edited into other documents. The graphical output for the infusion simulation is shown in Figure 19 for information.

Note: the concentration axis has a minimum value of 0.001 which corresponds to the value that is user defined prior to running (Row 26) where it says "Set a minimum for concentrations". If this value is set too low, the y-axis may look odd! The accuracy for the numerical integration is normally 1.0E-06 which seems to work well.

Figure 19: Graphics output from a 3-compartment infusion model simulation



When the 'Run' button is clicked, a Window will appear which allows the user to change certain parameters (shown in Figure 20). Note that the equations have been parsed ok from Excel[®] and the parameters are correct. The 3-compartment infusion simulation on an i7 computer only took 0.02 seconds so it seems very quick!

Figure 20: Run time Window displaying the user's equations and variables

Equatio	ns and parameters					×
	No. of equations 🛐 No. var	riables	5	Accuracy	1.00E-06	
1	Equations	Am c 1	ount(time	e 0) H	Parameters	Volumes
2	(n1*c1-n2*c2)	c2	0	r	0.1	100
3	(p3*c1-p4*c3)	с3	0	p3	0.5	100
4		с4	0	 p4	0.05	1
5		c5	0	 p5	1.2	1
6		c6	0	p6	0	1
7		с7	0	p7	0	1
8		c8	0	p8	0	1
9		c9	0	p9	0	1
10		c10	0	p10	0	1
11		c11	0	p11	0	1
12		c12	0	p12	0	1
13		c13	0	p13	0	1
14		c14	0	p14	0	1
15		c15	0	p15	0	1
16		c16	0	p16	0	1
17		c17	0	p17	0	1
18		c18	0	p18	0	1
	Boxes below for infusions on	ly				
	Infusion time 4 Dose 4(0				
	Cancel		OK			

3.4 Repeat Dose (RD) Simulator

3.4.1 Using built in explicit models

The repeat dose simulator will allow dosing regimens comprising different models, doses, dosing intervals and parameters in any sequence and permits up to 10 simulations, each with up to 200 doses, in a single run over a user defined time period. For simulating repeat dose profiles, select the spreadsheet labelled 'RD Simulator' and enter the appropriate values. Obviously, there will be more variables to enter the spreadsheet than for SD simulations as additional parameters will be required. User specific time points are now permitted from V7.1 onwards and explained within the spreadsheet.

The models are shown in Row 7, Column K which currently covers multi-compartment intravenous, infusion and oral functions with the sequence of parameters that need to be entered into the sheet at Row 33 onwards. If more than one RD simulation is required, all of the parameter information will have to be entered for each 'Subject' number starting at Row 24, Column A. The parameters and doses etc. need to be specified for each dose as the simulator allows for different possibilities. The variables that need user input are dose, dosing interval, model with parameters, infusion details if selected, and the overall profile time. For example, if the profile time is 240 h and the number of points per plot is 240, then the concentrations generated (Row 224) will be every hour. If the number of points per plot is 480, then concentrations every 0.5 h will be produced. Ensure that the no of points per plot is the same for each Subject and a multiple of the simulation time or some erroneous values may be generated.

As a specific example (Figure 21 for input, Figure 22) for output values and Figure 23 for graphics) a simulation was conducted for 2 Subjects using dissimilar doses and dosing intervals (1-compartment oral). After entering the parameters and clicking the 'Run' button, the picture in the spreadsheet (containing the 2-profiles) will automatically update and a high-quality graphic file produced in directory C:\PCModfit Vx.x\Results\ (x.x being the version number) with names such as RDSim9.PNG or SDSim125.PNG which can be used in other documents.

Model 7, 1-c	compartm	ent oral								
Subject 1										
No. pts./plot	240									
No. Subjects	2									
No. Doses	10									
Profile time	240									
Dose No.	1	2	3	4	5	6	7	8	9	10
Dose	20000	20000	20000	20000	20000	20000	20000	20000	20000	20000
Interval	0	24	24	24	24	24	24	24	24	24
Model	7	7	7	7	7	7	7	7	7	7
Inftime										
Infrate										
Bol. Dose										
Param. 1	1200	1200	1200	1200	1200	1200	1200	1200	1200	1200
Param. 2	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Param. 3	0.028881	0.028881	0.028881	0.028881	0.028881	0.028881	0.028881	0.028881	0.028881	0.028881
Subject 2										
No. Doses	10									
Profile time	240									
Dose No.	1	2	3	4	5	6	7	8	9	10
Dose	20000	10000	20000	10000	20000	10000	20000	10000	20000	10000
Interval	0	24	24	24	24	24	24	24	24	24
Model	7	7	7	7	7	7	7	7	7	7
Inftime										
Infrate										
Bol. Dose										
Param. 1	1200	1200	1200	1200	1200	1200	1200	1200	1200	1200
Param. 2	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Param. 3	0.028881	0.028881	0.028881	0.028881	0.028881	0.028881	0.028881	0.028881	0.028881	0.028881

Figure 21: Simulation RD (10 doses 1-compt oral) 2 Subjects: 1 same dose and different dose.

Time	Subject 1	Time	Subject 2
0	0.0000	0	0
1	6.4563	1	6.4562844
2	10.1884	2	10.188421
3	12.2735	3	12.273511
4	13.3647	4	13.3647
5	13.8580	5	13.857997
6	13.9935	6	13.993451
7	13.9165	7	13.916525
8	13.7153	8	13.715311
9	13.4431	9	13.443115
10	13.1321	10	13.132138
11	12.8018	11	12.801794
12	12.4637	12	12.463738
13	12.1249	13	12.124924
14	11.7895	14	11.789457
15	11.4597	15	11.459722
		Etc.	
235	20.4151	235	13.6103
236	19.8344	236	13.2231
237	19.2700	237	12.8468
238	18.7216	238	12.4811
239	18.1888	239	12.1259
240	17.6710	240	11.7807

Figure 22: Example RD simulation concentration output

Figure 23: Example RD simulation graphic output



A slightly more complicated simulation is included here to help the user with their own predictions. In this particular example, showing a 2-compartment model, an initial bolus and infusion dose is followed by several oral doses at different dosing intervals. The parameters used in this run are shown in Figure 24 for input, Figure 25 for output and Figure 26 for graphics. The simulation was conducted for 2 Subjects using the same regimen but half the dose throughout (just to demonstrate the layout). After entering the parameters and clicking the 'Run' button, the picture in the spreadsheet (containing the 2-profiles) will automatically update and a high-quality graphic file produced in directory C:\PCModfit Vx.x\Results\ (x.x being the version number) with names such as RDSim9.PNG or RDSim125.PNG which can be used in other documents.

Figure 24: Simulation (2-compt. model; bolus+infusion then oral) for 2 Subjects (input).

2-compartm	ent model	l, bolus + i	nfusion fo	llowed by	various o	ral doses ((V1 for ora	al slightly l	higher i.e.	120)
Subject 1										
No. pts./plot	240									
No. Subjects	2									
No. Doses	10									
Profile time	240									
Dose No.	1	2	3	4	5	6	7	8	9	10
Dose	0	20000	20000	20000	20000	20000	20000	20000	20000	20000
Interval	0	24	24	24	24	24	24	24	24	24
Model	5	8	8	8	8	8	8	8	8	8
Inftime	5									
Infrate	5000									
Bol. Dose	5000									
Param. 1	100	120	120	120	120	120	120	120	120	120
Param. 2	0.49307	0.50000	0.50000	0.50000	0.50000	0.50000	0.50000	0.50000	0.50000	0.50000
Param. 3	0.08201	0.49307	0.49307	0.49307	0.49307	0.49307	0.49307	0.49307	0.49307	0.49307
Param. 4	0.18871	0.08201	0.08201	0.08201	0.08201	0.08201	0.08201	0.08201	0.08201	0.08201
Param. 5		0.18871	0.18871	0.18871	0.18871	0.18871	0.18871	0.18871	0.18871	0.18871
Subject 2										
No. Doses	10									
Profile time	240									
Dose No.	1	2	3	4	5	6	7	8	9	10
Dose	0	10000	10000	10000	10000	10000	10000	10000	10000	10000
Interval	0	24	24	24	24	24	24	24	24	24
Model	5	8	8	8	8	8	8	8	8	8
Inftime	5									
Infrate	2500									
Bol. Dose	2500									
Param. 1	100	120	120	120	120	120	120	120	120	120
Param. 2	0.49307	0.50000	0.50000	0.50000	0.50000	0.50000	0.50000	0.50000	0.50000	0.50000
Param. 3	0.08201	0.49307	0.49307	0.49307	0.49307	0.49307	0.49307	0.49307	0.49307	0.49307
Param. 4	0.18871	0.08201	0.08201	0.08201	0.08201	0.08201	0.08201	0.08201	0.08201	0.08201
Param. 5		0.18871	0.18871	0.18871	0.18871	0.18871	0.18871	0.18871	0.18871	0.18871

Figure 25: Simulation (2-compt. model; bolus+infusion then oral) for 2 Subjects (output).

Time	Subject 1	Time	Subject 2
0	50.0000	0	25
1	62.4062	1	31.203114
2	70.3755	2	35.187761
3	76.1915	3	38.095757
4	80.9414	4	40.470712
5	85.1433	5	42.571653
6	52.5572	6	26.278581
7	36.8072	7	18.403617
8	29.0715	8	14.535763
9	25.1532	9	12.576625
10	23.0559	10	11.527931
11	21.8295	11	10.914748
12	21.0222	12	10.511097
		Etc.	
233	26.2576	233	13.1288
234	25.6941	234	12.8471
235	25.1509	235	12.5755
236	24.6242	236	12.3121
237	24.1116	237	12.0558
238	23.6115	238	11.8057
239	23.1229	239	11.5614
240	22.6451	240	11.3225



Figure 26: Simulation (2-compt. model; bolus+infusion then oral) for 2 Subjects (output graphics)

3.4.2 User defined 'Differential Equation' models (RD simulations)

This option for RD simulations will allow users to create dosing regimens with their own differential equations. The module allows for different models, doses, intervals and changes in variables in any sequence within a single run (up to 200 doses and up to 5000 data points) over a user defined time period. For simulating repeat dose profiles, select the spreadsheet labelled 'Diff. Eqn. Simulator (RD)' and follow the instructions. There are more variables to enter in the spreadsheet than required for single doses as additional parameters such as dosing intervals, number of doses, models etc. will be required. Users not conversant with creating differential equations in PK may find it useful to read Appendix 7 where an example is shown.

As a specific example, consider a dosing regimen where a drug is to be administered as a bolus + infusion and then a series of oral maintenance doses with different doses and intervals. Hopefully, the following information will be sufficient to help the user to set up a regimen for a successful simulation. The symbols in the equations used by PCModfit for this example are depicted in Figure 27.

As the first dose will be a bolus, the model schematic (shown in Figure 28) and the equations that the program will need are listed in Figure 29.

Symbols (PCModfit eqns.)	Parameter	Meaning
p1	k ₁₂	Transfer rate of drug from Compt. 1 to 2
p2	k ₂₁	Transfer rate of drug from Compt. 2 to 1
р3	k_{10}	Transfer rate of drug from Compt. 1 to Waste
p4	ka	Absorption rate (Compt. 3 to Compt. 1)
c1	A_1	Amount in Compt. 1 at time zero (bolus dose)
c2	A_2	Amount in Compt. 2 at time zero
c3	A_3	Amount in Compt. 3 at time zero (oral dose)
D	D	Dose (infusions only)
Т	Т	Infusion time
D/T	Rate (k ₀)	Must be used in infusion models (see Figure 31)

Figure 27: Symbols used in the 2-compartment model equations (bolus, infusion and oral)

Figure 28: Pictorial example of a 2-compartment bolus model

		pl	
Dose (Bolus)	 Blood (c1)	→ →	Tissue (c2)
	p3	p2	
	Waste		

Figure 29: Equations for a 2-compartment bolus model

Compartment	Equation
c1 (blood)	-c1*p1-c1*p3+p2*c2
c2 (tissue)	p1*c1-p2*c2

The amounts of drug in Compt. 1 (c1) and Compt. 2 (c2) at zero time (c0 values in the spreadsheet, Row 101 onwards) will be the Dose and zero, respectively.

For the infusion model (pictured in Figure 30) the equations are similar to the bolus but with the added term of rate (D/T) for Compt. 1 (Figure 31) and for such models should always be defined.

Figure 30: Pictorial example of a 2-compartment infusion model

				pl	
Infusion dose	•	Dlag	d(a1)		Tionna (a2)
(Rate*T)		БЮС	ba (c1)	◄	1 issue (c2)
			р3	p2	
				-	
		W	aste		

Figure 31: Equations for a 2-compartment infusion model

Compartment	Equation
c1 (blood)	D/T-c1*p1-c1*p3+p2*c2
c2 (tissue)	p1*c1-p2*c2

The amounts of drug in Compt. 1 (c1) and Compt. 2 (c2) at zero time (c0 values in the spreadsheet, Row 101 onwards) will both be zero.

For the oral model (pictured in Figure 32) the equations are different to the bolus and infusion models due to the addition of Compt. 3 (the gut) and hence the added term of absorption rate (k_a) (Figure 33) will need to be defined in the equations.

Figure 32: Pictorial example of a 2-compartment oral model



Figure 33: Equations for a 2-compartment oral model

Compartment	Equation
c1 (blood)	c3*p4-c1*p1-c1*p3+p2*c2
c2 (tissue)	p1*c1-p2*c2
c3 (gut)	-p4*c3

The amount of drug in Compt. 1 (c1) and Compt. 2 (c2) at time zero will both be zero. However, for compt. 3 (the gut) the value at time zero will be the oral dose.

How does the user set up a simulation using the program such as the one described?

<u>First step</u>

The cells in the spreadsheet with blue characters should not be moved or changed as the program may end up generating numbers that are completely meaningless! For the simulation, specifically, in the 'Diff. Eqn. Simulator (RD)' spreadsheet, Row 16 onwards (in this case) needs to be populated with the numbers of equations, compartments, parameters and actual equations for the simulation.

For this example, Model 1 is the bolus dose, Model 2 is the infusion and finally, Model 3 is the oral model. A screen clip from the spreadsheet is shown in Figure 34 to demonstrate this, with the appropriate data included. At the top of the spreadsheet there is an 'Examples' button which will display

several equations that can be copied into the appropriate cells to make things easier. The user may add their own equations if required in Row 21 onwards as shown in Figure 34, below.

Figure	34:	Spreadsheet	information	required	for Step 1	1 of the	simulation
		~ r					

15									
16	Model No.	1			2	3			
17	No. Eqns.	2		2			3		
18	No. Compts.	2			2			3	
19	No. Parameters	3			3	4			
						Equations			
20	Equation No.	Equations			Equations			Equations	
20 21	Equation No. 1	Equations -c1*p1-c1*p3+p2*c2	D/	/T-c1*p1-c1*p3	Equations 3+p2*c2		c3*p4-c1*p1-c1	Equations *p3+p2*c2	
20 21 22	Equation No.	Equations -c1*p1-c1*p3+p2*c2 p1*c1-p2*c2	D/ pl	/T-c1*p1-c1*p3 1*c1-p2*c2	Equations 3+p2*c2		c3*p4-c1*p1-c1 p1*c1-p2*c2	Equations *p3+p2*c2	
20 21 22 23	Equation No. 1 2 3	Equations -c1*p1-c1*p3+p2*c2 p1*c1-p2*c2	D/ p1	/T-c1*p1-c1*p3 1*c1-p2*c2	Equations 3+p2*c2		c3*p4-c1*p1-c1* p1*c1-p2*c2 -p4*c3	Equations *p3+p2*c2	
20 21 22	Equation No.	Equations -c1*p1-c1*p3+p2*c2 p1*c1-p2*c2	D/ pl	/T-c1*p1-c1*p3 1*c1-p2*c2	Equations 3+p2*c2		c3*p4-c1*p1-c1 p1*c1-p2*c2	Equations *p3+p2*c2	

Second step

Slightly further down the spreadsheet (Row 46 onwards) other information needs to be supplied (screen clip shown in Figure 35). The 'Minimum value for the logarithmic plot' (Row 46) and the 'Accuracy' (Row 48) should be entered and the numbers shown for each is a guide for the user. These values can be modified if required, although these settings seem to work well for most simulations. Hopefully, the remainder of Step 2 is self-explanatory and should be adapted for the required regimen.

Note that the 'No. pts.' (Row 53) must be a multiple (or fraction multiple) of the 'Profile time' (and vice-versa). For instance, if the profile time is 100 h, then the number of points can take values of 25, 50, 100, 200, 1000 etc. depending on the concentration-time values required (100 points would calculate values every hour). Also, regarding the number of points, although the maximum is 5000, bear in mind that it will take longer to generate these particularly if there are numerous doses and equations. Numerical integration can be a fairly complex process and sometimes fussy with respect to accuracy but 1.0E-07 seems to be ok in most situations. For this particular example, using a computer with an i7 processor, the 'number crunching' procedure only took 2.4 seconds to complete the simulation.

46	Minimum value for log	arithmic plot	1.00E-01	(If number too s	f number too small then log axis might be wide. Recommend 1.0E-03 initially).						
47											
48	Accuracy		1.00E-07	(Recommended)						
49											
50	Enter variables for sim	ulation		If model is not	an infusion ther	set Infusion tir	nes and infusior	Doses to zero.			
51	No. Doses (max. 100)	10									
52	Profile time	100		Profile time an	d No. Pts. (max.	5000) should b	e multiples (or f	ractions) of eac	h other.		
53	No. pts.	200		e.g. Profile tim	e of 240 h use N	o. Pts. = 60, 120), 240, 480, 2400) etc.			
54											
55	Dose No.	1	2	3	4	5	6	7	8	9	10
56	Interval	0	0	6	8	12	8	12	8	16	12
57	Model No.	1	2	3	3	3	3	3	3	3	3
58	Infusion time	0.0	4.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
59	Infusion dose	0.0	1000.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Figure 35: Screen clip from spreadsheet detailing some values for the current simulation

To move around the spreadsheet more easily, there are 'Previous' and 'Next' buttons at various places to avoid having to scroll the sheet to make life easier.

<u>Third step</u>

The next set of values to enter are the actual parameter values from Row 72 onwards. For this example, there are 3-parameters for Models 1 and 2 (p1, p2 and p3) with an additional one for Model 3 where the absorption rate ($p4 \equiv k_a$) is added (p1, p2, p3 and p4). These parameters should be entered for each dose and can be different for each one, if required, to increase flexibility.

Note that the Volume terms are not added here but in a later Section of the sheet (Row 131 onwards). As before, a screen clip of the Parameters section in the spreadsheet is shown (Figure 36) for information. The number of decimal places for each parameter can be changed depending on the simulation (or users) requirements.

67	Dose No.	1	2	3	4	5	6	7	8	9	10
68	Model No.	1	2	3	3	3	3	3	3	3	3
69											
70	Eqn. parameter										
71	symbols	Parameters									
72	P1	0.500	0.500	0.500	0.500	0.500	0.500	0.500	0.500	0.500	0.500
73	P2	0.100	0.100	0.100	0.100	0.100	0.100	0.100	0.100	0.100	0.100
74	P3	0.300	0.300	0.300	0.300	0.300	0.300	0.300	0.300	0.300	0.300
75	P4			0.300	0.300	0.300	0.300	0.300	0.300	0.300	0.300
76	P5										

Figure 36: Screen clip from spreadsheet detailing parameter values for the current simulation

Fourth step

The next set of values to enter are the actual amounts of drug at time zero (C0 values) from Row 101 onwards (clip shown in Figure 37). For this example, Model 1 (bolus) will have a value for Compt. 1 (c1) equal to the bolus dose and for Model 3 (oral) the 3rd compartment (c3) should have the corresponding oral Dose. The infusion (Model 2) will have C0 values of zero for both compartments. Logically, other values will be all equal to zero as shown.

Figure 37: Screen clip from spreadsheet detailing C0 values for the current simulation

96	Dose No.	1	2	3	4	5	6	7	8	9	10
97	Model No.	1	2	3	3	3	3	3	3	3	3
98											
99	Eqn. compt.										
100	symbols	C0 value									
101	C1	125	0	0	0	0	0	0	0	0	0
102	C2	0	0	0	0	0	0	0	0	0	0
103	C3			1200	800	600	800	600	800	900	1000
104	C4										

<u>Fifth step</u>

The last, but not least, set of values to enter are the Volumes for each compartment and model (screen clip shown in Figure 38) from Row 131 onwards in the spreadsheet. Note that, if the volume terms are set to 1.0, then the program will assume that the volumes are unknown and the results (Row 186 onwards) will represent amounts rather than concentrations. Often, for compartment 1, the volume term is known (maybe from modelling or NCA methods) but for the other compartments it is not. An approximation can be used to assign volume values for other compartments based on the rate constants for the purpose of simulations e.g. for a 3-compartment model where compartment 2 and 3 are separately connected to compartment 1, the following relationships can be used.

Volume 2 = Volume $1 \times k_{12}/k_{21}$ and Volume 3 = Volume $1 \times k_{13}/k_{31}$

Figure 38: Screen clip from spreadsheet detailing Volume values for the current simulation

125	Dose No.	1	2	3	4	5	6	7	8	9	10
126	Model No.	1	2	3	3	3	3	3	3	3	3
127											
128											
129	Enter volumes										
130	for each Compt.	Volumes									
131	Compt. 1	10.0	10.0	10.0	10.0	10.0	10.0	10.0	10.0	10.0	10.0
132	Compt. 2	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0
133	Compt. 3			1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0

<u>Sixth step</u>

Assuming that all of the above data has been entered into the 'Diff. Eqn. Simulator (RD)' spreadsheet, then a final check, prior to running the simulation, can be made by clicking the 'Initialise' button (see Figure 40 screen clip). This will initiate the program to check all entries and set up the 'number crunching' variables (it must be clicked before running). There will be a sanity check made on the equations and it also tests the entered data to see if any variables are inconsistent or missing. After a successful initialisation, a small Window (Figure 39) will appear informing the user that no errors were found.

Figure 39: Message showing no errors were found after Initialisation

Microsoft Excel	×
Checked all entered data and no errors detected.	
OK	

If an error is detected then an appropriate message box will pop-up, hopefully referencing where the culprit is! The usual ones are equation errors, where a parameter or an infusion term is missing or a parameter is absent. The majority of the error messages indicate which Row or region in the spreadsheet contains the anomalous data and/or empty cell(s).

Although there are numerous checks built into the program that will be carried out on initialisation and on execution of the numerical integrator but no doubt, the odd one may be missed. However, the graphs and the concentration/amount-time data (Row 187 onwards) will normally show an unexpected result.

Figure 40: Screen clip from spreadsheet showing 'Initialise' and 'Run' buttons

152	<u>Step 6</u>										
153	Once the above has be	en populated, click	the 'Initialise' bu	itton (below) to c	onduct a						
154	sanity check on user entered data and store all variables prior to running the simulation.										
155	Then click the 'Run' b	Then click the 'Run' button to execute.									
156	The graphs (below) wi	he graphs (below) will automatically update and the ConcTime data									
157	will be listed from Roy	w 186 onwards.									
158											
159											
160	Previous	Initialise	Run								
161											
162	Step 1										
163											

Finally, when the 'Run' button is clicked, the simulation will be activated and start. If 5 or more doses are requested, then a 'Busy' bar will appear on the screen indicating how much longer it will take to finish...usually just a few seconds but this will be dependent on the computer processor and the number of equations.

The two graphs on the spreadsheet will automatically update together with the concentration/amount data. The results from this example simulation are shown in Figure 41 through to Figure 43, all copied directly from the spreadsheet. The Profile time was 100 h with 200 data points requested and hence the concentration/amount values were calculated every 0.5 h.





Figure 42: Simulation result graphic for all 3-compartments



186	Time	Compt. 1 (Blood)	Compt. 2 (Tissue)	Compt. 3 (Gut)
187	0.00	12.500	0.000	0.000
188	0.50	18.762	0.773	0.000
189	1.00	23.144	1.764	0.000
190	1.50	26.302	2.889	0.000
191	2.00	28.660	4.091	0.000
192	2.50	30.493	5.336	0.000
193	3.00	31.981	6.601	0.000
194	3.50	33.240	7.870	0.000
195	4.00	34.345	9.135	0.000
196	4.50	25.021	10.119	0.000
197	5.00	18.925	10.686	0.000
198	5.50	14.924	10.982	0.000
199	6.00	12.282	11.105	1200.000
200	6.50	24.262	11.486	1032.800
201	7.00	30.511	12.281	888.980
		Etc.		
379	96.00	14.462	20.888	15.365
380	96.50	14.138	20.567	13.225
381	97.00	13.831	20.246	11.383
382	97.50	13.538	19.926	9.797
383	98.00	13.257	19.607	8.432
384	98.50	12.988	19.291	7.258
385	99.00	12.729	18.977	6.247
386	99.50	12.480	18.666	5.377
387	100.00	12.239	18.359	4.628

Figure 43: Numerical results from the bolus + infusion followed by oral maintenance simulation

Out of interest, the same simulation was conducted using the Repeat Dose Simulator with explicit models rather than those requiring differential equations and the results were essentially identical. The graphical result is shown below.



3.5 Superposition option

PCModfit V7.2 onwards is now twice as fast for the Superposition option when compared to previous versions due to code modifications on cell Fonts used in the results transfer process into Excel; the numerical values are not changed. There is an additional option in V7.1 and V6.9 which allows 'Superposition' to be conducted for oral profiles (or others that have zero concentration at time zero) that are inappropriate for full modelling and only a half-life estimate is available. This is a common phenomenon in both non-clinical and clinical studies. There is a Summary table within the spreadsheet indicating the accumulation values by comparing parameters from Dose 1 to the last Dose for a quick assessment. In addition (new to V7.1) the user can now manually override the estimated $t\frac{1}{2}$ value (cell G4) when required (sometimes useful for very sparse data but when the $t\frac{1}{2}$ is known) and can now add their own data points to the repeat dose plots very easily, which is good for showing pre-dose values at later time points within a repeat dosing regimen (add data to cell K6 down).

Assuming that a single dose profile of a drug is available and an assessment of potential concentrations at, for instance, steady state is required, then the principle of Superposition can be used. However, it makes the assumption that the PK model is unknown, and that the kinetics are linear and unchanging over a repeat dose regimen in addition to the premise that all doses are independent of each other. Having said that, it is a valuable tool to estimate concentration-time repeat dose profiles from single dose data without resorting to full modelling procedures particularly when data are sparse. Earlier versions of PCModfit contained a Superposition option but they were limited as the doses and dosing intervals had to be equal.

In V7.1, this upgrade, due to popular usage, the module has been rewritten in Fortran (for speed), extensively updated and also verified by two independent users in addition to many who have tested it. In addition to being able to vary the dosing interval, users can now change each dose across the entire regimen as well (thanks to suggestions by Angus McLean, Ph.D., from the USA and Dr med. Christian de Mey from ACPS in Germany). There are several further additions including various plots of the results together with selection of accuracy to dictate the number of points required for each run. Using the highest accuracy, which can take some time, there can be up to 1,000,000 points generated which is getting close to the number that Excel[®] can handle. The author recommends a value of 0.01 which seems to be a very good compromise.

Summary plots and various parameters are output for each dose, which are useful for both simple and complex regimens. To assist the user, there are a couple of examples with start-up variables and associated output shown below.

Example 1, is a single oral dose data set and a Superposition profile (10 doses) was generated with the same dose but with different dosing intervals and utilising the last 7 points for estimation of $t\frac{1}{2}$ (all setup data taken from the Superposition Sheet and shown in Figure 44).

As a suggestion to the user, start the sequence of events by entering the concentration-time data, the dose for this data set and number of doses and the profile time. Then enter the number points required for t¹/₂ assignment (yellow cells). Finally, enter the doses (relative to cell B3) and the dosing intervals required. The next option to select is the 'Accuracy' – a brief explanation is required for this. The three options are 0.1, 0.01 and 0.001 and whichever is selected will dictate the frequency of time values (and thus concentrations) which will directly impact on the accuracy of the final numbers. After much use, the author recommends that 0.01 is a good compromise and overall, oftentimes produces accurate values. A value of 0.1 is fast and will yield to the user a very rough estimate before perhaps selecting a lower value. If 0.001 is chosen, a time point every 0.001 of the time unit will be generated. This can take a while and will produce hundreds of thousands of values which usually doesn't show much, if any for some regimens, improvement over 0.01. Pragmatism is a good rule of thumb when it comes to Accuracy values and a trade off against time. Also note, that if a value of say 0.1 is chosen and some of the time points are to 3 decimal places then these values may be skipped by the procedure as they can't be calculated e.g., time of 3.233 with step sizes of 0.1 cannot be attained. Taking a blood sample with such a degree of time precision is not feasible anyway. Experimenting with the program will be of great value in helping to decide which Accuracy figure is most appropriate for your work. In the meantime, go for 0.01 as this is easily good enough for the majority of profiles and shows values that are very close indeed to theoretical ones.

	А		В	ŀ	-		J					
1	Superpos	ition		No. dos	es (≤50)	10						
2	Enter dose f	or pro	file below	Profile	time 🛛	132.0						
3	Dose =		100.0	t _{1/}	2 =		time					
4				λ	=		time ⁻¹					
5	Ac	tual d	ata	C ₀ ($\lambda_z) =$							
6	Time (h)		Vol 1	n fo	r t _{1/2}	7						
7	0		0									
8	1		28.1782									
9	2		33.4365									
10	3		31.189									
11	4		26.9383									
12	5		22.5713									
13	6		18.6697									
14	7		15.3553									
15	8		12.5976									
16	9		10.3235									
17	10		8.4556									
18	11		6.9242									
19	12		5.6695									
	P C	2	R	S	Т	U	V	W	Х	Y	Z	
	1st do	se (al	ways zero tir	ne)								
Int	ervals = 0.	0	12.0	16.0	12.0	12.0	16.0	12.0	16.0	12.0	12.0	
Do	se = 100	0.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	
	C		D	F	E	G		Н		I	K	
13	U		U	E	F	9	Accur	11 Pacy (smalle	ı et takos lon	J gest recor	mend 0 01)	<u> </u>
14	Run						Accui				inicitu 0.01)	,
15				% Done	100		0	.100	0.010	0.001		

Figure 44: Example 1 - input data (time, concentrations, intervals and no. of doses etc.)

The graphical output from the program for Example 1 is shown in Figure 45 wherein; the concentration-time profile is depicted for information.





The numerical results from the Superposition Example 1, are shown in Figure 46 and contain C_{min} and C_{max} in addition to $AUC_{0-\tau}$, for all doses, together with the predicted concentration data for the t¹/₂ assignment. There are also plots for C_{min} and C_{max} vs. Dose number and for the 1st and last dose.

Figure 46: Results showing C_{min} and C_{max} in addition to AUC_{0- τ} for all doses (Example 1)

Р	Q	R	S	T	U	V	W	Х	Y	Ζ
	1st dose (al	lways zero t	ime)							
Intervals =	0.0	12.0	16.0	12.0	12.0	16.0	12.0	16.0	12.0	12.0
Dose =	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Informatio	nformation only (updated automatically)									
Dose time	0.0	12.0	28.0	40.0	52.0	68.0	80.0	96.0	108.0	120.0
Dose no.	1	2	3	4	5	6	7	8	9	10
C _{min}	5.67	2.80	5.93	6.21	2.82	5.93	2.81	5.93	6.21	6.24
C _{max}	33.44	37.25	35.31	37.42	37.61	35.33	37.42	35.32	37.42	37.61
AUC _{0-τ}	217.47	260.45	230.24	244.54	263.08	230.34	261.70	230.29	244.54	245.86
Note: AU	C _{0-τ} for la	st dose is a	actually A	UC _{0-profile} t	ime)					
AUC last	dose is ca	lculated fi	rom the la	st dose an	d if a com	parison is	to be mad	le to the 1s	st	
dose (from	dose (from $0-\tau$) then the profile time should reflect this e.g. if last dose is at 32 h and the 1st dosing									
interval (*	τ) is 5 h th	en the pro	ofile time	should be	equal to 3	7 h.				

Predicted	summary (1st and last	t dose)
Time	Dose 1	Time	Last Dose
0.000	0.000	0.000	6.215
1.000	28.178	1.000	33.273
2.000	33.437	2.000	37.612
3.000	31.189	3.000	34.612
4.000	26.938	4.000	29.744
5.000	22.571	5.000	24.871
6.000	18.670	6.000	20.555
7.000	15.355	7.000	16.901
8.000	12.598	8.000	13.864
9.000	10.324	9.000	11.362
10.000	8.456	10.000	9.307
11.000	6.924	11.000	7.622
12.000	5.670	12.000	6.241

K	L	М	N
Fitted Line d	ata for	<u>Time</u>	Pts. for t½
t _{1/2} based on	Dose 1	6.00	18.71817
(Cell Q3).		7.00	15.34323
		8.00	12.57681
		9.00	10.30918
		10.00	8.45041
		11.00	6.92678
		12.00	5.67786

34		Predicted	profile valu	les								
35	Time	Dose1	Dose2	Dose3	Dose4	Dose5	Dose6	Dose7	Dose8	Dose9	Dose10	Total
36	0.000	0.000										0.000
37	0.010	0.282										0.282
38	0.020	0.564										0.564
39	0.030	0.845										0.845
40	0.040	1.127										1.127
41	0.050	1.409										1.409
13231	131.950	0.000	0.000	0.000	0.000	0.000	0.000	0.002	0.048	0.527	5.732	6.310
13232	131.960	0.000	0.000	0.000	0.000	0.000	0.000	0.002	0.048	0.526	5.720	6.296
13233	131.970	0.000	0.000	0.000	0.000	0.000	0.000	0.002	0.048	0.525	5.707	6.282
13234	131.980	0.000	0.000	0.000	0.000	0.000	0.000	0.002	0.048	0.524	5.695	6.269
13235	131.990	0.000	0.000	0.000	0.000	0.000	0.000	0.002	0.048	0.523	5.682	6.255
13236	132.000	0.000	0.000	0.000	0.000	0.000	0.000	0.002	0.048	0.522	5.670	6.241
13237												



Example 2; the same set of concentration time data was used as for Example 1, however this time different doses were used just to demonstrate its versatility. Note that each dose (shown in Figure 47) is compared to the original data dose (cell B3) and the concentrations adjusted automatically for this scenario. All of the output both numerical and pictorial will automatically update in the spreadsheet on completion of the run. The graphic output from this run is shown in Figure 48 for information.

Figure 47: Example 2 setu	o parameters showing	different doses and intervals.
---------------------------	----------------------	--------------------------------

Р	Q	R	S	Т	U	V	W	Х	Y	Z
	1st dose (al	lways zero t	ime)							
Intervals =	0.0	12.0	16.0	12.0	12.0	16.0	12.0	16.0	12.0	12.0
Dose =	100.0	75.0	75.0	100.0	100.0	75.0	75.0	100.0	100.0	100.0
Information only (updated automatically)										
Dose time	0.0	12.0	28.0	40.0	52.0	68.0	80.0	96.0	108.0	120.0
Dose no.	1	2	3	4	5	6	7	8	9	10
C _{min}	5.67	2.16	4.45	6.08	2.81	4.51	2.11	5.86	6.21	6.24
C _{max}	33.44	28.89	26.53	36.43	37.52	26.97	28.11	34.85	37.38	37.61
AUC _{0-τ}	217.47	202.17	172.95	237.80	262.42	175.95	196.58	227.10	244.25	245.83




3.6 Deconvolution

The deconvolution method in PCModfit for oral data has been completely rewritten and now uses a Loo-Riegelman approach (Ref. J. Pharm. Sci., 57:918, 1968) with modified equations by Wagner (Ref. J. Pharm. Sci., Vol. 72, No. 7, July 1983) both of which require intravenous parameters to be available. One of the primary reasons for conducting Deconvolution is to gain an estimate of a drug input rate which can be very useful when comparing different formulations for oral administration or in inhalation studies in addition to other dosing routes. For information, the pictorial model (3 compartment oral) and equations used in PCModfit are shown for 1, 2 and 3 compartment oral models to indicate the transfer rate parameters.



1-compartment: $A_T/V_p = C_T + k_{10} \int_0^T Cdt$ 2-compartment: $A_T/V_p = C_T + k_{10} \int_0^T Cdt + k_{12} e^{-k_{21}T} \int_0^T Ce^{k_{21}t} dt$ 3-compartment: $A_T/V_p = C_T + k_{10} \int_0^T Cdt + k_{12} e^{-k_{21}T} \int_0^T Ce^{k_{21}t} dt + k_{13} e^{-k_{31}T} \int_0^T Ce^{k_{31}t} dt$

where:

 C_T is the concentration at time T, A_T is the amount of drug absorbed from time 0 to T (sampling time) and V_p the volume of the central compartment. For the analyses, the volume term is not required; just the rate constants as shown in the spreadsheet options.

The functions contain various integration steps and for all of these the appropriate AUC values are calculated using methods wherein; ascending values are analysed using linear trapezoidal and descending values with logarithmic trapezoidal approach to try and minimise the summation errors.

The procedure ('LR Deconvolution' sheet in PCModfit) will, depending on the model chosen, estimate either the <u>% Absorbed</u> or <u>% Remaining to be absorbed</u> of a drug vs. <u>Time</u> data. The data results and plots produced can be utilised to estimate absorption rates (k_a values) either by simple regression on '% Remaining *vs*. Time' data or by an increasing exponential function for the '% Absorbed *vs*. Time'. The procedure is relatively easy to execute with all calculations conducted in Excel[®] for ease of use. In the examples below, the LR Deconvolution routine was run using sets of simulated oral data exhibiting 1, 2 and 3-compartment kinetics, all with known i.v. parameters. The oral data were generated using the 'SD Simulator' option with the parameters shown in the following Tables.

Note that there is a <u>% Cut-off</u> value which can be varied by the user depending on the data sets. Specifying a value too low can cause error accumulation at later time points due to the nature of the functions so a value around 1-10 % usually works ok. Another reason for a defining a Cut-off setting is the fact that at later time points, for most profiles, the absorption would be complete so the later values would be essentially redundant. During the analysis, the picture in the spreadsheet (containing the Deconvolution profile) will automatically update and a high-quality graphic file will be created in directory C:\PCModfit Vx.x\Results\ (x.x being the version number) with names such as LR3.PNG or LR15.PNG which can be used in other documents. In

addition to the text file output, the deconvoluted data can be copied into the clipboard for pasting into other documents.

As an estimate of k_a is often required, the following examples for all models (1, 2 and 3 compartment) show both % Remaining and % Absorbed approaches with a 1 % Cut-off level together with the input parameters required for the analyses. The 3-sets of oral data are shown in Figure 49 together with the parameters used to generate the oral data (utilising the 'SD Simulator' option in the program).

	Concentratio	on-time data for 1	, 2 and 3-compartment	oral profiles	
Time	1-Compartment	Time	2-Compartment	Time	3-Compartment
0	0.0	0	0.0	0.0	0.000
0.1	13.5782	0.05	6.9582	0.05	9.1404
0.2	24.6029	0.10	12.9117	0.10	16.7126
0.3	33.4620	0.15	17.9702	0.20	27.9573
0.4	40.4879	0.25	25.7880	0.25	31.9732
0.5	45.9651	0.50	35.5163	0.50	41.1683
1.0	57.5101	0.75	36.7513	0.75	40.1184
1.5	55.0451	1.0	33.8825	1.0	35.1676
2.0	47.7139	2.0	16.1379	2.0	16.0230
3.0	31.8032	3.0	6.6452	3.0	8.9043
4.0	19.9285	4.0	3.2592	4.0	6.8564
5.0	12.2298	6.0	1.7742	5.0	6.1221
6.0	7.4495	8.0	1.4781	6.0	5.6942
8.0	2.7464	12.0	1.1342	8.0	5.0330
10.0	1.0106	16.0	0.8740	10.0	4.4698
12.0	0.3718	20.0	0.6735	12.0	3.9782
Dose	1000	24.0	0.5190	16.0	3.1707
V	10	30.0	0.3510	20.0	2.5477
k _a	1.5	36.0	0.2375	24.0	2.0634
k ₁₀	0.50	40.0	0.1830	30.0	1.5251
		48.0	0.1087	36.0	1.1447
		Dose	1000	40.0	0.9527
		V	10	48.0	0.6705
		k _a	1.5	60.0	0.4085
		k 10	1.0	72.0	0.2555
		k 12	0.5	84.0	0.1625
		k ₂₁	0.1	96.0	0.1044
				108.0	0.0675
				112.0	0.0584
				116.0	0.0506
				120.0	0.0438
				Dose	1000
				V	10
				k _a	2.0
				k 10	0.5
				k ₁₂	1.0
				k ₂₁	0.2
				k 13	0.1
				k 31	0.05

Figure 49: Example profiles of oral data for Deconvolution analysis (parameters included)

<u>Note</u>: the parameters (obtained from i.v. data) below each data set were used to generate the oral profiles shown here. The parameters in 'Blue' will be the ones required for running the program.

Specifically, the steps required to perform a Deconvolution analysis are detailed as follows for the 2-compartment data although the results are also presented for all 3 profiles shown later in this Section.

<u>Step 1</u>

Enter the data and parameters for a particular model, in this example a 2-compartment, into the spreadsheet shown in Figure 50 (although many profiles can be analysed in one batch, the number of compartments must be the same for each run as the 'Options' section requires a single model to be defined, shown in Figure 51). Note that the oral profile requires $AUC_{0-\infty}$ so the correct calculations can be expedited. This can be easily conducted using the NCA option within the program. For information, the points used for the oral NCA are shown below which yielded values for $AUC_{0-\infty}$ and λ_z of 99.2555 and 0.065153, respectively, for n=4 points.

Enter the or	ral AUC₀-∞ va	lues from NCA				N	CA ana	alysis fo	or AUC ₀	<u>-∞</u>	
	AUC₀-∞	99.2555		1	00 -	Compts.2 λz	= -0.06515	$t_{2}^{1/2} = 10.$	$64 R^2 = 1$.000	
		V 1		_							
	(k10)	1.00									
	(k12)	0.50	í	Î Î	10						
	(k21)	0.10	1	۳/g/		•					
	(k13)			n) -:							
	(k31)				1		•				
								•••			
Oral Data	Time	Compts.2				-			•		
	0	0.0		0).1	ļ,					***** •
	0.05	6.9582				0 10)	20	30	40	50
	0.10	12.9117							Time (h)	
	0.15	17.9702			_						-
	0.25	25.7880				<u>NCA</u>	Pro	file		Compts.2	
	0.50	35.5163				Results	AU	C time	range	0 to 48	
	0.75	36.7513					Tm	ax		0.75	
	1.00	33.8825					Cm	ax		36.75	
	2.00	16.1379					Lin	AUC		99.8994	
	3.00	6.6452					Log	AUC		97.4765	
	4.00	3.2592					Lin	Log Al	JC	97.5879	
	6.00	1.7742					AU	MC		559.6810	
	8.00	1.4781					AU	MC∞		665.3225	
	12.00	1.1342					λz			0.065153	
	16.00	0.8740					t ¹ /2	AUG		10.64	
	20.00	0.6735						AUC∞		101.5670	
	24.00	0.5190				Value used	Log			99.1442	
	30.00	0.3510				value used	Lin/	LOG A	U €∞	77.2555	
	36.00	0.2375					K ²	, n	41 /	1.0000	
	40.00	0.1830					No.	pts. for	• t ¹ /2	4	
	48.00	0.1087					No.	pts. (to	tal)	21	

Figure 50: PCModfit input for a 2-compt. model data set (with NCA results for estimating AUC_{0-x})

Step 2

After entering the data as outlined in Step 1, the Options section in the spreadsheet (Figure 51) will require populating by clicking the appropriate Check Boxes to define the type of analysis, model, data layout and entering a % Cut-off value (recommend 1 to 10 %).

Figure 51: Example LR analysis (input and options)

<u>Options</u>		<u>Select</u>	<u>Model</u>				<u>Select</u>
% Absorbed		~	1-compartm	nent i.v. bolu	ıs (k ₁₀)		
% Remaining to be abs	orbed		2-compartm	ent i.v. bolu	ıs (k ₁₀ , k ₁₂ , k	(₂₁)	~
			3-compartm	ent i.v. bolu	ıs (k ₁₀ , k ₁₂ , k	(₂₁ , k ₁₃ , k ₃₁)	
% Cut off (reduce po	st absorptio	on errors)	Data lay	<u>out</u>			
(usually 10 to 30 %)		1.00	Time, Co	nc., Conc., (Conc. etc. (u	sual)	
			Time, Co	nc., Time, C	Conc., etc.		~
			Time, Co	ne., 1 line, e	one., etc.		-

Once this is setup, click the 'Run' button and the graph will be updated (Figure 52). Then click 'Next' to finish or to continue with the next profile. At the end, click 'Next' again to ensure a small Window pops-up (similar to the one below) to indicate that the program has finished and to show where the generated files are stored.



Figure 52: Example graphic output (% Absorbed) for 2-compartment oral data



The shortcut button 'Row 148' will scroll down to display the results (in column E onwards) and these can be copied for use to either estimate k_a values or to use in other documents. If a result is required for % Remaining instead of % Absorbed, then simply select this option and repeat 'Run'.

The set of results for the 3-profiles in these example sets, shown in Figure 49, using both types of analysis are displayed in Figure 53 using a 1 % Cut-off value to reduce later time point cumulative errors post-absorption.

Figure 53: Both types of Deconvoluted results from 1, 2 and 3-compartment oral data (1 % cut off)

	1-co	mpt. data			2-coi	npt. data		3-compt. data				
Time	Conc.	%Abs	%Rem	Time	Conc.	%Abs	%Rem	Time	Conc.	%Abs	%Rem	
0	0.0	0	100.0	0	0.0	0	100.0	0.0	0.0	0	100.0	
0.1	13.5782	14.05	85.950	0.05	6.9582	7.273	92.727	0.05	9.1404	9.511	90.489	
0.2	24.6029	26.14	73.857	0.10	12.9117	14.021	85.979	0.10	16.7126	18.117	81.883	
0.3	33.4620	36.55	63.449	0.15	17.9702	20.282	79.718	0.20	27.9573	32.908	67.092	
0.4	40.4879	45.51	54.490	0.25	25.7880	31.453	68.547	0.25	31.9732	39.286	60.714	
0.5	45.9651	53.22	46.778	0.50	35.5163	52.750	47.250	0.50	41.1683	62.695	37.305	
1.0	57.5101	77.93	22.067	0.75	36.7513	67.453	32.547	0.75	40.1184	76.989	23.011	
1.5	55.0451	89.65	10.354	1.0	33.8825	77.597	22.403	1.0	35.1676	85.708	14.292	
2.0	47.7139	95.19	4.810	2.0	16.1379	93.880	6.120	2.0	16.0230	97.199	2.801	
3.0	31.8032	98.93	1.075	3.0	6.6452	97.888	2.112					
				4.0	3.2592	98.967	1.033					

% Abs% Absorbed% Rem% Remaining to be absorbed

Figure 54: Deconvoluted graphic results from 1, 2 and 3-compartment oral data (1 % cut off)



<u>Step 3</u>

To obtain estimates of the absorption parameter (k_a) for each of the 3-profiles, two approaches can be used depending on how good the results are and a summary of both types for these examples are presented together in Figure 55.

	1-co	ompt. data			2-con	npt. data			3-con	ıpt. data	
Time	Conc.	%Abs	%Rem	Time	Conc.	%Abs	%Rem	Time	Conc.	%Abs	%Rem
0	0.0	0	100.0	0	0.0	0	100.0	0.0	0.0	0	100.0
0.1	13.5782	14.05	85.950	0.05	6.9582	7.273	92.727	0.05	9.1404	9.511	90.489
0.2	24.6029	26.14	73.857	0.10	12.9117	14.021	85.979	0.10	16.7126	18.117	81.883
0.3	33.4620	36.55	63.449	0.15	17.9702	20.282	79.718	0.20	27.9573	32.908	67.092
0.4	40.4879	45.51	54.490	0.25	25.7880	31.453	68.547	0.25	31.9732	39.286	60.714
0.5	45.9651	53.22	46.778	0.50	35.5163	52.750	47.250	0.50	41.1683	62.695	37.305
1.0	57.5101	77.93	22.067	0.75	36.7513	67.453	32.547	0.75	40.1184	76.989	23.011
1.5	55.0451	89.65	10.354	1.0	33.8825	77.597	22.403	1.0	35.1676	85.708	14.292
2.0	47.7139	95.19	4.810	2.0	16.1379	93.880	6.120	2.0	16.0230	97.199	2.801
3.0	31.8032	98.93	1.075	3.0	6.6452	97.888	2.112				
				4.0	3.2592	98.967	1.033				
Analy	ysis type	Modelling	<u>NCA</u>	Anal	<u>ysis type</u>	Modelling	<u>NCA</u>	Analy	z <mark>sis type</mark>	Modelling	<u>NCA</u>
k _a De	econv.	1.517	1.512	k _a Deconv.		1.520	1.495	k _a De	conv.	2.017	1.946
k _a Tł	neory	1.	50	k _a Theory		1.50		k _a Theory		2.00	
No. j	ots.	10	10	No. j	pts.	11	8	No. p	ts.	9	8

Figure 55: Results of k_a estimates from %Absorbed and %Remaining data

3.7 Time above an MIC option

There are occasions when it is useful to gain an estimate of time and/or AUC of a profile above a certain concentration (e.g., MIC level) that are typically used for drugs that are antibiotic and antifungal in nature. The PCModfit spreadsheet option 'Time above', will allow users to conduct this sort of analysis easily and quickly. As an example, 7 different sets of data were analysed (2 doses over a 24 h time period) to gain an estimate of time and exposure above a MIC value of 150 ng/mL across the complete profiles. The data used for the analysis are shown in Figure 56 with the results and a graphical representation of the analysis depicted in Figure 57. These were copied from the 'Time above' spreadsheet in PCModfit and note that there is now an additional option in V7.1 onwards that allows the user to enter data in 2 different ways by the appropriate CheckBox selection before clicking the 'Run' button. V7.2 onwards now allows axis titles and legends to be added before running.

- 1. The same nominal time for all data sets (select 'Time, Conc., Conc., Conc'. etc.) as used in this example.
- 2. Different time values for each data set (select 'Time, Conc., Time, Conc.' etc.) as is often encountered in Phase II studies (brief layout also shown below the time values are the same as shown in this example but can be different if required).

Time (h)	Set1	Set2	Set3	Set4	Set5	Set6	Set7
0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
0.25	107.77	150.88	106.69	130.40	85.14	94.84	129.32
0.5	186.44	208.82	229.32	165.93	261.02	193.90	124.92
0.75	242.71	157.76	242.71	245.14	179.61	281.55	235.43
1	281.78	318.41	388.86	180.34	211.34	231.06	315.60
1.25	307.69	396.91	421.53	338.45	341.53	295.38	276.92
1.5	323.56	326.79	449.74	236.20	310.61	407.68	430.33
1.75	331.82	252.18	451.28	434.69	391.55	438.00	401.50
2	334.37	270.84	224.02	234.06	347.74	384.52	431.33
3	311.89	230.80	308.77	324.37	277.58	361.79	233.92
4	269.38	358.28	180.49	323.26	164.32	226.28	355.59
6	186.70	112.02	160.56	153.09	175.50	248.31	261.38
8	125.98	148.65	163.77	152.43	129.76	122.20	100.78
10	84.56	96.39	104.00	81.17	62.57	74.41	104.00
12	56.70	56.70	53.29	78.24	47.62	73.14	34.02
14	372.37	361.20	338.86	484.08	472.91	312.79	502.70
16	294.86	386.27	191.66	188.71	380.37	271.27	244.73
18	203.77	167.09	283.25	132.45	144.68	181.36	197.66
20	137.42	115.44	83.83	177.28	167.66	185.52	170.40
22	92.23	112.52	58.10	75.63	65.48	75.63	81.16
24	61.84	43.29	76.06	51.33	47.62	82.24	56.89

Figure 56: Example time-concentration data (ng/mL) sets used for analysis (n=7)

or

Time (h)	Set1	Time (h)	Set2	Time (h)	Set3	etc.	
0	0.0	0	0.0	0	0.0		
0.25	107.77	0.25	150.88	0.25	106.69		
0.5	186.44	0.5	208.82	0.5	229.32		
0.75	242.71	0.75	157.76	0.75	242.71		
1	281.78	1	318.41	1	388.86		
etc.							

Figure 57: Time and exposure results and graph

	No. Profiles found =	7												
Profile Ref.	Set1	Set2	Set3	Set4	Set5	Set6	Set7	Min.	Max.	Mean	GMean	Median	SD	CV
No. pts. at or above MIC	13	13	14	14	13	14	13	13	14	13	13	13	1	4
Time at or above MIC	13.9	11.5	14.8	14.5	14.1	15.2	14.8	11.5	15.2	14.1	14.0	14.5	1.2	8.7
AUC _{0-t} values	4541.4	4546.3	4242.8	4485.8	4527.3	4598.6	4965.9	4242.8	4965.9	4558.3	4554.1	4541.4	213.7	4.7
AUC above MIC	1472.2	1479.9	1225.6	1367.9	1546.4	1507.2	1909.7	1225.6	1909.7	1501.3	1489.4	1479.9	209.8	14.0
No. pts. in data set	21.0	21.0	21.0	21.0	21.0	21.0	21.0	21.0	21.0	21.0	21.0	21.0	0.0	0.0
C _{max} /MIC	2.48	2.65	3.01	3.23	3.2	2.9	3.4	2.5	3.4	3.0	3.0	3.0	0.3	10.6
Last time pt. found	24.0	24.0	24.0	24.0	24.0	24.0	24.0	24.0	24.0	24.0	24.0	24.0	0.0	0.0

Notes: AUC values are calculated using the linear trapezoidal method.

MIC concentration must be in the same units as the concentration values.



3.8 Compartmental analysis (principles and modelling data)

There are occasions when compartmental analysis of data sets is desirable to gain a further understanding of the pharmacokinetics of a particular drug and to then conduct predictions under various conditions. The concept of compartments has been around for many years and essentially considers a biological system to be made up of hypothetical regions or compartments. As an example, a biological entity (human, rodent etc.) could contain one or more compartments (numbered accordingly) such as the Gut (0), blood (1), highly perfused tissues (2) and poorly perfused tissues (3) with sometimes additional ones depending on the drug behaviour. These compartments are not isolated or simply enclosed systems (as portrayed in the pictures below) but rather the drug being investigated may happily transfer between compartments and indeed 'leak' into other areas of the body thus making for an overall dynamic process and not a static one. Compartmental analysis (with all of its mathematical intricacies and nuances) can be considered an approximation into the biological fate of a particular drug. It can be particularly helpful in trying to decipher the what the drug and/or metabolites are doing mathematically in a biological system and potentially, how long it resides in a particular region or compartment. Simplistically, the following pictures represent a few different scenarios to help any naïve reader understand the basic concepts. The parameters such as ka, k12 etc., are mathematical transfer rates of drug molecules moving from one compartment to another over various time periods.



2-compt. oral (3-exponentials). Dose administered into compartment 0.

3-compt. oral (4-exponentials). Dose administered into compartment 0.



Intravenous 2-compt. (2 exponentials) and 3-compt. (3-exponentials). Doses administered into compartment 1.

	k12		
Blood (1)	→ ←	Tissue (2)	
k10	k21		
Waste			



3.8.1 Control data set up and initialisation

In the 'Modelling' spreadsheet (Row 18) and in Figure 58 there is a description of the Keywords that can be used for Control initiation. To make life easier for the user, select the requirements for a fitting run first, then click the 'Keywords' button to show what the layout should be e.g.,

	<u>Algorithm</u>	W	eighting	<u>Pr</u>	ofile type	<u>No. of Profiles</u>	<u>No. poin</u>	ts for fitted line
	DFP (WLS)		1/Conc		Single dose	2 -		200
✓	Marquardt (IRWLS)	~	1/Conc ²		Repeat dose			500
	Simplex (WLS)		Unweighted		Repeat dose	No. of Doses	~	1000
	Simplex (IRWLS)				Mixed models	5 -		5000
								10000
	Parameters	Co	<u>nstraints</u>		<u>Data layout</u>	-	Useful for	r profiles with
	Computer estimates		Yes		Time conc time	e conc	long time	s (500 to 1000
	User estimates	~	No	~	Time conc conc	с	is usual b	ut is dependent
							on profile	time and shape).
	<u>Plotting</u>	Mod	<u>el number</u>	<u>Graph</u>	axis titles (upda	<u>ated at Run time)</u>	RD bolus	may need 5000
~	Yes		10 -	X-axis	Time (h)		or more.	
	No	Only use Repeat do	ed for Single or ose (not Mixed)	Y-axis	Conc. (µg/mL)		Select be	fore running.

For this example, clicking the Keywords button (on row 52 of the Sheet) will generate a layout as follows. Then enter your own values into the cells as shown for this example. Once the setup values have been entered, click the 'Activate' button which stores the information ready for running after the concentration-time data have been added.

'Keywords' output	User entered	<u>d values</u>	
Title	Title	Vol_1	Vol_2
Dose	Dose	0.0	0.0
Ndoses	Ndoses	5	5
Pars V _{po}	Pars V _{po}	32.000	32.000
ka	k _a	0.800	0.800
k ₁₂	k ₁₂	0.020	0.020
k ₂₁	k ₂₁	0.025	0.025
k ₁₀	k ₁₀	0.040	0.040
Doseint	Doseint	24.000	24.000
		36.0	36.0
		24.0	24.0
		24.0	24.0
Repdose	Repdose	1000.0	1000.0
		1000.0	1000.0
		1000.0	1000.0
		1000.0	1000.0
		1000.0	1000.0

For information, all the Keywords are shown as follows for information.

Keywords for single dose profiles

Title	Each profile should have a title	Compulsory (will be added if absent)
Dose	Dose of drug (careful with units)	Compulsory (oral or bolus only. Zero if infusion)
Ndoses	Number of doses given	Compulsory but updated automatically to 1
Pars	Model parameters (in sequence)	Optional (some models generate starting parameters)
Inftime	Infusion time	Compulsory (infusion models only)
Infrate	Infusion rate	Compulsory (infusion models only)
Infbol	Bolus dose for bolus + infusion only	Compulsory (bolus dose for bolus + infusion models)
Conmin	Minimum parameter value	Optional
Conmax	Maximum parameter value	Optional

Keywords for repeat dose profiles

Example model no. for each dose (for Mixed models only). Not used for Single or Repeat dose only

Model					
number for	16	10	16	10	16
each dose.					

Title	Each profile should have a title	Compulsory (will be added if absent)
Dose	Not used but must be present	Compulsory (0.0 will be added automatically)
Ndoses	Number of doses given	Compulsory
Pars	Parameters	Compulsory
Doseint	Dosing interval (1 less than Ndoses)	Compulsory (1st dose starts at time 0.0)
Inftime	Infusion time	Compulsory (infusion models)
Infrate	Infusion rate	Compulsory (infusion models)
Infbol	Bolus dose for bolus + infusion only	Compulsory (bolus dose for bolus + infusion models)
Repdose	Dose for each interval	Compulsory (oral or bolus without infusion)
Conmin	Minimum parameter value	Optional
Conmax	Maximum parameter value	Optional

In Figure 59 there are several examples of single dose scenarios and how to set up the Control layout prior to modelling data to help the user. The Control data must be entered into the 'Modelling' spreadsheet starting at Row 54.

Contro	l layout	Model description	Comments
Title Dose Inftime Infrate	Subject_1 0 4 100	Model 19: infusion 3-compartment, single dose with program starting estimates.	In this case, the Dose will be zero but calculated in PCModfit from the infusion time and rate. Subject_1 can be changed to the user requirement; without spaces e.g., Sub1, Vol1 etc.
Title Dose	Vol_1 10	Model 10: oral 2-compartment, single dose with program starting estimates.	Dose as 10 units. Be cautious with units e.g., use mg if the Vol. is in L so the output will be in μ g/mL.
Title Dose Pars	Vol-1 100 8 1.2 0.08 0.8	Model 7: oral 1-compartment with lag-time, single dose with user starting estimates (sequence: V, k_a , k_{10} , t_{lag}) lag-time is t_{lag} .	Pars is the keyword for user parameters.
Title Dose Pars	Ref:1 0 24 1.0 0.12 0.06 0.04 1.30	Model 19: infusion 3-compartment, single dose with user starting estimates (sequence: V, k_{12} , k_{21} , k_{13} , k_{31} , k_{10} .	In this case, the Dose will be zero but calculated in PCModfit from the infusion time and rate. The parameters must be entered in sequence.
Inftime Infrate	5 20		
Title Dose Pars Inftime Infrate	\$99 0 12 1.0 0.12 0.06 0.04 1.30 5 20	Model 19: infusion 3-compartment, single dose with user starting estimates (sequence: V, k_{12} , k_{21} , k_{13} , k_{31} , k_{10} . Same as above except; see Comments to the right.	In this case, constraints have been used such that 5-parameters $(k_{12}, k_{21}, k_{13}, k_{31}, k_{10})$ will be fixed during the modelling process whereas, the volume term V, will be allowed to change within the limits 0.5 to 100. When a parameter has both constraints equal to the parameter it will not be used in the fitting as in this example. This facility is sometimes useful but
Conmin	$\begin{array}{c} 0.5 \\ 1.0 \\ 0.12 \\ 0.06 \\ 0.04 \\ 1.30 \\ 100 \\ 1.0 \\ 0.12 \\ 0.06 \\ 0.04 \\ 1.30 \end{array}$		will only work properly when iteratively reweighted least squares (IRWLS, Marquardt) is selected at run-time.

Figure 60:	Examples of	Control layout f	for repeat dose	scenarios
------------	-------------	-------------------------	-----------------	-----------

Control	l layout	Model description	Comments
Title	Vol25	Model 8: oral 1-compartment without lag-time,	In this case, Dose is zero because the
Dose	0	repeat dose with user starting estimates because	dose for each administration is picked
Ndoses	5	program starting estimates are not allowed for	from the 'Repdose' keyword. The
Pars	20	repeat dose scenarios (sequence: V, k _a , k ₁₀). This	dosing interval is defined in the
	1.2	example shows how a regimen with different	'Doseint' keyword and please note that
	0.08	doses and dosing intervals can be created for	this will have one less value than the
Doseint	24	modelling.	number of doses ('Ndoses') as the first
	16		dose is assumed to be at time zero.
	24		
	18		
Repdose	100		
	80		
	90		
	100		
	100		
Title	Vol25	Model 17: infusion 2-compartment, repeat dose	In this case, Dose is zero because the
Dose	0	(n=4) with user starting estimates because	dose for each administration is picked
Ndoses	4	program starting estimates are not allowed for	from the 'Inftime' and 'Infrate'
Pars	12.0	repeat dose scenarios (sequence: V, k ₁₂ , k ₂₁ , k ₁₀).	keywords. The dosing interval is
	0.3	This example shows how a regimen with different	defined in the 'Doseint' keyword and
	0.1	infusion times, rates and dosing intervals can be	please note that this will have one less
	0.4	created for modelling.	value than the number of doses
Doseint	24.0		('Ndoses') as the first dose is assumed
	36.0		to be at time zero.
	24.0		Please note how the infusion time and
Inftime	10.0		rate are laid out for each dose. These
	8.0		must be entered in the order they are
	10.0		given.
	20.0		
Infrate	100.0		
	125.0		
	100.0		
	50.0		

3.8.2 Concentration-time data layout for modelling

The concentration-time data can be entered into the 'Modelling' spreadsheet starting at Row 154. There are two options for data layout both in columns, namely, Time-Conc-Conc or if they were different times, as for Vol.2, then Time-Conc-Time-Conc the same as the NCA option (Section 3.1). An example of each layout is shown below in Figure 61.

Time	Vol.1	Vol.2		Time	Vol.1	Time	Vol.2
0	-	-	or	0	-	0	-
1.0	1.26	0.623		1.0	1.26	1.1	0.623
2.0	2.02	1.18		2.0	2.02	1.9	1.18
4.0	4.09	2.72		4.0	4.09	4.2	2.72
4.50	4.29	2.25		4.50	4.29	4.4	2.25
5.0	2.76	1.44		5.0	2.76	5.0	1.44
6.0	1.27	1.1		6.0	1.27	6.0	1.1
7.0	0.87	0.786		7.0	0.87	7.0	0.786
8.0	0.99	0.733		8.0	0.99	8.1	0.733
12.0	1.0	0.465		12.0	1.0	12.0	0.465
24.0	0.43	0.201		24.0	0.43	24.5	0.201

There is one further alternative for layout of concentration-time data modelling; if for example, more than a single subject was to be modelled within the same run, Figure 62 shows a typical layout. When the fitting process is initiated, the data shown (Vol.1 &Vol.2) will be treated as 1-profile and the Control data should also depict a single subject. This can be useful when there are data available for say, 10 volunteers and all of these are to be analysed in one go, so an overall picture of data and modelled line can be generated.

Note: if there are zero values within the combined data set then just leave these cells blank, as shown or the weighting scheme may bias the result.

Time	Vol.1 & 2
0	-
1.0	1.26
2.0	2.02
4.0	4.09
4.50	4.29
5.0	2.76
6.0	1.27
7.0	0.87
8.0	0.99
12.0	1.0
24.0	0.43
0	-
1.0	0.623
2.0	1.18
4.0	2.72
4.50	2.25
5.0	1.44
6.0	1.1
7.0	0.786
8.0	0.733
12.0	0.465
24.0	0.201

Figure 62: Data layout for analysing more than 1 profile in a single run.

When the fitting process has been started, summary progress will be shown in a Window (like the one below) at the top left of the screen.

	PCModfit (Output					_		×
Fitting using file C:\PCModfit V6\adata.txt									
	Subject	_1							
	Iter	SOS	1	2	3	4	5	6	
	0	0.917638E-01	18.8	0.534	0.464	0.123E-01	0.793E-02	0.110E-0	91
	1	0.228987E-01	10.5	1.75	0.665	0.292E-01	0.919E-02	0.200E-0	91
	2	0.228987E-01	10.5	1.75	0.665	0.292E-01	0.919E-02	0.200E-0	91
	3	0.228987E-01	10.5	1.75	0.665	0.292E-01	0.919E-02	0.200E-0	91
									~
<									>:

If plotting was selected, then the Charts in the spreadsheet will be updated with the data and modelled line.

The information described in this section outlines what to expect when modelling concentration-time data. Please appreciate though, as for other modelling software, that if the data are rubbish to start with, so too will be the modelling results! One important factor to note concerns the number of data points. If for example the chosen model has 8 parameters, then the number of points will need to be significantly greater than 8 and realistically, may require 16-20 points as not all phases (or compartments) will be adequately defined and the parameter errors could well be much higher than the parameter values themselves; thus, indicating that the model is either over-defined or the data are inadequate.

Regarding the choice of algorithm, it is sometimes pertinent to try out more than one approach with different weighting schemes due to the varying nature of the profiles; these can be quite different even between data sets

within the same study. As a rough guide, weighting as $1/\hat{C}^2$ (IRWLS) or $1/C^2$ (WLS) will tend to emphasise the lower values whereas unweighted will 'home in' to the higher values. A weighting of $1/\hat{C}$ or 1/C is a compromise and tends to emphasise the middle concentrations which can be useful for some types of profile and can minimise bias towards the extreme values.

For the modelling of data using PCModfit, besides unweighted, there are two additional options for helping with the type of weighting scheme; Weighted Least Squares (WLS) or Iteratively Reweighted Least Squares (IRWLS). The best choice can only be made by trying both types as each profile could be very different to others in the same group. The WLS uses the actual data points for the weighting whereas, the IRWLS will make use of the predicted values at each time point which will change throughout the run. There are occasions when one or more points visually seem to be 'outliers' and for these situations the IRWLS may be the best option as it can, but not always, show less bias towards the aberrant values.

The results generated from a modelling process, should be examined in detail to try, and help the user decide if the answers are meaningful; or not! If, for example, the curve through the data visually appears acceptable, it doesn't necessarily mean that the final parameters are valid. The percentage errors on the parameters are important and, for example, if one or more values are showing errors as 300 %, the probability is, that there is no confidence in the variable so using it elsewhere for further work, should be conducted with caution. As a specific example, consider the fictitious results from modelling a 1-compartment oral profile data set with parameters and errors shown below.

	V	ka	k ₁₀	t _{lag}
Subj.1	10.34	0.49	0.062	1.51
%Error	10.1	125.2	3.3	147.2

These results would indicate that there is considerable error in the parameters k_a (absorption rate) and t_{lag} (lagtime). Without scrutinising the profile, the results are suggesting that there may not be any, or a very limited number of data points during the absorption phase, hence the large errors. For this example, it might be more appropriate to use a similar model but without a lag-time parameter!

The next Section (3.9) has several examples of data layout and fitting output/results to help the user either 'try out' or to use as a basis for their own analysis of data sets.

Note that for all examples, from V7.5 onwards the summary Excel file will contain more information than shown below.

3.9 Compartmental analysis (Example data and results)

The itemised data sets were fitted using simulated data to demonstrate that the parameter results were very close to the theoretical values and to show the data layout, modelling settings and graphical output. For additional help with setting up the Control layout it is worth looking at the new Section 4.2.

3.9.1 3-exponential i.v. bolus repeat dose (Model 6).

V7.3 onwards allows repeat dose with polyexponential models 1 to 6.

	Data layout				Control layout						
Time	Subj.1	Subj.2	Subj.3	Subj.4	Subj.5	Title	Subj.1	Subj.2	Subj.3	Subj.4	Subj.5
0.0	100.0	104.0	96.0	103.0	97.0	Dose	0.00E+00	0.00E+00	0.00E+00	0.00E+00	0.00E+00
0.25	81.90877	81.90877	81.08969	86.00421	86.00421	Ndoses	5.00E+00	5.00E+00	5.00E+00	5.00E+00	5.00E+00
0.5	67.74115	66.38632	69.09597	68.41856	65.70891	Pars	7.50E+01	7.50E+01	7.50E+01	7.50E+01	7.50E+01
0.75	56.63104	56.63104	57.19735	57.19735	59.46259		8.00E-01	8.00E-01	8.00E-01	8.00E-01	8.00E-01
1	47.90392	45.50872	49.34103	46.46680	45.50872		1.20E+01	1.20E+01	1.20E+01	1.20E+01	1.20E+01
1.5	35.61327	37.03780	35.61327	36.32554	36.68167		1.50E-01	1.50E-01	1.50E-01	1.50E-01	1.50E-01
2	27.91175	26.51616	27.07439	28.74910	29.02822		4.00E+00	4.00E+00	4.00E+00	4.00E+00	4.00E+00
3	19.80408	19.20996	18.81388	20.59624	19.80408		1.00E-02	1.00E-02	1.00E-02	1.00E-02	1.00E-02
4	16.13566	15.65159	16.45837	15.49023	15.97430	Doseint	2.40E+01	2.40E+01	2.40E+01	2.40E+01	2.40E+01
5	14.16120	14.30282	14.44443	14.01959	14.58604		5.00E+01	5.00E+01	5.00E+01	5.00E+01	5.00E+01
6	12.86510	12.47915	12.22184	12.22184	13.50835		2.40E+01	2.40E+01	2.40E+01	2.40E+01	2.40E+01
8	11.02751	11.57889	11.24806	11.13779	10.69668		2.40E+01	2.40E+01	2.40E+01	2.40E+01	2.40E+01
12	8.45156	8.45156	8.53608	8.78962	8.62059	Repdose	1.00E+03	1.00E+03	1.00E+03	1.00E+03	1.00E+03
16	6.65922	6.65922	6.52603	6.39285	6.59262		1.00E+03	1.00E+03	1.00E+03	1.00E+03	1.00E+03
20	5.38164	5.43546	5.59691	5.22019	5.27401		5.00E+02	5.00E+02	5.00E+02	5.00E+02	5.00E+02
24	104.45470	101.32106	109.67743	105.49924	102.36560		1.00E+03	1.00E+03	1.00E+03	1.00E+03	1.00E+03
25	52.16785	54.77625	52.68953	52.68953	49.55946		1.00E+03	1.00E+03	1.00E+03	1.00E+03	1.00E+03
44	7.63972	7.56332	8.02171	7.48693	7.48693						
74	53.08783	53.61871	53.08783	55.21134	55.74222						
76	16.90697	17.75232	16.06162	16.56883	17.41418						
92	5.07956	5.28274	4.92717	4.87638	4.87638						
94	4.70168	4.70168	4.70168	4.79571	4.46660						
98	104.07983	109.28383	106.16143	107.20223	100.95744						
99	51.85094	49.77690	49.77690	49.25839	49.25839						
100	31.73353	31.09886	31.09886	30.46419	33.00287						
105	15.15802	14.40012	15.15802	15.46118	14.85486						
122	106.61466	103.41622	108.74695	106.61466	103.41622						
124	34.06484	33.38354	33.04289	35.08678	35.08678						
126	21.88193	21.00665	21.44429	21.88193	21.88193						
130	16.09078	16.89532	16.41260	16.57351	16.41260						
135	12.33408	12.95079	12.45742	12.82745	12.21074						
140	9.824984	9.62848	9.33373	9.72673	10.31623						
150	6.820056	6.95646	7.02466	6.47905	6.75186						
162	4.880039	5.07524	5.02644	4.78244	4.88004						
168	4.226501	4.01518	4.01518	4.39556	4.05744						
180	3.244545	3.40677	3.37433	3.17965	3.11476						
190	2.633991	2.55497	2.50229	2.58131	2.66033						
200	2.148283	2.083834	2.148283	2.083834	2.234214						
210	1./00801	1.843023	1.703136	1.843623	1.755851						
224 249	1.323/08	1.339020	1.299255	1.299253	1.312311						
240 260	0.620041	0.620241	0.630442	0.620041	0.793440						
240 260	0.620041	0.628241	0.630442	0.677292	0.793440						

1.5 is the correct time but previous manuals stated 2 which was an error.

Summary Results (stored in Excel file automatically)

Date	22/12/2022 19:17
Algorithm	Marquardt (IRWLS)
Weighting	1/Conc2
Model	6

Parameter	Pars A	λ1	В	λ_2	С	λ3	Akaike	Sos
Subj.1	79.99997	1.00000	15.00002	0.10000	5.00001	0.02000	-1139.35430	0.00000
%Error	0.00	0.00	0.00	0.00	0.00	0.00		
Subj.2	81.20399	1.01068	14.60025	0.09451	4.83280	0.01962	-117.94338	0.04533
%Error	1.85	2.94	4.27	6.02	5.48	2.33		
Subj.3	81.87724	1.02509	14.53135	0.09544	4.96638	0.02010	-130.15740	0.03389
%Error	1.60	2.53	3.71	5.24	4.68	1.96		
Subj.4	82.15728	1.02621	15.43145	0.09978	4.78457	0.01958	-128.54669	0.03521
%Error	1.65	2.63	3.77	5.05	4.54	1.97		
Subj.5	78.21083	0.99464	15.73731	0.10469	5.02496	0.02011	-123.56559	0.03965
%Error	1.81	2.96	4.28	5.50	4.59	1.96		
	The Par	ameter stats.	below will	be omitted	l for a sing	le profile		
Parameter stats.								
Mean	80.68986	1.01132	15.06008	0.09888	4.92175	0.01988		
Geom. Mean	80.67680	1.01124	15.05286	0.09882	4.92082	0.01988		
SD	1.61625	0.01430	0.52229	0.00408	0.10665	0.00026		
SEM	0.72281	0.00640	0.23358	0.00183	0.04770	0.00012		
%CV	2.00	1.41	3.47	4.13	2.17	1.32		

Result Plots (separately stored automatically and can be viewed within 'Modelling' spreadsheet) 10,000 points selected in Fitting to allow for rapid peaks. Subj. 1 and 5 shown for brevity.



Linear

Logarithmic

3.9.2 1-Compt. bolus (Model 11)

Data layout

Control lavou	t.
Control layou	J.

Time	Subj.1	Subj.2	Subj.3
0	4.8	5.3	4.85
0.125	5.019	5.1	5.019
0.25	4.938	5.1	4.987
0.5	5.02	4.8	4.828
0.75	4.96	4.7	4.671
1.0	4.86	5.00	4.71
2.0	4.43	4.66	4.43
4.0	3.97	4.26	4.18
6.0	3.67	3.82	3.78
8.0	3.18	3.18	3.29
10.0	3.06	2.91	3.03
12.0	2.77	2.66	2.63
16.0	2.31	2.29	2.34
24.0	1.431	1.4307	1.4759
36.0	0.827	0.8678	0.8678
48.0	0.467	0.4536	0.4581
60.0	0.256	0.2365	0.2564
72.0	0.137	0.1325	0.1434

Title	Subj.1	Subj.2	Subj.3
Dose	5.00E+02	5.00E+02	5.00E+02
Ndoses	1.00E+00	1.00E+00	1.00E+00

Date	22/12/2022 17:46						
Algorithm	Marquardt (IRWLS)						
Weighting	1/Conc2						
Model	11						
Parameter	Pars V _{iv}	k_{10}	Akaike	Sos			
Subj.1	100.45344	0.04974	-74.8031	0.012551			
%Error	0.83	0.61					
Subj.2	98.60480	0.05068	-64.6697	0.022038			
%Error	1.10	0.79					
Subj.3	100.88546	0.04928	-81.2097	0.008792			
%Error	0.70	0.51					
	The Parame	ter stats. b	elow will b	e omitted f	or a single	profile	
Parameter stats.							
Mean	99.98123	0.04990					
Geom. Mean	99.97632	0.04990					
SD	1.21144	0.00072					
SEM	0.69942	0.00041					
%CV	1.21	1.44					

Result Plots (separately stored automatically and can be viewed within 'Modelling' spreadsheet)



3.9.3 2-Compt. bolus (Model 12)

Data layout

Time	Subj.1	Subj.2	Subj.3
0.0	4.66	4.513	4.893
0.125	4.188	3.94	3.98
0.25	3.477	3.55	3.48
0.50	2.381	2.26	2.31
0.75	1.608	1.64	1.71
1.0	1.187	1.13	1.14
2.0	0.332	0.338	0.322
4.0	0.111	0.112	0.110
6.0	0.100	0.097	0.106
8.0	0.093	0.102	0.095
10.0	0.095	0.094	0.092
12.0	0.0931	0.096	0.091
16.0	0.0881	0.083	0.082
24.0	0.0713	0.077	0.074
36.0	0.0642	0.064	0.064
48.0	0.0493	0.053	0.051
60.0	0.0422	0.0405	0.0405
72.0	0.0361	0.0326	0.0357

Control layout

Title	Subj.1	Subj.2	Subj.3
Dose	5.00E+02	5.00E+02	5.00E+02
Ndoses	1.00E+00	1.00E+00	1.00E+00

Date	22/12/2022 12:07						
Algorithm	Marquardt (IRWLS)						
Weighting	1/Conc2						
Model	12						
Parameter	Pars V _{iv}	k ₁₂	k ₂₁	k ₁₀	Akaike	Sos	
Subj.1	101.68484	1.00183	0.04896	0.48552	-67.1803	0.015349	
%Error	1.88	1.90	2.20	2.18			
Subj.2	104.85710	0.98794	0.05181	0.48496	-59.2201	0.023886	
%Error	2.34	2.41	2.70	2.63			
Subj.3	101.01492	1.01549	0.04953	0.49360	-68.9248	0.013932	
%Error	1.79	1.80	2.08	2.06			
	The Parame	eter stats. b	elow will b	e omitted f	or a single	profile	
Mean	102.51895	1.00175	0.05010	0.48803			
Geom. Mean	102.50535	1.00169	0.05009	0.48801			
SD	2.05241	0.01378	0.00151	0.00483			
SEM	1.18496	0.00795	0.00087	0.00279			
%CV	2.00	1.38	3.01	0.99			

Result Plots (separately stored automatically and can be viewed within 'Modelling' spreadsheet)



3.9.4 3-Compt. bolus (Model 13)

Data layout

Time	Subj.1	Subj.2	Subj.3
0.0	4.750	5.200	4.750
0.125	3.608	3.796	3.833
0.25	2.695	2.894	2.837
0.50	1.731	1.682	1.567
0.75	1.035	0.965	0.985
1.0	0.667	0.654	0.635
2.0	0.225	0.227	0.214
4.0	0.152	0.163	0.165
6.0	0.141	0.142	0.131
8.0	0.121	0.126	0.126
10.0	0.109	0.110	0.109
12.0	0.0899	0.0945	0.0936
16.0	0.0722	0.0729	0.0790
24.0	0.0513	0.0544	0.0507
36.0	0.0324	0.0334	0.0334
48.0	0.0244	0.0225	0.0235
60.0	0.0168	0.0175	0.0170
72.0	0.0122	0.0126	0.0124

Control layout

Title	Subj.1	Subj.2	Subj.3
Dose	5.00E+02	5.00E+02	5.00E+02
Ndoses	1.00E+00	1.00E+00	1.00E+00

Date	22/12/2022 10:38							
Algorithm	Marquardt (IRWLS)							
Weighting	1/Conc2							
Model	13							
Parameter	Pars V _{iv}	k ₁₂	k ₂₁	k ₁₃	k ₃₁	k ₁₀	Akaike	Sos
Subj.1	105.43632	0.97181	0.18983	0.43335	0.04461	0.75924	-66.817	0.012541
%Error	2.14	6.60	7.68	14.78	12.86	2.11		
Subj.2	97.37270	1.11661	0.19059	0.41500	0.04015	0.80127	-71.608	0.009611
%Error	1.89	4.62	5.78	11.74	12.01	1.91		
Subj.3	101.61009	1.13610	0.18172	0.38310	0.03951	0.78104	-64.937	0.013922
%Error	2.27	5.93	7.14	16.66	16.89	2.36		
	The Parame	ter stats. b	elow will b	e omitted f	or a single j	profile		
Parameter stats.								
Mean	101.47304	1.07484	0.18738	0.41049	0.04142	0.78052		
Geom. Mean	101.41949	1.07226	0.18734	0.40995	0.04136	0.78033		
SD	4.03356	0.08976	0.00491	0.02543	0.00277	0.02102		
SEM	2.32877	0.05182	0.00284	0.01468	0.00160	0.01214		
%CV	3.98	8.35	2.62	6.19	6.70	2.69		

Result Plots (separately stored automatically and can be viewed within 'Modelling' spreadsheet



3.9.5 1-Compt. infusion (Model 15)

Data layout

Subj.1	Subj.2	Subj.3
0.000	0.000	0.000
0.592	0.648	0.617
1.292	1.205	1.267
2.346	2.444	2.518
3.497	3.533	3.533
5.072	4.926	4.975
4.593	4.407	4.454
4.030	4.198	4.114
3.874	3.950	3.608
3.471	3.334	3.574
3.234	3.079	3.079
2.7575	2.9264	2.7294
2.3038	2.2346	2.3498
1.6060	1.4979	1.5288
0.8136	0.8645	0.8814
0.4791	0.4651	0.4465
0.2680	0.2502	0.2451
0.1401	0.1331	0.1443
	Subj.1 0.000 0.592 1.292 2.346 3.497 5.072 4.593 4.030 3.874 3.471 3.234 2.7575 2.3038 1.6060 0.8136 0.4791 0.2680 0.1401	Subj.1Subj.2 0.000 0.000 0.592 0.648 1.292 1.205 2.346 2.444 3.497 3.533 5.072 4.926 4.593 4.407 4.030 4.198 3.874 3.950 3.471 3.334 3.234 3.079 2.7575 2.9264 2.3038 2.2346 1.6060 1.4979 0.8136 0.8645 0.4791 0.4651 0.2680 0.2502 0.1401 0.1331

Control layout

Title	Subj.1	Subj.2	Subj.3
Dose	0.00E+00	0.00E+00	0.00E+00
Ndoses	1.00E+00	1.00E+00	1.00E+00
Inftime	1.00E+00	1.00E+00	1.00E+00
Infrate	5.00E+02	5.00E+02	5.00E+02

Date	21/12/2022 10:32						
Algorithm	Marquardt (IRWLS)						
Weighting	1/Conc2						
Model	15						
Parameter	Pars V _{iv}	k 10	Akaike	Sos			
Subj.1	100.74745	0.04953	-62.82166	0.01963			
%Error	1.11	0.81					
Subj.2	100.38113	0.05029	-68.19147	0.01431			
%Error	0.95	0.68					
Subj.3	100.70590	0.04993	-66.58536	0.01573			
%Error	1.00	0.72					
	The Parame	ter stats. b	elow will b	e omitted f	or a single	profile	
Parameter stats.							
Mean	100.61149	0.04992					
Geom. Mean	100.61136	0.04992					
SD	0.20058	0.00038					
SEM	0.11580	0.00022					
%CV	0.20	0.77					

Result Plots (separately stored automatically and can be viewed within 'Modelling' spreadsheet



3.9.6 2-Compt. infusion (Model 17)

Data layout

Time	Subj.1	Subj.2	Subj.3
0	0.0	0.0	0.0
0.125	0.581	0.553	0.576
0.25	1.043	1.022	0.991
0.5	1.710	1.727	1.833
0.75	2.216	2.239	2.239
1.0	2.558	2.532	2.532
2.0	0.615	0.667	0.661
4.0	0.131	0.127	0.134
6.0	0.105	0.098	0.098
8.0	0.101	0.096	0.103
10.0	0.098	0.095	0.097
12.0	0.096	0.088	0.091
16.0	0.082	0.084	0.086
24.0	0.072	0.075	0.073
36.0	0.0610	0.0598	0.0629
48.0	0.0512	0.0507	0.0497
60.0	0.0408	0.0429	0.0408
72.0	0.0353	0.0332	0.0360

Control layout

Title	Subj.1	Subj.2	Subj.3
Dose	0.00E+00	0.00E+00	0.00E+00
Ndoses	1.00E+00	1.00E+00	1.00E+00
Inftime	1.00E+00	1.00E+00	1.00E+00
Infrate	5.00E+02	5.00E+02	5.00E+02

Date	22/12/2022 14:52						
Algorithm	Marquardt (IRWLS)						
Weighting	1/Conc2						
Model	17						
Parameter	Pars V _{iv}	k ₁₂	k ₂₁	k ₁₀	Akaike	Sos	
Subj.1	100.27528	1.02969	0.05186	0.50747	-67.67456	0.01166	
%Error	1.64	2.22	2.12	1.94			
Subj.2	102.84593	0.97248	0.04874	0.49134	-81.76746	0.00509	
%Error	1.07	1.44	1.43	1.29			
Subj.3	101.34703	0.97679	0.04961	0.49273	-63.27023	0.01511	
%Error	1.85	2.50	2.45	2.22			
	The Parame	eter stats. b	elow will b	e omitted f	or a single p	orofile	
Parameter stats.							
Mean	101.48941	0.99299	0.05007	0.49718			
Geom. Mean	101.48394	0.99265	0.05005	0.49713			
SD	1.29123	0.03186	0.00161	0.00894			
SEM	0.74549	0.01839	0.00093	0.00516			
%CV	1.27	3.21	3.22	1.80			

Result Plots (separately stored automatically and can be viewed within 'Modelling' spreadsheet



3.9.7 3-Compt. infusion (Model 19, using V7.6 onwards)

Data layout

Time	Subj.1	Subj.2	Subj.3
0	0	0	0
0.125	0.571	0.527	0.560
0.25	0.981	1.000	0.915
0.5	1.529	1.574	1.469
0.75	1.730	1.858	1.876
1.0	2.041	2.021	2.061
2.0	0.376	0.368	0.347
4.0	0.167	0.164	0.169
6.0	0.143	0.150	0.148
8.0	0.118	0.130	0.122
10.0	0.105	0.111	0.112
12.0	0.096	0.097	0.093
16.0	0.075	0.076	0.075
24.0	0.054	0.054	0.055
36.0	0.0340	0.0360	0.0340
48.0	0.0245	0.0240	0.0240
60.0	0.0172	0.0179	0.0162
72.0	0.0122	0.0123	0.0120

Control layout

Subj.1	Subj.2	Subj.3
0.00E+00	0.00E+00	0.00E+00
1.00E+00	1.00E+00	1.00E+00
1.00E+00	1.00E+00	1.00E+00
5.00E+02	5.00E+02	5.00E+02
	Subj.1 0.00E+00 1.00E+00 1.00E+00 5.00E+02	Subj.1Subj.20.00E+000.00E+001.00E+001.00E+001.00E+001.00E+005.00E+025.00E+02

Summary Results (stored in Excel file automatically)

Linear Plotting files stored in C:\PCModfit V7.6\Results\Fitplotlin3.png to Fitplotlin5.png Date 13/01/2023 12:53 Algorithm Marquardt (IRWLS) Log. Plotting files stored in C:\PCModfit V7.6\Results\Fitplotlog3.png to Fitplotlog5.png Weighting 1/Conc2 Model 19 Setup information used for this run is shown at the end of this summary. Parameter Pars Viv Akaike **k**12 **k**21 **k**13 **k**31 **k**10 Sos λ1 λ2 λ3 98.98078 0.05454 0.80763 -66.666 0.00978 2.37877 0.14100 0.02855 Profile_1 0.88093 0.21744 0.58779 %Error 1.90 7.79 9.20 12.32 8.88 1.98 Profile_2 98.55711 0.97258 0.20410 0.51474 0.05081 0.79670 -65.519 0.01046 2.38619 0.12505 0.02769 %Error 1.96 7.48 8.77 14.50 10.86 2.08 Profile_3 98.59068 0.99749 0.21391 0.54688 0.81942 -64.672 0.01100 2.47047 0.13201 0.02880 0.05359 %Error 2.05 7.61 9.13 14.44 10.34 2.15

Result Plots (separately stored automatically and can be viewed within 'Modelling' spreadsheet



3.9.8 1-Compt. infusion + bolus (Model 14)

Data layout

Time	Subj.1	Subj.2	Subj.3
0	2.625	2.375	2.425
0.125	3.014	3.139	3.076
0.25	3.600	3.897	3.563
0.5	4.907	4.711	4.662
0.75	6.210	6.089	5.906
1.0	7.400	7.400	7.183
2.0	7.039	6.901	6.901
4.0	6.494	6.369	5.995
6.0	5.933	5.707	5.707
8.0	5.061	5.266	5.317
10.0	4.441	4.857	4.626
12.0	4.1858	4.1440	4.3533
16.0	3.4614	3.3928	3.2900
24.0	2.3662	2.3891	2.3891
36.0	1.2355	1.2103	1.2355
48.0	0.6988	0.7265	0.6712
60.0	0.3797	0.3873	0.3797
72.0	0.2147	0.2021	0.2167

Control layout

Title	Subj.1	Subj.2	Subj.3
Dose	0.00E+00	0.00E+00	0.00E+00
Ndoses	1.00E+00	1.00E+00	1.00E+00
Inftime	1.00E+00	1.00E+00	1.00E+00
Infrate	5.00E+02	5.00E+02	5.00E+02
Infbol	2.50E+02	2.50E+02	2.50E+02

Date	22/12/2022 13:32						
Algorithm	Marquardt (IRWLS)						
Weighting	1/Conc2						
Model	14						
Parameter	Pars V _{iv}	k ₁₀	Akaike	Sos			
Subj.1	99.23910	0.04996	-75.23095	0.01226			
%Error	0.82	0.60					
Subj.2	99.23869	0.05005	-69.17595	0.01716			
%Error	0.97	0.71					
Subj.3	101.45704	0.04955	-72.03295	0.01464			
%Error	0.89	0.66					
	The Parame	ter stats. b	elow will b	e omitted f	or a single	profile	
Parameter stats.							
Mean	99.97828	0.04985					
Geom. Mean	99.97284	0.04985					
SD	1.28065	0.00027					
SEM	0.73938	0.00016					
%CV	1.28	0.54					

Result Plots (separately stored automatically and can be viewed within 'Modelling' spreadsheet



3.9.9 2-Compt. infusion + bolus (Model 16)

Data layout

Subj.1	Subj.2	Subj.3
2.450	2.450	2.475
2.538	2.776	2.723
2.654	2.847	2.819
2.923	3.012	2.923
2.966	3.059	3.214
3.256	3.064	3.192
0.774	0.840	0.815
0.182	0.182	0.185
0.161	0.159	0.147
0.150	0.143	0.150
0.149	0.141	0.135
0.1363	0.1446	0.1336
0.1226	0.1329	0.1252
0.1110	0.1087	0.1178
0.0931	0.0969	0.0913
0.0774	0.0804	0.0751
0.0655	0.0623	0.0642
0.0497	0.0502	0.0528
	Subj.1 2.450 2.538 2.654 2.923 2.966 3.256 0.774 0.182 0.161 0.150 0.149 0.1363 0.1226 0.1110 0.0931 0.0774 0.0655 0.0497	Subj.1Subj.22.4502.4502.5382.7762.6542.8472.9233.0122.9663.0593.2563.0640.7740.8400.1820.1820.1610.1590.1500.1430.1490.1410.13630.14460.12260.13290.11100.10870.09310.09690.07740.8040.06550.06230.04970.0502

Control layout

Title	Subj.1	Subj.2	Subj.3
Dose	0.00E+00	0.00E+00	0.00E+00
Ndoses	1.00E+00	1.00E+00	1.00E+00
Inftime	1.00E+00	1.00E+00	1.00E+00
Infrate	5.00E+02	5.00E+02	5.00E+02
Infbol	2.50E+02	2.50E+02	2.50E+02

Date	22/12/2022 14:12						
Algorithm	Marquardt (IRWLS)						
Weighting	1/Conc2						
Model	16						
Parameter	Pars V _{iv}	k ₁₂	k ₂₁	k ₁₀	Akaike	Sos	
Subj.1	101.71031	1.02711	0.05190	0.49923	-67.82955	0.01481	
%Error	1.71	2.33	2.25	2.07			
Subj.2	99.02216	1.00314	0.05038	0.50353	-63.56208	0.01877	
%Error	1.91	2.61	2.54	2.32			
Subj.3	98.86905	1.00134	0.04814	0.49963	-76.11530	0.00934	
%Error	1.34	1.82	1.82	1.68			
	The Parame	eter stats. b	elow will b	e omitted f	or a single j	profile	<u>.</u>
Parameter stats.							
Mean	99.86717	1.01053	0.05014	0.50080			
Geom. Mean	99.85870	1.01046	0.05012	0.50079			
SD	1.59804	0.01439	0.00189	0.00237			
SEM	0.92263	0.00831	0.00109	0.00137			
%CV	1.60	1.42	3.77	0.47			

Result Plots (separately stored automatically and can be viewed within 'Modelling' spreadsheet



3.9.10 3-Compt. infusion + bolus (Model 18)

Data layout

Time	Subj.1	Subj.2	Subj.3
0	2.400	2.600	2.500
0.125	2.350	2.447	2.544
0.25	2.300	2.419	2.490
0.5	2.347	2.416	2.416
0.75	2.273	2.342	2.203
1.0	2.268	2.315	2.431
2.0	0.470	0.447	0.480
4.0	0.239	0.244	0.237
6.0	0.201	0.212	0.209
8.0	0.175	0.181	0.177
10.0	0.158	0.162	0.154
12.0	0.1389	0.1503	0.1432
16.0	0.1171	0.1113	0.1125
24.0	0.0756	0.0795	0.0827
36.0	0.0533	0.0496	0.0517
48.0	0.0352	0.0362	0.0362
60.0	0.0268	0.0247	0.0260
72.0	0.0184	0.0175	0.0188

Control layout

Title	Subj.1	Subj.2	Subj.3
Dose	0.00E+00	0.00E+00	0.00E+00
Ndoses	1.00E+00	1.00E+00	1.00E+00
Inftime	1.00E+00	1.00E+00	1.00E+00
Infrate	5.00E+02	5.00E+02	5.00E+02
Infbol	2.50E+02	2.50E+02	2.50E+02

Date	22/12/2022 14:01							
Algorithm	Marquardt (IRWLS)							
Weighting	1/Conc2							
Model	18							
Parameter	Pars V _{iv}	k ₁₂	k ₂₁	k ₁₃	k ₃₁	k ₁₀	Akaike	Sos
Subj.1	103.96193	0.94330	0.19313	0.50561	0.04990	0.77768	-74.70333	0.00809
%Error	1.60	6.94	7.71	13.43	10.01	1.73		
Subj.2	96.10493	1.07029	0.19440	0.49078	0.04931	0.83870	-77.52794	0.00692
%Error	1.52	5.70	6.56	12.76	9.51	1.64		
Subj.3	98.38804	0.93717	0.18972	0.51969	0.05011	0.80668	-68.79722	0.01123
%Error	1.88	8.59	9.29	16.16	11.80	2.02		
	The Parame	eter stats. b	elow will b	e omitted f	or a single j	profile		
Parameter stats.								
Mean	99.48497	0.98359	0.19242	0.50536	0.04977	0.80768		
Geom. Mean	99.43076	0.98173	0.19241	0.50522	0.04977	0.80730		
SD	4.04173	0.07515	0.00242	0.01446	0.00041	0.03052		
SEM	2.33349	0.04339	0.00140	0.00835	0.00024	0.01762		
%CV	4.06	7.64	1.26	2.86	0.83	3.78		

Result Plots (separately stored automatically and can be viewed within 'Modelling' spreadsheet



3.9.11 1-Compt. oral (Model 8)

Data layout

Time	Subj.1	Subj.2	Subj.3
0.0	-	-	-
0.5	2.672	2.672	2.594
1.0	3.863	3.748	3.786
1.5	4.318	4.274	4.318
2.0	4.492	4.675	4.629
2.5	4.611	4.657	4.750
3.0	4.614	4.661	4.754
3.5	4.586	4.586	4.632
4.0	4.588	4.680	4.634
5.0	4.574	4.395	4.574
6.0	4.332	4.332	4.332
8.0	4.1214	4.1214	4.1214
10.0	3.9600	3.9600	3.9600
12.0	3.6916	3.7669	3.8422
16.0	3.4766	3.4425	3.3402
24.0	2.7348	2.8464	2.7627
36.0	2.0260	2.0673	2.0880
48.0	1.5315	1.5162	1.5621

Control layout

Title	Subj.1	Subj.2	Subj.3		
Dose	1000	1000	1000		
Ndoses	1.00E+00	1.00E+00	1.00E+00		

							T
Date	22/12/2022 14:32						
Algorithm	Marquardt (IRWLS)						
Weighting	1/Conc2						
Model	8						
Parameter	Pars V _{po}	ka	k ₁₀	Akaike	Sos		
Subj.1	201.31445	1.54501	0.02501	-94.50718	0.00271		
%Error	0.51	1.99	1.13				
Subj.2	200.40647	1.51193	0.02493	-91.34219	0.00326		
%Error	0.56	2.15	1.25				
Subj.3	199.16524	1.46780	0.02493	-94.09527	0.00277		
%Error	0.52	1.96	1.15				
	The Parame	eter stats. b	elow will b	e omitted fo	or a single j	profile	
Parameter stats.							
Mean	200.29539	1.50825	0.02496				
Geom. Mean	200.29345	1.50792	0.02496				
SD	1.07890	0.03874	0.00005				
SEM	0.62290	0.02236	0.00003				
%CV	0.54	2.57	0.19				


3.9.12 1-Compt. oral with lag-time (Model 7)

Data layout

Time Subj.1 Subj.2 Subj.3 0.0 _ _ _ 0.5 ---1.0 ---1.5 2.6462.620 2.646 2.0 3.863 3.748 3.825 2.5 4.274 4.362 4.274 3.0 4.584 4.492 4.675 3.5 4.657 4.611 4.611 4.754 4.0 4.614 4.754 5.0 4.588 4.680 4.634 4.485 6.0 4.485 4.485 8.0 4.2256 4.2256 4.2683 10.0 3.9790 4.0602 3.9790 12.0 3.9008 3.9008 3.9394 16.0 3.4947 3.5296 3.4598 24.0 2.9184 2.8612 2.8612 36.0 2.09842.0984 2.1620 48.0 1.5703 1.5389 1.5546

Control layout

Title	Subj.1	Subj.2	Subj.3		
Dose	1000	1000	1000		
Ndoses	1.00E+00	1.00E+00	1.00E+00		

Summary Results (stored in Excel file automatically)

				1			Τ
Date	22/12/2022 14:27						
Algorithm	Marquardt (IRWLS)						
Weighting	1/Conc2						
Model	7						
Parameter	Pars V _{po}	ka	k ₁₀	t _{lag}	Akaike	Sos	
Subj.1	200.35519	1.47141	0.02493	0.97962	-87.52345	0.00172	
%Error	0.57	5.07	1.14	2.94			
Subj.2	198.70707	1.36594	0.02550	0.95575	-92.76954	0.00121	
%Error	0.48	4.05	0.94	2.53			
Subj.3	198.79492	1.43108	0.02517	0.97268	-79.60868	0.00291	
%Error	0.74	6.46	1.47	3.83			
	The Parame	eter stats. b	elow will b	e omitted f	or a single j	profile	
Parameter stats.							
Mean	199.28573	1.42281	0.02520	0.96935			
Geom. Mean	199.28429	1.42214	0.02520	0.96929			
SD	0.92722	0.05322	0.00028	0.01228			
SEM	0.53533	0.03072	0.00016	0.00709			
%CV	0.47	3.74	1.13	1.27			



3.9.13 2-Compt. oral (Model 10)

Data layout

Time	Subj.1	Subj.2	Subj.3
0.00	-	-	-
0.25	1.464	1.478	1.478
0.50	2.393	2.322	2.346
0.75	2.836	2.808	2.836
1.00	2.975	3.065	3.005
1.25	3.062	3.032	3.002
1.50	3.013	2.954	2.983
2.00	2.636	2.584	2.663
2.50	2.227	2.227	2.205
3.00	1.876	1.857	1.894
4.00	1.238	1.238	1.263
5.00	0.8199	0.8534	0.8534
6.00	0.5581	0.5525	0.5470
8.00	0.2384	0.2384	0.2408
10.00	0.1097	0.1119	0.1108
12.00	0.0540	0.0540	0.0546
16.00	0.0193	0.0193	0.0191
20.00	0.0120	0.0117	0.0121
24.00	0.01020	0.01010	0.00980
28.00	0.00927	0.00900	0.00900
32.00	0.00848	0.00831	0.00848
36.00	0.00778	0.00778	0.00794
48.00	0.00627	0.00609	0.00634
60.00	0.00506	0.00486	0.00501
72.00	0.00388	0.00388	0.00400

Summary Results (stored in Excel file automatically)

Date	22/12/2022 14:12							
Algorithm	Marquardt (IRWLS)							
Weighting	1/Conc2							
Model	10							
Parameter	Pars V _{po}	ka	k ₁₂	k ₂₁	k ₁₀	Akaike	Sos	
Subj.1	200.29728	1.52010	0.02510	0.02057	0.40035	-128.88527	0.00307	
%Error	0.60	1.24	0.72	1.37	0.39			
Subj.2	201.66261	1.52019	0.02456	0.02043	0.39862	-129.54670	0.00298	
%Error	0.59	1.22	0.71	1.36	0.38			
Subj.3	200.13006	1.50576	0.02522	0.01975	0.39907	-130.11220	0.00291	
%Error	0.59	1.20	0.73	1.39	0.38			
	The Parame	eter stats. b	elow will b	e omitted f	or a single	profile		
Parameter stats.								
Mean	200.69665	1.51535	0.02496	0.02025	0.39935			
Geom. Mean	200.69548	1.51533	0.02496	0.02025	0.39935			
SD	0.84071	0.00831	0.00035	0.00044	0.00090			
SEM	0.48539	0.00479	0.00020	0.00025	0.00052			
%CV	0.42	0.55	1.40	2.18	0.22			

Control layout

Title	Subj.1	Subj.2	Subj.3
Dose	1000	1000	1000
Ndoses	1.00E+00	1.00E+00	1.00E+00



3.9.14 2-Compt. oral with lag-time (Model 9)

D	•	
Data	layou	C

Time	Subj.1	Subj.2	Subj.3
0.00	-	-	-
0.25	-	-	-
0.50	-	-	-
0.75	-	-	-
1.00	-	-	-
1.25	1.464	1.478	1.478
1.50	2.322	2.369	2.322
2.00	2.975	2.945	2.945
2.50	2.895	3.013	3.013
3.00	2.636	2.663	2.610
4.00	1.876	1.857	1.838
5.00	1.2375	1.2754	1.2502
6.00	0.8367	0.8367	0.8450
8.00	0.3693	0.3620	0.3693
10.00	0.1648	0.1664	0.1615
12.00	0.0780	0.0773	0.0780
16.00	0.0237	0.0237	0.0230
20.00	0.0128	0.0130	0.0131
24.00	0.01021	0.01021	0.01042
28.00	0.00947	0.00919	0.00947
32.00	0.00856	0.00847	0.00856
36.00	0.00809	0.00777	0.00785
48.00	0.00639	0.00646	0.00633
60.00	0.00495	0.00495	0.00505
72.00	0.00407	0.00407	0.00399

Control layout

Title	Subj.1	Subj.2	Subj.3
Dose	1000	1000	1000
Ndoses	1.00E+00	1.00E+00	1.00E+00

Summary Results (stored in Excel file automatically)

Date	22/12/2022 10:52							
Algorithm	Marquardt (IRWLS)							
Weighting	1/Conc2							
Model	9							
Parameter	Pars V _{po}	ka	k ₁₂	k ₂₁	k ₁₀	t _{lag}	Akaike	Sos
Subj.1	202.80842	1.50333	0.02497	0.02005	0.39666	0.99933	-111.25082	0.00211
%Error	0.69	2.41	0.77	1.40	0.45	0.77		
Subj.2	201.31737	1.53723	0.02469	0.01979	0.39665	1.00465	-103.35205	0.00313
%Error	0.83	2.95	0.94	1.73	0.53	0.92		
Subj.3	201.12157	1.48631	0.02493	0.02044	0.39942	0.99626	-106.53358	0.00267
%Error	0.78	2.70	0.85	1.55	0.51	0.88		
	The Parame	eter stats. b	elow will b	e omitted f	or a single	profile		
Parameter stats.								
Mean	201.74912	1.50896	0.02486	0.02009	0.39758	1.00008		
Geom. Mean	201.74772	1.50881	0.02486	0.02009	0.39758	1.00007		
SD	0.92259	0.02592	0.00015	0.00033	0.00160	0.00425		
SEM	0.53266	0.01497	0.00009	0.00019	0.00092	0.00245		
%CV	0.46	1.72	0.60	1.63	0.40	0.42		



3.9.15 3-Compt. oral (Model 43)

Data layout

Time (h)	Subj.1	Subj.2
0	-	-
0.05	1.222	1.028
0.10	2.403	2.025
0.25	5.716	4.839
0.30	6.747	5.721
0.40	8.704	7.403
0.50	10.527	8.981
1.0	17.891	15.497
2.0	26.073	23.260
3.0	28.858	26.486
4.0	28.760	27.127
6.0	25.070	24.904
8.0	20.468	21.337
10.0	16.466	17.952
12.0	13.309	15.123
14.0	10.887	12.846
16.0	9.030	11.023
20.0	6.461	8.346
24.0	4.825	6.505
30.0	3.305	4.650
36.0	2.387	3.441
40.0	1.966	2.860
44.0	1.643	2.405
48.0	1.391	2.044
50.0	1.284	1.891
55.0	1.063	1.571
60.0	0.889	1.321
64.0	0.775	1.159
66.0	0.724	1.088
70.0	0.635	0.961
72.0	0.595	0.905
96.0	0.282	0.465
120.0	0.137	0.251
144.0	0.0665	0.137
168.0	0.0324	0.0750

Control layout

Title	Subj.1	Subj.2
Dose	1.00E+03	1.00E+03
Ndoses	1.00E+00	1.00E+00
Pars V ₁	8.00E+00	8.00E+00
ka	2.00E-01	2.00E-01
k ₁₂	1.50E-01	1.50E-01
k ₂₁	1.80E-01	1.80E-01
k 13	5.00E-02	5.00E-02
k ₃₁	3.00E-02	3.00E-02
k ₁₀	1.80E-01	1.80E-01

Summary Results (stored in Excel file automatically)

Date	22/12/2022 15:47								
Algorithm	Marquardt (IRWLS)								
Weighting	1/Conc2								
Model	43								
Parameter	Pars V _{po}	ka	k ₁₂	k ₂₁	k ₁₃	k ₃₁	k ₁₀	Akaike	Sos
Set1	10.01025	0.24876	0.14735	0.16987	0.05410	0.04031	0.21876	-395.16999	5.94E-06
%Error	0.65	0.64	0.14	0.62	0.69	0.05	0.65		
Set2	12.51483	0.26123	0.15804	0.17554	0.03526	0.03378	0.15161	-417.21177	3.10E-06
%Error	0.58	0.58	0.41	0.43	0.60	0.05	0.59		
	The Parame	ter stats.	below w	ill be om	itted for	a single p	orofile		
Parameter stats.									
Mean	11.26254	0.25499	0.15270	0.17270	0.04468	0.03704	0.18518		
Geom. Mean	11.19270	0.25492	0.15260	0.17268	0.04367	0.03690	0.18211		
SD	1.77100	0.00882	0.00756	0.00400	0.01332	0.00462	0.04748		
SEM	1.25229	0.00624	0.00535	0.00283	0.00942	0.00326	0.03357		
%CV	15.72	3.46	4.95	2.32	29.82	12.46	25.64		



3.9.16 3-Compt. oral with lag-time (Model 42)

Data layout

Time (h)	Subj.1	Subj.2
0	-	-
1.05	1.222	1.028
1.10	2.403	2.025
1.25	5.716	4.839
1.30	6.747	5.721
1.40	8.704	7.403
1.50	10.527	8.981
2.00	17.891	15.497
3.00	26.073	23.260
4.00	28.858	26.485
5.00	28.760	27.127
7.00	25.070	24.903
9.00	20.468	21.337
11.00	16.466	17.952
13.00	13.309	15.123
15.00	10.887	12.846
17.00	9.030	11.023
21.00	6.461	8.346
25.00	4.825	6.505
31.00	3.305	4.650
37.00	2.387	3.441
41.00	1.966	2.860
45.00	1.643	2.405
49.00	1.391	2.044
51.00	1.284	1.891
56.00	1.062	1.571
61.00	0.888	1.321
65.00	0.775	1.159
67.00	0.724	1.088
71.00	0.6351	0.9613
73.00	0.5953	0.9053
97.00	0.2824	0.4651
121.00	0.1368	0.2506
145.00	0.0665	0.1369
169.00	0.0324	0.0750

Control layout

Title	Subj.1	Subj.2		
Dose	1.00E+03	1.00E+03		
Ndoses	1.00E+00	1.00E+00		
Pars V ₁	8.00E+00	8.00E+00		
ka	2.00E-01	2.00E-01		
k ₁₂	1.50E-01	1.50E-01		
k ₂₁	1.80E-01	1.80E-01		
k ₁₃	5.00E-02	5.00E-02		
k ₃₁	3.00E-02	3.00E-02		
k 10	1.80E-01	1.80E-01		
t _{lag}	8.00E-01	8.50E-01		

Summary Results (stored in Excel file automatically)

Date	22/12/2022	2 15:56								
Algorithm	Marquardt	(IRWLS)								
Weighting	1/Conc2									
Model	42									
Parameter	Pars V_{po}	ka	k ₁₂	k ₂₁	k ₁₃	k ₃₁	k ₁₀	t _{lag}	Akaike	Sos
Subj.1	10.06678	0.25015	0.14730	0.17090	0.05381	0.04033	0.21753	1.00000	-438.70039	1.56E-06
%Error	0.36	0.35	0.09	0.33	0.38	0.03	0.36	0.0016		
Subj.2	12.44466	0.25978	0.15863	0.17476	0.03545	0.03377	0.15247	1.00001	-476.90413	5.06E-07
%Error	0.25	0.25	0.18	0.18	0.26	0.02	0.25	0.0009		
	The	e Parame	ter stats.	below v	vill be on	nitted fo	r a single	e profile		
Parameter stats.										
Mean	11.25572	0.25497	0.15297	0.17283	0.04463	0.03705	0.18500	1.00000		
Geom. Mean	11.19275	0.25492	0.15286	0.17282	0.04368	0.03691	0.18212	1.00000		
SD	1.68142	0.00681	0.00801	0.00273	0.01299	0.00463	0.04600	0.00000		
SEM	1.18894	0.00482	0.00567	0.00193	0.00918	0.00328	0.03253	0.00000		
%CV	14.94	2.67	5.24	1.58	29.10	12.50	24.87	0.00		



3.9.17 Repeat dose infusion, varying rate, time, & interval (Model 17: 2-Compt., V7.7)

Time	Subj.1	Time	Subj.2	Title	Subj.1	Subj.2
0	-	0	-	Dose	0	0
2	10.44	2	10.41	Ndoses	4	4
4	13.02	4	13.0	Pars V ₁	8	8
6	13.89	6	13.80	k ₁₂	0.3	0.3
8	14.36	8	14.40	k ₂₁	0.1	0.1
10	14.74	10	14.70	k ₁₀	0.7	0.7
12	4.64	12	4.71	Doseint	24	24
16	1.79	16	1.77		36	36
24	1.28	24	1.31		24	24
26	14.25	26	14.14	Inftime	10	10
28	17.4	28	17.35		8	8
32	18.94	32	18.98		10	10
60	1.24	60	1.22		20	20
62	11.6	62	11.56	Infusts	100	100
68	15.32	68	15.17	Imrate	100	100
70	15.63	70	15.63		125	125
72	5.47	72	5.44		100	100
80	2.11	80	2.16		50	50
84	1.85	84	1.84			
86	6.95	86	6.91			
90	8.46	90	8.49			
96	8.79	96	8.78			
104	9.07	104	9.06			
106	3.91	106	3.92			
112	2.1	112	2.12			
120	1.61	120	1.59			

Summary Results (stored in Excel file automatically)

Date	22/12/2022 16:51	Linear Plot	inear Plotting files stored in C:\PCModfit V7.6\Results\Fitplotlin7.png to Fitplotlin8.png						
Algorithm	Marquardt (IRWLS)	Log. Plottir	ng files store	ed in C:\PC	Modfit V7.6\Re	sults\Fitplotlo	g7.png to Fitp	lotlog8.png	
Weighting	1/Conc2								
Model	17								
Parameter	Pars V _{iv}	k 12	k 21	k 10	Akaike	Sos	λ_1	λ2	
Subj.1	10.00968	0.24982	0.04975	0.49922	-285.16474	0.0000081	0.76637	0.03241	
%Error	0.04	0.06	0.08	0.04					
Subj.2	10.05049	0.25009	0.05086	0.49845	-150.63381	0.0017549	0.76632	0.03308	
%Error	0.66	0.91	1.18	0.65					
The Parameter s	tats. below will be on	nitted for a	single profi	ile					
Parameter stats.									
Mean	10.03008	0.24995	0.05031	0.49883					
Geom. Mean	10.03006	0.24995	0.05030	0.49883					
SD	0.02886	0.00020	0.00079	0.00055					
SEM	0.02041	0.00014	0.00056	0.00039					
%CV	0.29	0.08	1.57	0.11					





3.9.18 Repeat dose infusion, varying rate, time, & interval (with constraints, V7.7)

This example used the same data as the previous one except the first parameter V_{iv} was fixed. The algorithm used was Marquardt (IRWLS) and note that the starting estimate was close to theoretical one (from the previous results) and the same value was defined for Conmin and Conmax (min. and max. constraint, respectively). By setting this (selected under constraints in the 'Fitting options') it informs PCModfit to ignore the V_{iv} parameter during the iteration process and thus, no error calculation was reported for V_{iv} in the results (both sets showing a zero value). Note that several of the other parameter errors were slightly lower than the previous one, as the number of variables was reduced by one which influences the error calculations.

	Da	ata layout		Control layout			
Time	Subj.1	Time	Subj.2	Title	Subj.1	Subj.2	
0	-	0	-	Dose	0	0	
2	10.44	2	10.41	Ndoses	4	4	
4	13.02	4	13.0	Pars V _{iv}	10.00968	10.05049	
6	13.89	6	13.80	k ₁₂	0.3	0.3	
8	14.36	8	14.40	ka	0.1	0.1	
10	14.74	10	14.70	1. 1.	0.7	0.7	
12	4.64	12	4.71	K ₁₀	0.7	0.7	
16	1.79	16	1.77	Doseint	24	24	
24	1.28	24	1.31		36	36	
26	14.25	26	14.14		24	24	
28	17.4	28	17.35	Inftime	10	10	
32	18.94	32	18.98		8	8	
60	1.24	60	1.22		10	10	
62	11.6	62	11.56		20	20	
68	15.32	68	15.17	Infrate	100	100	
70	15.63	70	15.63		125	125	
72	5.47	72	5.44		100	100	
80	2.11	80	2.16		50	50	
84	1.85	84	1.84	Conmin	10.00968	10.05049	
86	6.95	86	6.91		1.00E-06	1.00E-06	
90	8.46	90	8.49		1.00E-06	1.00E-06	
96	8.79	96	8.78		1.00E-06	1.00E-06	
104	9.07	104	9.06	Conmax	10.00968	10.05049	
106	3 91	106	3.92		1.00E + 06	1.00E+06	
112	2.1	112	2.12		1.00E+06	1.00E+06	
120	1.61	120	1 59		1.00E+06	1.00E+06	
140	1.01	140	1.57				

Summary Results (stored in Excel file automatically)

Date	23/12/2022 13:51	Linear Plot	inear Plotting files stored in C:\PCModfit V7.6\Results\Fitplotlin2.png to Fitplotlin3.png					
Algorithm	Marquardt (IRWLS)	Log. Plottin	ng files store	ed in C:\PC	Modfit V7.6\Re	sults\Fitplotlo	g2.png to Fitpl	otlog3.png
Weighting	1/Conc2							
Model	17							
Parameter	Pars V _{iv}	k ₁₂	k 21	k 10	Akaike	Sos	λ1	λ_2
Subj.1	10.00968	0.24982	0.04975	0.49922	-285.16474	0.0000081	0.76637	0.03241
%Error	0.00	0.04	0.07	0.01				
Subj.2	10.05049	0.25009	0.05086	0.49844	-150.63376	0.0017549	0.76632	0.03308
%Error	0.00	0.59	1.10	0.20				
The Parameter s	tats. below will be on	nitted for a	single profi	ile				
Parameter stats.								
Mean	10.03008	0.24995	0.05031	0.49883				
Geom. Mean	10.03006	0.24995	0.05030	0.49883				
SD	0.02886	0.00020	0.00079	0.00055				
SEM	0.02041	0.00014	0.00056	0.00039				
%CV	0.29	0.08	1.57	0.11				



3.9.19 Repeat dose oral, varying dose and interval (Model 10: 2-Compt.)

Data layout				Control la	yout
Time	Subj.1	Subj.2	Title	Subj.1	Subj.2
0	-	-	Dose	0	0
0.25	47.25	47.24	Ndoses	6	6
0.5	59.57	59.57	Pars V ₁	8	8
1	47.49	47.49	k _a	1.5	1.5
2	15.40	15.40	K 12	0.15	0.15
3	4.06	4.06	ka	0.07	0.07
4	1.23	1.23	K 21	1.2	1.0
5	0.60	0.60		1.2	1.2
5.5	48.16	48.16	Doseint	5	5
6	38.45	38.45) 10	5 12
7	12.74	12.74		12	12
10	0.84	0.84		0 12	0
10.5	40.5	40.47	Dondoso	12	12
11	32.4	32.37	Kepuose	1200	1200
12	10.93	10.93		1200	1200
22	0.642	0.64		1500	1500
22.5	60.2	60.20		1200	1200
23	48.1	48.10		2000	2000
24	16.0	15.99		2000	2000
25	4.6	4.62			
26	1.77	1.77			
28	0.951	0.95			
30	0.845	0.85			
30.5	48.5	48.48			
31	38.8	38.80			
32	13.1	13.10			
33	3.983	3.98			
34	1.693	1.69			
35	1.159	1.16			
42	0.761	0.76			
42.25	63.7	63.75			
42.5	80.2	80.17			
43	64.0	64.04			
44	21.2	21.24			
45	6.073	6.07			
46	2.28	2.28			
47	1.4	1.41			
48	1.2	1.20			
52	0.969	0.97			
53	0.927	0.93			
54	0.887	0.89			
55	0.849	0.85			
56	0.813	0.81			
57	0.778	0.78			
58	0.744	0.74			

0.712

0.682

0.71

0.68

59

60

Summary Results (stored in Excel file automatically)

Date	22/12/2022 16:51						
Algorithm	Marquardt (IRWLS)						
Weighting	1/Conc2						
Model	10						
Parameter	Pars V _{po}	ka	k ₁₂	k ₂₁	k ₁₀	Akaike	Sos
Subj.1	9.95366	1.98992	0.20094	0.04996	1.50691	-405.83270	0.0001186
%Error	0.41	0.48	0.43	0.19	0.41		
Subj.2	9.92200	1.98246	0.20155	0.05016	1.51182	-391.08764	0.0001634
%Error	0.51	0.59	0.53	0.22	0.51		
	The Para	meter stats	. below will	be omitted fo	or a single p	rofile	
Parameter							
stats.							
Mean	9.93783	1.98619	0.20125	0.05006	1.50937		
Geom. Mean	9.93782	1.98619	0.20124	0.05006	1.50936		
SD	0.02239	0.00528	0.00044	0.00014	0.00347		
SEM	0.01583	0.00373	0.00031	0.00010	0.00246		
%CV	0.23	0.27	0.22	0.28	0.23		

Result Plots (separately stored automatically and can be viewed within 'Modelling' spreadsheet



70

. 70

3.9.20 IVIVC using published data. RD i.v., varying dose and interval.

An IVIVC convolution application using model 11 (1-compartment i.v.) with published data.

Literature Reference:

In Vitro-In Vivo Correlation (IVIVC) and Determining Drug Concentrations in Blood from Dissolution Testing - A Simple and Practical Approach. Saeed A. Qureshi, The Open Drug Delivery Journal, 2010, 4, 38-47.

	Data layout			Control layout
Time	Diltiazem	Diltiazem	Title	Diltiazem
0.000	data	(Fitted result)	Dose	0.00E+00
0.000	-	-	Ndoses	1.00E+01
0.080	4.471	4.471	Pars	300000
0.170	10.160	10.160		0.180000
0.250	15.204	15.204	Doseint	0.080
0.500	28.550	28.550		0.090
0.750	42.128	42.128		0.080
1.000	49.486	49.486		0.250
1.500	58.132	58.132		0.250
2.000	56.448	56.448		0.230
3.000	46.943	46.943		0.500
4.000	37.786	37.786		1.000
5.000	30.415	30.415	Repdose	0
6.000	24.482	24.482	•	1658800
7.000	19.706	19.706		2142800
8.000	15.862	15.862		1936000
9.000	12.768	12.768		5249200
10.000	10.277	10.277		5596800
11.000	8.272	8.272		3555200
12,000	6 659	6 659		5095200
13,000	5 360	5 360		1592800
14 000	4 314	4 314		558800
15,000	3 473	3 473	No of poin	ts for graphics fitted line was 1000
16,000	2 795	2 795	Model used	I was No. 11 with 10 doses.
17,000	2.750	2.250		
18,000	1 811	1 811		
19,000	1.011	1.011		
20,000	1.438	1.430		
20.000	0.045	0.045		
21.000	0.943	0.740		
22.000	0.760	0.700		
23.000	0.612	0.612		
24.000	0.493	0.493		

Summary Results (stored in Excel file automatically)

Date	24/12/2022 16:09 Marquardt			
Algorithm	(IRWLS)			
Weighting	1/Conc2			
Model	11			
Parameter	Pars V _{iv}	k ₁₀	Akaike	Sos
Diltiazem	371167.63	0.2169976	-388.22834	0.209852E-05
%Error	0.0078	0.0030		



4. Compartmental analysis using Mixed inputs (i.v. and oral)

4.1 Introduction

There are occasions when modelling data from repeated doses with mixed inputs such as intravenous, infusion, bolus, or oral dosing is required. At the request of several users, PCModfit V7.5 onwards, will now allow such scenarios. An example could comprise, i.v. bolus and infusion followed by oral maintenance with the option of varying doses and intervals. This can often be applicable to drugs such as antibiotics and antifungals, as examples. The new Fitting options layout is shown below as an example.

	<u>Algorithm</u>	Weighting	Profile type		No. of Profiles	No. point	ts for fitted line
	DFP (WLS)	□ 1/Conc		Single dose	5 -		200
~	Marquardt (IRWLS)	\checkmark 1/Conc ²		Papaget dosa			500
	Simplex (WLS)	Unweighted		Repeat dose	No. of Doses	~	1000
	Simplex (IRWLS)		~	Mixed models	5 -		5000
							10000
	Parameters <u>Constraints</u>		Data layout			Useful for	profiles with
	Computer estimates	Yes		Time conc time	e conc	long times	(500 to 1000
	User estimates	□ No	~	Time conc conc	с	is usual bu	it is dependent
						on profile	time and shape).
	Plotting	Model number	<u>Graph</u>	axis titles (upd	<u>ated at Run time)</u>	RD bolus	may need 5000
~	Yes	9 -	X-axis	Time (h)		or more.	
	No	Only used for Single or Repeat dose (not Mixed)	Y-axis	Conc. (µg/mL)		Select bef	ore running.

Obviously, if intravenous and oral models are combined, there will be an increase in the number of parameters used in the fitting procedure. If a 2-compartment model is the desired choice, as an example, the i.v. parameters V_{iv} (volume of compt. 1 after i.v.), k_{12} , k_{21} and k_{10} will be required but with the addition of V_{po} (volume of compt. 1 after oral) and k_a (absorption rate). Note that the rate constants k_{12} , k_{21} and k_{10} are assumed to be the same for both i.v. and oral administration. The parameter V_{po} will likely be different to V_{iv} as the former, will include the fraction of dose absorbed (F) after oral dosing.

When mixing inputs, the program does not permit changes in the number of compartments within the same profile. Specifically, if an i.v. model is to be mixed with an oral model and the PK after i.v. is described by a 2-compartment system, as an example, then the oral dose would be assumed to be a 2-compartment as well. The beginning of Section 3.9 describes the compartments pictorially for information.

As an aide memoir, the combinations of allowable models within a repeat dose profile are shown below for information.

For 1-compartment: use model numbers 7 and/or 8 (oral), 11 (i.v. bolus), 14 and/or 15 (i.v. infusions).

For 2-compartment: use model numbers 9 and/or 10 (oral), 12 (i.v. bolus), 16 and/or 17 (i.v. infusions).

For 3-compartment: use model numbers 42 and/or 43 (oral), 13 (i.v. bolus), 18 and/or 19 (i.v. infusions).

Whichever compartment number is best for a given set of data, the sequence of the dose route can be varied together with the doses and intervals. Examples are shown in this Section to help with the approach to fitting such varied scenarios.

4.2 Examples

For this Section, the data are not real but serve to demonstrate that the new methods used (V7.5 onwards), and the fitting results are correct. The information below should help the user with setting up the Modelling sheet for solving such scenarios. Other examples will be added in due course.

4.2.1 2-compartment bolus + infusion followed by oral maintenance (varying doses and intervals)

For this example, the dosing regimen is a realistic one wherein; a bolus injection + infusion was given at the start (e.g., patient in hospital), followed by an oral maintenance (at home) with different doses and over varying dosing intervals (much like some patients who forget dose times and doses!).

Specifically, the 2-compartment models used for this example were numbers 16 (bolus + infusion) and 10 (oral with no lag-time). To begin with, populate the Fitting options section on the modelling spreadsheet as shown below. Note the boxes that are ticked and specify the No. of Profiles (1 in this case) and the No. of Doses (10). Hopefully, the remainder are self-explanatory.

	<u>Algorithm</u>	Weighting	<u>Pr</u>	ofile type	No. of Profiles	No. points for fitted line		
	DFP (WLS)	□ 1/Conc		Single dose	1 -		200	
~	Marquardt (IRWLS)	\checkmark 1/Conc ²		Papart dosa			500	
	Simplex (WLS)	Unweighted	Ľ	Repeat dose	No. of Doses	~	1000	
	Simplex (IRWLS)		~	Mixed models	10 -		5000	
					10		10000	
	Parameters <u>Constraints</u>		Data layout			Useful for profiles with		
	Computer estimates	□ Yes		Time conc time	e conc	long times (500 to 1000		
v	User estimates	✓ No	~	Time conc conc	2	is usual but is dependent		
						on profile	time and shape).	
	Plotting	Model number	<u>Graph</u>	<u>axis titles (upd</u>	<u>ated at Run time)</u>	RD bolus may need 5000		
✓	Yes	9 🔻	X-axis	Time (h)		or more.		
	No	Only used for Single or Repeat dose (not Mixed)	Y-axis	Conc. (µg/mL)		Select bef	ore running.	

Once the above is populated, move down to Row 54, and enter the model numbers for each dose, in this case model 16 for the initial doses (bolus + infusion) and 10 (oral) for the remainder, as shown.

Then click the 'Keywords' button which will lay out the expected input data for the user to add the appropriate values. Some values will be set to zero as they would not be required for certain models. The program will sort out the sequence of parameters for populating using 'Mixed models'. To store the input setup data for the program, just click 'Activate' to show a message that it is stored in a file. Then click the 'Row 1154' button to enter the time and concentration data. Once entered, click the 'Activate' button to store the values and then return to the Fitting options by clicking 'Row 45'. If everything is looking good, click the 'Run' button and within a few seconds the modelling will be completed, and an Excel window will appear with a detailed summary of the results. The graphics (both linear and log) can be shown by clicking the 'Next' button on the 'Modelling' sheet (just below the graphs) which prompts the program to update both plots and store these in separate files (location and names shown at the end of the summary sheet). The input data should look like that shown on the next page followed by a snippet of the results file and pictures from the Modelling spreadsheet. Note that the fitted volume terms for i.v. (10 L) and oral (20 L) are different as the F value was different when the data were generated. In other words, only 50% of the drug was absorbed after oral dosing.

Setu	p parameters	Time-Concentration Data (rounded)						
Title	Set1	Comments	Time (h)	Set1				
Dose	0.0		0.00	10.000				
Ndoses	10		1.00	14.540				
Pars V _{iv}	8.000	User starting estimates.	2.00	18.000				
k 12	0.050	_	3.00	20.630				
k 21	0.015		4.00	22.650				
k 10	0.150		5.00	24.210				
Vpo	15.000		8.00	27.110				
ka	0.800		10.00	28.190				
Doseint	24.0	Only 9 needed as the	11.00	21.610				
	20.0	first dose is assumed	12.00	16.660				
	24.0	to be time zero.	13.00	12.940				
	18.0		15.00	8.020				
	24.0		17.00	5.230				
	24.0		20.00	3.110				
	24.0		24.00	2.000				
	30.0		26.00	24.880				
T 0.1	24.0		27.00	25.440				
Inftime	10.0	Infusion time (e.g.,	30.00	17.320				
	0.0	n, min etc.).	32.00	P 100				
	0.0	For the models that	34.00	8.100 5.660				
	0.0	do not require cortain	30.00	3.000				
	0.0	values just use zero	40.00	2 380				
	0.0	as shown e.g. oral	45.00	2.380				
	0.0	models have no bolus	47.00	13 970				
	0.0	or infusion info	48.00	12.940				
	0.0	or infusion info.	50.00	9.830				
Infrate	80.0	Infusion rate (e.g.,	52.00	7.080				
	0	mg/h, µg/min etc.).	56.00	3.890				
	0		60.00	2.630				
	0	For the models that	66.00	2.000				
	0	do not require certain	69.00	18.830				
	0	values just use zero	75.00	14.650				
	0	as shown e.g., oral	80.00	5.930				
	0	models have no bolus	86.00	2.960				
	0	or infusion info.	87.00	19.740				
	0		89.00	26.280				
Infbol	100	Bolus dose for model	95.00	10.520				
	0	16 (bolus $+$ infusion).	100.00	4.830				
	0		108.00	2.750				
	0	Not required for oral	124.00	20.200				
	0	models	124.00	4.940				
	0	moders.	137.00	2.700				
	ů 0		157.00	2,770				
	Ő		158.00	2.310				
	Ő		161.00	25.970				
Repdose	0	Not required for model	188.00	2.250				
•	1000	16 but would be if the	189.00	19.180				
	500	model was bolus only	191.00	25.930				
	1000	(models 11, 12 or 13).	212.00	2.520				
	1000		216.00	24.160				
	1000	The remainder are the	220.00	12.660				
	500	oral doses.	225.00	5.560				
	1000		240.00	2.430				
	1000		244.00	2.280				
	1000		248.00	2.140				
			255.00	1.940				
			270.00	1.570				
			∠ð0.00 200.00	1.370				
			290.00 294 AA	1.190				
			296.00	1 090				
			300.00	1.030				

Modelling result from summary file (much more detailed in the actual file).

Date	20/12/2022 14:03	0/12/2022 14:03								
Algorithm	Marquardt (IRWLS	larquardt (IRWLS)								
Weighting	1/Conc2	Conc2								
Model	Mixed	lixed								
Setup inform	nation and plot file	s detailed for	this run at tl	ne end of this	summary Wo	rkbook as a re	cord.			
Parameter	Pars V _{iv}	k ₁₂	k ₂₁	k ₁₀	V_{po}	ka	Akaike	Sos		
Set1	9.9984959	8.00E-02	2.00E-02	0.200026	20.00104	0.5001066	-590.3523	8.18E-05		
%Error	5.48E-02	7.31E-02	7.34E-02	4.16E-02	4.76E-02	7.71E-02				

Although the concentration data were rounded to 2 decimal places, these final parameter values are very close to the theoretical ones (shown below).

Parameter	Pars V _{iv}	k ₁₂	k ₂₁	k ₁₀	V_{po}	ka
Set1	10.0	0.080	0.020	0.20	20.0	0.50

Plots generated (copied from spreadsheet, Log and Linear)



4.2.2 1-compartment bolus + infusion, oral (lag), bolus, oral (lag) then bolus + infusion (V7.6)

For this example, the dosing regimen is just for testing wherein; a bolus + infusion, oral with lag-time, a bolus, oral with lag-time and finally with a bolus + infusion with different doses and over varying dosing intervals.

Specifically, the 1-compartment models used for this example were numbers 14 (bolus + infusion), 7 (oral with lag-time) and 11 (bolus). To begin with, populate the Fitting options section on the modelling spreadsheet as shown below. Note the boxes that are ticked and specify the No. of Profiles (1 in this case) and the No. of Doses (5). Hopefully, the remainder are self-explanatory.

	<u>Algorithm</u>	W	eighting	Pr	ofile type	No. of Profiles	No. poin	No. points for fitted line	
	DFP (WLS)		1/Conc		Single dose	1 -		200	
	Marquardt (IRWLS) Simplex (WLS)	✓	1/Conc ²	~	Repeat dose	No. of Doses		500 1000	
	Simplex (IRWLS)		Unweighted	~	Mixed models	5 -		5000	
								10000	
	Parameters <u>Constraints</u>			<u>Data layout</u>	Useful for	profiles with			
	Computer estimates		Yes		Time conc time	e conc	long times (500 to 1000		
~	User estimates	✓	No	~	Time conc conc	2	is usual but dependent on		
							profile tim	e and shape).	
	<u>Plotting</u>	Mod	lel number	<u>Graph</u>	axis titles (upd	<u>ated at Run time)</u>	RD bolus	may need 5000	
•	Yes		5 -	X-axis	Time (h)		or more.		
	No	Only use Repeat de	ed for Single or ose (not Mixed)	Y-axis	Conc. (µg/mL)		Select bef	ore running.	

Once the above is populated, move down to Row 54, and enter the model numbers for each dose, in this case model 16 for the initial doses (bolus + infusion) and 10 (oral) for the remainder, as shown.

Model number 14 7 11 7 1 for each dose.	del mber each se.	14 7	7	11	7	14
---	----------------------------	------	---	----	---	----

Then click the 'Keywords' button which will lay out the expected input data for the user to add the appropriate values. Some values will be set to zero as they would not be required for certain models. The program will sort out the sequence of parameters for populating using 'Mixed models'. To store the input setup data for the program, just click 'Activate' to show a message that it is stored in a file. Then click the 'Row 1154' button to enter the time and concentration data. Once entered, click the 'Activate' button to store the values and then return to the Fitting options by clicking 'Row 45'. If everything is looking good, click the 'Run' button and within a few seconds the modelling will be completed, and an Excel window will appear with a detailed summary of the results. The graphics (both linear and log) can be shown by clicking the 'Next' button on the 'Modelling' sheet (just below the graphs) which prompts the program to update both plots and store these in separate files (location and names shown at the end of the summary sheet). The input data should look like that shown on the next page followed by a snippet of the results file and pictures from the Modelling spreadsheet. Note that the fitted volume terms for i.v. (30 L) and oral (50 L) are different as the F value was different when the data were generated.

Setup	parameters	Time-Concentration Data (rounded)						
Title	Set1	Comments	Time (h)	Set1				
Dose	0		0	16.667				
Ndoses	5		1	48.368				
Pars Viv	25	User starting estimates.	2	46.009				
k 10	0.04		3	43.765				
V _{po}	40		4	41.63				
ka	0.6		8	34.084				
tlag	0.25		12	27.906				
Doseint	24	Only 4 needed as the	16	22.847				
	36	first dose is assumed	20	18.706				
	24	to be time zero.	24	15.315				
	24		25	21.075				
Inftime	1	Infusion time (e.g.,	26	27.224				
	0	h, min etc.).	27	29.121				
	0		28	29.15				
	0		30	27.288				
	1		36	20.407				
Infrate	1000	For the models that	40	16.71				
	0	do not require values	45	13.014				
	0	just use zero as shown	48	11.201				
	0	e.g., oral models have	59	6.462				
	1000	no bolus or infusion.	60	19.481				
Infbol	500	Bolus dose for model	61	18.53				
	0	14 (bolus + infusion).	62	17.627				
	0		66	14.432				
	0		80	7.167				
	250		84	5.867				
Repdose	0		85	12.088				
	1000	Oral (model 7)	86	18.675				
	400	Bolus (model 11)	8/	20.99				
	1000	Oral (model 7)	88	21.415				
	0		89	21.022				
			90	20.289				
			91	19.431				
			90 104	10.205				
			104	8 784				
			107	16 680				
			100	10.009				
			109	46.020				
			110	41 648				
			112	34 099				
			120	27.918				
			130	16 933				
			140	10.755				
			140	6 549				
			150	6 229				
			150	0.22)				

Modelling result from summary file (much more detailed in the actual file).

Date	24/12/2022 15:37										
Algorithm	Marquardt (IRWLS	Iarquardt (IRWLS)									
Weighting	1/Conc2	/Conc2									
Model	Mixed										
Setup inform	Setup information used for this run is shown at the end of this summary.										
Parameter	Pars V _{iv}	k 10	Vpo	ka	tlag	Akaike	Sos	λ_1			
Set1	29.999616	5.00E-02	49.99934	0.7999517	0.4999443	-792.1537	2.67E-08	0.0500			
%Error	7.95E-04	6.99E-04	1.33E-03	7.14E-03	9.52E-03						

Although the concentration data were rounded to 3 decimal places, these final parameter values are very close to the theoretical ones (shown below).

Parameter	Pars V _{iv}	k ₁₀	V_{po}	ka	t_{lag}	
Set1	30.0	0.050	50.0	0.80	0.50	

Plots generated (copied from spreadsheet, Log and Linear)



4.2.3 3-compartment bolus + infusion followed by oral maintenance (varying doses and intervals)

For this example, the dosing regimen is a bolus injection + infusion followed by an oral maintenance with different doses and over varying dosing intervals.

Specifically, the 3-compartment models used for this example were numbers 18 (bolus + infusion) and 43 (oral with no lag-time). To begin with, populate the Fitting options section on the modelling spreadsheet as shown below. Note the boxes that are ticked and specify the No. of Profiles (1 in this case) and the No. of Doses (10). Hopefully, the remainder are self-explanatory.

	<u>Algorithm</u>	Weighting	<u>P</u> 1	ofile type	No. of Profiles	No. points for fitted line		
	DFP (WLS)	□ 1/Conc		Single dose	1 -		200	
V	Marquardt (IRWLS)	\checkmark 1/Conc ²		Papast dosa			500	
	Simplex (WLS)	□ Unweighted	V	Repeat dose	No. of Doses	~	1000	
	Simplex (IRWLS)		~	Mixed models	10 -		5000	
							10000	
	Parameters <u>Constraints</u>		Data layout			Useful for profiles with		
	Computer estimates	□ Yes		Time conc time	e conc	long times (500 to 1000		
	User estimates	✓ No	~	Time conc conc	2	is usual bu	it is dependent	
						on profile	time and shape).	
	<u>Plotting</u>	Model number	<u>Graph</u>	<u>n axis titles (upd</u>	<u>ated at Run time)</u>	RD bolus	may need 5000	
✓	Yes	9 🔻	X-axis	Time (h)		or more.		
	No	Only used for Single or Repeat dose (not Mixed)	Y-axis	Conc. (µg/mL)		Select bef	ore running.	

Once the above is populated, move down to Row 54, and enter the 3-compartment model numbers for each dose, in this case model 18 for the initial doses (bolus + infusion) and 43 (oral) for the remainder, as shown.

Model number for each dose.	18	43	43	43	43	43	43	43	43	43
--------------------------------------	----	----	----	----	----	----	----	----	----	----

Then click the 'Keywords' button which will lay out the expected input data for the user to add the appropriate values. Some values will be set to zero as they would not be required for certain models. The program will sort out the sequence of parameters for populating using 'Mixed models'. To store the input setup data for the program, just click 'Activate' to show a message that it is stored in a file. Then click the 'Row 1154' button to enter the time and concentration data. Once entered, click the 'Activate' button to store the values and then return to the Fitting options by clicking 'Row 45'. If everything is looking good, click the 'Run' button and within a few seconds the modelling will be completed, and an Excel window will appear with a detailed summary of the results. The graphics (both linear and log) can be shown by clicking the 'Next' button on the 'Modelling' sheet (just below the graphs) which prompts the program to update both plots and store these in separate files (location and names shown at the end of the summary sheet). The input data should look like that shown on the next page followed by a snippet of the results file and pictures from the Modelling spreadsheet. Note that the fitted volume terms for i.v. (10 L) and oral (20 L) are different as the F value was different when the data were generated.

Setup pa	arameters	Time-Concentration Data (rounded)								
Title	Set1	Comments	Time (h)	Set1	Time (h)	Set1				
Dose	0		0.0	10.00	130.0	4.288				
Ndoses	10		0.5	10.298	134.0	3.665				
Pars V _{iv}	8.0	User starting estimates.	1.0	10.665	135.5	12.959				
k ₁₂	0.50	Note there are 8	1.5	11.070	137.0	10.457				
k ₂₁	0.25	parameters.	2.0	11.494	142.0	5.387				
k ₁₃	0.15		2.5	11.925	148.0	3.975				
k 31	0.020		3.0	12.355	150.0	3.664				
k 10	0.20		4.0	13.194	158.0	2.746				
V _{po}	25.0		5.0	13.993	158.5	15.636				
ka	0.5		6.0	14.746	159.5	21.595				
Doseint	24.0	Only 9 needed as the	8.0	16.115	160.0	20.587				
	20.0	first dose is assumed	9.0	16.737	166.0	7.349				
	24.0	to be time zero.	10.0	17.320	178.0	3.893				
	18.0		10.5	14.251	188.0	2.683				
	24.0		11.0	12.166	189.5	21.535				
	24.0		12.0	9.693	212.0	3.281				
	24.0		14.0	7.539	214.0	21.056				
	30.0		16.0	6.463	218.0	9.574				
	24.0		18.0	5.679	228.0	4.858				
Inftime	10	Infusion time (e.g.,	20.0	5.033	248.0	2.328				
	0	h, min etc.).	24.0	4.016	270.0	1.349				
	0		24.5	16.844	290.0	0.889				
	0	For the models that	25.0	21.805	296.0	0.788				
	0	do not require certain	25.5	22.687	300.0	0.727				
	0	values just use zero	26.5	19.782						
	0	as shown e.g., oral	28.0	14.196						
	0	models have no bolus	30.0	9.889						
	0	or infusion info.	36.0	6.001						
	0		40.0	4.845						
Infrate	80	Infusion rate (e.g.,	44.0	3.998						
	0	mg/h, μg/min etc.).	45.0	12.820						
	0		45.5	13.227						
	0	For the models that	46.0	12.662						
	0	do not require certain	48.0	8.824						
	0	values just use zero	52.0	5.463						
	0	as shown e.g., oral	56.0	4.345						
	0	models have no bolus	60.0	3.626						
	0	or infusion info.	65.0	2.969						
T., (h 1	0	D.1 1 C 1.1	68.0	2.663						
INDOI	100	Bolus dose for model	69.0	20.571						
	0	18 (bolus + infusion).	09.5	21.308						
	0		70.0	20.499						
	0	Not required for oral	72.0	0.113						
	0	not required for oral	74.0	9.113						
	0	models.	70.0	5 5 6 3						
	0		80.0 86.0	<i>J.303</i> <i>A</i> 149						
	0		87.5	22 863						
	0		89.0	17 070						
Rendose	0	Not required for model	91.0	11.979						
Republic	1000	18 but would be if the	96.0	7 095						
	500	model was holds only	100.0	5 707						
	1000	(models 11 12 or 13)	106.0	4 338						
	1000	(1100015 11, 12 01 15).	110.0	3.692						
	1000	The remainder are the	111.5	22.468						
	500	oral doses.	113.0	17.637						
	1000		118.0	7.982						
	1000		120.0	6.928						
	1000									

Modelling result from summary file (much more detailed in the actual file).

Date	29/12/2022 16:59	9								
Algorithm	Marquardt (IRW	farquardt (IRWLS)								
Weighting	1/Conc2									
Model	Mixed									
Setup info	rmation and plot	files detaile	d for this ru	in at the en	d of this su	mmary Wo	rkbook as	a record.		
Parameter	Pars V_{iv}	k ₁₂	k ₂₁	k ₁₃	k ₃₁	k_{10}	V_{po}	\mathbf{k}_{a}	Akaike	Sos
Set1	10.00009	0.4000142	0.2000284	0.1000056	0.0300009	0.2500013	19.99978	0.7500121	-1128.681	8.66E-07
%Error	7.97E-03	1.76E-02	2.18E-02	4.05E-02	3.17E-02	8.61E-03	9.16E-03	1.02E-02		

Although the concentration data were rounded to 3 decimal places, these final parameter values are very close to the theoretical ones (shown below).

Pars V _{iv}	k ₁₂	k ₂₁	k ₁₃	k ₃₁	k ₁₀	V_{po}	ka
10.0	0.40	0.20	0.10	0.030	0.25	20.0	0.75

Plots generated (copied from spreadsheet, Log and Linear)



4.2.4 2-compt. bolus + infusion followed by oral maintenance V7.6, varying dose, and interval.

For this example, using V7.6, the dosing regimen is a bolus injection + infusion followed by an oral maintenance with different doses and over varying dosing intervals. The sampling is taken on Days 1 and 10 only, to reflect what may be chosen for a study (the data is hypothetical, but the result demonstrates the validity of the procedure). In V7.6 output, note the additions of plot file names at the beginning and the λ_n values in the Excel summary file, which are now added after several users requested these additions.

The other update to note is that for compartmental models the λ_n values are now calculated for 'Single' and 'Repeat' dose options in addition to 'Mixed', as for this example.

Specifically, the 2-compartment models used for this example were numbers 16 (bolus + infusion) and 10 (oral with no lag-time). To begin with, populate the Fitting options section on the modelling spreadsheet as shown below. Note the boxes that are ticked and specify the No. of Profiles (1 in this case) and the No. of Doses (10). Hopefully, the remainder are self-explanatory.

	<u>Algorithm</u>	Weighting	Pr	ofile type	No. of Profiles	No. points for fitted line
	DFP (WLS)	□ 1/Conc		Single dose	1 -	2 00
v	Marquardt (IRWLS)	\checkmark 1/Conc ²		Papart dosa		5 00
	Simplex (WLS)	Unweighted		Repeat dose	No. of Doses	✓ 1000
	Simplex (IRWLS)		~	Mixed models		5000
						□ 10000
	Parameters	Constraints		Data layout		Useful for profiles with
	Computer estimates	□ Yes		Time conc time	e conc	long times (500 to 1000
	User estimates	✓ No	~	☑ Time conc conc		is usual but is dependent
						on profile time and shape).
	<u>Plotting</u>	Model number	<u>Graph</u>	axis titles (upd	<u>ated at Run time)</u>	RD bolus may need 5000
✓	Yes	9 🔻	X-axis Time (h)		or more.	
	No	Only used for Single or Repeat dose (not Mixed)	Y-axis	axis Conc. (µg/mL)		Select before running.

Once the above is populated, move down to Row 54, and enter the 2-compartment model numbers for each dose, in this case model 16 for the initial doses (bolus + infusion) and 10 (oral) for the remainder, as shown.

Model number for each dose.	16	10	10	10	10	10	10	10	10	10
--------------------------------------	----	----	----	----	----	----	----	----	----	----

Then click the 'Keywords' button which will lay out the expected input data for the user to add the appropriate values. Some values will be set to zero as they would not be required for certain models. The program will sort out the sequence of parameters for populating using 'Mixed models'. To store the input setup data for the program, just click 'Activate' to show a message that it is stored in a file. Then click the 'Row 1154' button to enter the time and concentration data. Once entered, click the 'Activate' button to store the values and then return to the Fitting options by clicking 'Row 45'. If everything is looking good, click the 'Run' button and within a few seconds the modelling will be completed, and an Excel window will appear with a detailed summary of the results. The graphics (both linear and log) can be shown by clicking the 'Next' button on the 'Modelling' sheet (just below the graphs) which prompts the program to update both plots and store these in separate files (location and names shown at the beginning of the summary sheet). The input data should look like that shown on the next page followed by a snippet of the results file and pictures from the Modelling spreadsheet.

Note that the fitted volume terms for i.v. (20 L) and oral (30 L) are different as the F value was different when the data were generated.

S	etup parameters	Time	Time-Concentration Data (rounded)						
Title	Set1	Comments	Time (h)	Set1					
Dose	0	Automatically set when	0.00	50.00					
Ndoses	10	Keywords' is clicked.	1.00	53.15					
Pars V _{iv}	15.000	User starting estimates.	3.00	60.06					
k ₁₂	0.080	Note there are 6	4.00	63.70					
k 21	0.170	parameters.	5.00	67.39					
k ₁₀	0.060	- The second	8.00	53.50					
Vpo	25.000		10.00	47.92					
ka	0.300		12.00	43.92					
Doseint	24.0	Only 9 needed as the	16.00	38.44					
	23.0	first dose is assumed	20.00	34.55					
	24.0	to be time zero.	24.00	31.39					
	25.0		216.00	23.08					
	24.0		217.00	34.76					
	22.0		218.00	40.22					
	26.0		219.00	42.22					
	24.0		220.00	42.35					
	24.0		221.00	41.54					
Inftime	5.0	Infusion time	222.00	40.30					
	0.0		223.00	38.91					
	0.0	For the models that	224.00	37.51					
	0.0	do not require certain	225.00	36.18					
	0.0	values just use zero	230.00	30.86					
	0.0	as shown e.g., oral	240.00	24.10					
	0.0	models have no bolus	250.00	19.22					
	0.0	or infusion info.	254.00	17.57					
	0.0		256.00	16.80					
	0.0		260.00	15.36					
Infrate	200.0	Infusion rate (e.g.,	270.00	12.27					
	0.0	mg/h, μg/min etc.).	280.00	9.81					
	0.0								
	0.0	For the models that							
	0.0	do not require certain							
	0.0	values just use zero							
	0.0	as shown e.g., oral							
	0.0	models have no bolus							
	0.0	or infusion info.							
	0.0								
Infbol	1000.0	Bolus dose for model							
	0.0	16 (bolus + infusion).							
	0.0								
	0.0	Not required for oral							
	0.0	models (use 0.0).							
	0.0								
	0.0								
	0.0								
	0.0								
D 1	0.0								
Repdose	0.0	Not required for model							
	2000.0	16 but would be if the							
	1000.0	model was bolus only							
	1000.0	(models 11, 12 or 13).							
	500.0	The second budget of							
	1000.0	i ne remainder are the							
	500.0	oral doses.							
	1000.0								
	1000.0								
	1000.0								

Modelling result from summary file (much more detailed in the actual file).

12/01/2023 10:10	Linear Plot	ting files st	ored in C	PCModfit	t V7.6\Resu	lts\Fitplotlin	85.png to l	Fitplotlin8	5.png
Marquardt (IRWLS)	Log. Plottir	ng files stor	ed in C:\I	PCModfit V	7.6\Result	s\Fitplotlog8	5.png to Fi	tplotlog85	.png
1/Conc2									
Mixed									
mation used for this ru	un is shown	at the end o	of this sum	mary.					
Pars V _{iv}	k ₁₂	k ₂₁	k_{10}	$\mathbf{V}_{\mathbf{po}}$	$\mathbf{k}_{\mathbf{a}}$	Akaike	Sos	λ1	λ_2
20.00540	0.099610	0.149446	0.039995	30.18546	0.500212	-295.8807	2.45E-05	0.26663	0.02242
0.08	0.43	0.36	0.10	0.11	0.30				
	12/01/2023 10:10 Marquardt (IRWLS) 1/Conc2 Mixed mation used for this ro Pars V _{iv} 20.00540 0.08	12/01/2023 10:10 Linear Plot Marquardt (IRWLS) Log. Plottin 1/Conc2 Mixed mation used for this run is shown Pars Viv Pars Viv k12 20.00540 0.099610 0.08 0.43	$12/01/2023$ $10:10$ Linear Plotting files storeMarquardt (IRWLS)Log. Plotting files store $1/Conc2$ Mixedmation used for this run is shown at the end ofPars V_{iv} k_{12} k_{21} 20.00540 0.099610 0.149446 0.08 0.43 0.36	12/01/2023 10:10Linear Plotting files stored in C:Marquardt (IRWLS)Log. Plotting files stored in C:1/Conc2Mixedmation used for this run is shown at the end of this summedPars V_{iv} k_{12} k_{21} k_{10} 20.005400.0996100.1494460.080.430.360.10	12/01/2023 10:10Linear Plotting files stored in C:\PCModfitMarquardt (IRWLS)Log. Plotting files stored in C:\PCModfit1/Conc2Mixedmation used for this run is shown at the end of this summary.Pars V_{iv} k_{12} k_{21} k_{10} V_{po} 20.005400.0996100.1494460.03999530.185460.080.430.360.100.11	12/01/2023 10:10 Linear Plotting files stored in C:\PCModfit V7.6\Result Marquardt (IRWLS) Log. Plotting files stored in C:\PCModfit V7.6\Results 1/Conc2 Mixed mation used for this run is shown at the end of this summary. Pars V_{iv} k_{12} k_{21} k_{10} V_{po} k_a 20.00540 0.099610 0.149446 0.039995 30.18546 0.500212 0.08 0.43 0.36 0.10 0.11 0.30	$\begin{array}{c ccccc} 12/01/2023 \ 10:10 & Linear Plotting files stored in & C:\PCModfit V7.6\Results\Fitplotling Marquardt (IRWLS) & Log. Plotting files stored in & C:\PCModfit V7.6\Results\Fitplotlog8: 1/Conc2 & Mixed & & & & & & & & & & & & & & & & & & &$	12/01/2023 10:10Linear Plotting files stored inC:\PCModfit V7.6\Results\Fitplotlin85.pngtoMarquardt (IRWLS)Log. Plotting files stored inC:\PCModfit V7.6\Results\Fitplotlog85.pngto1/Conc2Mixedmation used for this run is shown at the end of this summary.Pars V_{iv} k_{12} k_{21} k_{10} V_{po} k_a AkaikeSos20.005400.0996100.1494460.03999530.185460.500212-295.88072.45E-050.080.430.360.100.110.30	12/01/2023 10:10Linear Plotting files stored in C:\PCModfit V7.6\Results\Fitplotlin85.pngtoFitplotlin85Marquardt (IRWLS)Log. Plotting files stored in C:\PCModfit V7.6\Results\Fitplotlog85.pngtoFitplotlog851/Conc2Mixedmation used for this run is shown at the end of this summary.Pars Viv k_{12} k_{21} k_{10} V_{po} k_a AkaikeSos λ_1 20.005400.0996100.1494460.03999530.185460.500212-295.88072.45E-050.266630.080.430.360.100.110.300.300.30

New additions in V7.6

Even though the concentration data were rounded to 2 decimal places, these final parameter values are very close to the theoretical ones (shown below).

Pars V _{iv}	k ₁₂	k ₂₁	k 10	Vpo	ka
20.0	0.10	0.15	0.04	30.0	0.500

Plots generated (copied from spreadsheet, Linear and Log)



4.2.5 2-compt. Oral, varying with and without lag-time models and doses and intervals.

For this example, using V7.7, the dosing regimen alternates oral with lag-time then oral without, as shown in the Model numbers below. The doses and dosing intervals are also varied.

Specifically, the 2-compartment models used for this example were numbers 9 (with lag-time) and 10 (without lag-time). Note the boxes that are ticked and specify the No. of Profiles (1 in this case) and the No. of Doses (6). Hopefully, the remainder are self-explanatory.

<u>Algorithm</u> <u>Weighting</u>		eighting	Profile type No. of Profiles		No. poin	No. points for fitted line	
DFP (WLS)		1/Conc		Single dose	1 -		200
Marquardt (IRWLS)		$1/C = x^{2}$		Papast dosa			500
Simplex (WLS)		1/Conc		Repeat dose	No. of Doses	~	1000
Simplex (IRWLS)		Unweighted	~	Mixed models	6 -		5000
							10000
Parameters	Co	<u>nstraints</u>	Data layout			Useful for	profiles with
Computer estimates		Yes		$\Box \text{Time conc time conc}$		long time	s (500 to 1000
User estimates	~	No	~	\checkmark Time conc conc		is usual but dependen	
						profile time and shape	
<u>Plotting</u>	<u>Model number</u>		<u>Graph</u>	Graph axis titles (updated at Run tin		at Run time) RD bolus may need	
Yes	8 💌		X-axis	Time (h)		or more.	
No	Only use Repeat de	ed for Single or ose (not Mixed)	Y-axis	Conc. (µg/mL)		Select before runn	

Once the above is populated, move down to Row 54, and enter the 2-compartment oral model numbers for each dose, as shown.

doso	Model number for each	9	10	9	10	9	10
------	-----------------------------	---	----	---	----	---	----

Then click the 'Keywords' button which will lay out the expected input data for the user to add the appropriate values. The program will sort out the sequence of parameters for populating using 'Mixed models'. To store the input setup data for the program, just click 'Activate' to show a message that it is stored in a file. Then click the 'Row 1154' button to enter the time and concentration data. Once entered, click the 'Activate' button to store the values and then return to the Fitting options by clicking 'Row 45'. If everything is looking good, click the 'Run' button and within a few seconds the modelling will be completed, and an Excel window will appear with a detailed summary of the results. The graphics (both linear and log) can be shown by clicking the 'Next' button on the 'Modelling' sheet (just below the graphs) which prompts the program to update both plots and store these in separate files (location and names shown at the beginning of the results file and pictures from the Modelling spreadsheet.

	Setup parameters		Time-Concentration Data (rounded)				
Title	Profile 1	Comments	Time	Profile 1			
Dose	0.0	Automatically set when	0	0 -			
Ndoses	6	Keywords' is clicked.	1	0			
Pars V _{po}	18.00		2	0			
ka	0.40	Note there are 6 parameters.	3	8.48			
k ₁₂	0.10	-	4	11.57			
k ₂₁	0.03		5	11.89			
k ₁₀	0.15		6	10.93			
tlag	1.50		7	9.46			
Doseint	24.0	Only 5 needed as the first dose	8	7.92			
	20.0	is assumed to be time zero.	9	6.49			
	24.0		10	5.25			
	18.0		11	4.21			
	24.0		12	3.38			
Repdose	500.0	Oral doses.	14	2.18			
	1000.0		15	1.77			
	500.0		16	1.46			
	1000.0		19	0.88			
	1000.0		20	0.77			
	1000.0		24	0.52			
			25	17.46			
			26	23.6			
			27	24.23			
			28	22.28			
			29 30	19.34			
			110	2.38			
			110	19.26			
			112	25.36			
			113	25.95			
			114	23.97			
			115	21			
			116	17.87			
			118	12.45			
			119	8 65			
			120	6.21			
			124	4.7			
			126	3.78			
			127	3.47			
			128	3.22			
			129	3.02			
			130	2.87			
			144	2.06			
			152	1.64			
			168	1.04			
			175	1.33			
			180	1.24			
			185	1.16			
			190	1.08			
			194	1.02			
			195	1.01			
			197	0.98			
			200	0.94			

Modelling result from summary file (much more detailed in the actual file).

Date	21/01/2023 15:10	Linear Plot	ting files st	ored in C:	\PCModfit	t V7.7\Resu	ılts\Fitplotlin	13.png to	Fitplotlin1	3.png
Algorithm	Marquardt (IRWLS) Log. Plotting files stored in C:\PCModfit V7.7\Results\Fitplotlog13.png to Fitplotlog13.png									
Weighting	1/Conc2									
Model	Mixed									
Setup inform	mation used for this r	un is shown	at the end o	of this sum	nary.					
Parameter	Pars V _{po}	ka	k ₁₂	k ₂₁	k 10	t _{lag}	Akaike	Sos	λ1	λ_2
Profile_1	20.03772	0.50121	0.07979	0.01995	0.19960	2.00021	-464.7346	8.72E-05	0.28539	0.01395
%Error	0.14	0.21	0.18	0.13	0.13	0.11				

Even though the concentration data were rounded to 2 decimal places, these final parameter values are very close to the theoretical ones (shown below).

Pars V _{po}	ka	k ₁₂	k 21	k 10	t _{lag}
20.0	0.5	0.08	0.02	0.2	2.0

Plots generated (copied from spreadsheet, Linear and Log)





4.2.6 3-compartment oral with and without lag-time (varying doses and intervals, V7.7)

For this example, the dosing regimen is a 3-compt. repeat dose oral, alternating with and without lag-time and with different doses and dosing intervals.

Specifically, the 3-compartment oral models used for this example were numbers 42 (with lag-time) and 43 (no lag-time) varying doses and intervals. To begin with, populate the Fitting options section on the modelling spreadsheet as shown below. Note the boxes that are ticked and specify the No. of Profiles (1 in this case) and the No. of Doses (10). Hopefully, the remainder are self-explanatory.

Algorithm		Weighting	Profile type		No. of Profiles	<u>No. poin</u>	lo. points for fitted line		
	DFP (WLS)	□ 1/Conc		Single dose	1 -		200		
	Marquardt (IRWLS)	\checkmark 1/Conc ²		Demost dess			500		
	Simplex (WLS)	□ Unweighted		Repeat dose	No. of Doses	~	1000		
	Simplex (IRWLS)		~	Mixed models	10 -		5000		
							10000		
	Parameters	neters <u>Constraints</u>		Data layout			Useful for profiles with		
	\Box Computer estimates \Box Yes			\Box Time conc time conc			long times (500 to 1000		
v	User estimates	🗹 No	~	\checkmark Time conc conc		is usual but is dependent			
					on profile time and shape).				
Plotting Model number		Model number	Graph axis titles (updated at Run time)			RD bolus may need 5000			
	Yes	9 🔻	X-axis	Time (h)		or more.			
	No	Only used for Single or Repeat dose (not Mixed)	Y-axis	Conc. (µg/mL)		Select before running.			

Once the above is populated, move down to Row 54, and enter the 3-compartment model numbers for each dose, in this case model 18 for the initial doses (bolus + infusion) and 43 (oral) for the remainder, as shown.

Model number for each dose.	42	43	42	43	42	43	42	43	42	43
--------------------------------------	----	----	----	----	----	----	----	----	----	----

Then click the 'Keywords' button which will lay out the expected input data for the user to add the appropriate values. Some values will be set to zero as they would not be required for certain models. The program will sort out the sequence of parameters for populating using 'Mixed models'. To store the input setup data for the program, just click 'Activate' to show a message that it is stored in a file. Then click the 'Row 1154' button to enter the time and concentration data. Once entered, click the 'Activate' button to store the values and then return to the Fitting options by clicking 'Row 45'. If everything is looking good, click the 'Run' button and within a few seconds the modelling will be completed, and an Excel window will appear with a detailed summary of the results.

The graphics (both linear and log) can be shown by clicking the 'Next' button on the 'Modelling' sheet (just below the graphs) which prompts the program to update both plots and store these in separate files (location and names shown at the end of the summary sheet). The input data should look like that shown on the next page followed by a snippet of the results file and pictures from the Modelling spreadsheet.
Setup parameters		Tim	e-Concentration Data (rounded)			
Title	Profile_1	<u>Comments</u>	Time (h)	Profile_1		
Dose	0.0		0.0	0.00		
Ndoses	10		1.00	0.00		
Pars V _{po}	20.00	User starting estimates. Note there	2.00	0.00		
ka	0.60	are 8 parameters.	2.50	9.779		
k ₁₂	0.35		3.00	13.778		
k ₂₁	0.22		3.50	14.705		
k ₁₃	0.08		4.00	14.117		
k ₃₁	0.02		6.00	8.872		
k ₁₀	0.20		10.00	4.232		
t _{lag}	1.60		11.00	3.811		
Doseint	24.0	Only 9 needed as the first dose	12.00	3.488		
	20.0	is assumed to be time zero.	13.00	3.227		
	24.0		15.00	2.810		
	18.0		17.00	2.476		
	24.0		20.00	2.073		
	24.0		24.00	1.665		
	24.0		210.00	2.248		
	30.0		210.25	6.612		
	22.0		210.50	9.543		
Repdose	1000	Oral doses, one for each dose.	210.75	11.412		
	500		211.00	12.503		
	500		211.50	13.161		
	1000		212.00	12.683		
	1000		212.50	11.722		
	1000		213.00	10.624		
	1000		214.00	8.613		
	1000		215.00	7.119		
	500		216.00	6.093		
	750		220.00	4.244		
			224.00	3.431		
			230.00	2.637		
			236.00	2.103		
			242.00	1.727		
			250.00	1.376		
			260.00	1.075		
			270.00	0.860		
			280.00	0.698		
			295.00	0.516		
			300.00	0.467		

Modelling result from summary file (much more detailed in the actual file).

Date 22/01/2023 11:46			Linear	Plotting	files stor	ed in C:\	PCModf	it V7.7∖R	esults\Fi	tplotlin16.	png to Fi	tplotlin16	ó.png
Algorithm Marquardt (IRWLS)		Log. P	Log. Plotting files stored in C:\PCModfit V7.7\Results\Fitplotlog16.png to Fitplotlog16.png										
Weighting	Weighting 1/Conc2												
Model	Mixed												
Setup inform	Setup information used for this run is shown at the end of this summary.												
Parameter	Pars V _{po}	ka	k ₁₂	k 21	k 13	k 31	k 10	t _{lag}	Akaike	Sos	λ1	λ_2	λ3
Profile_1	25.0224	0.70059	0.39963	0.19999	0.09984	0.02997	0.24978	2.00001	-456.68	6.02E-07	0.87177	0.08790	0.01954
%Error	0.31	0.28	0.36	0.07	0.28	0.06	0.30	0.01					

Although the concentration data were rounded to 3 decimal places, these final parameter values are very close to the theoretical ones (shown below).

Pars V _{po}	ka	k ₁₂	k 21	k 13	k 31	k 10	tlag
25.0	0.70	0.40	0.20	0.10	0.03	0.25	2.0

Plots generated (copied from spreadsheet, Log and Linear)



5. Models and symbols

There are many pharmacokinetic models available in PCModfit and this section of the manual details the models and the parameters in the sequence used by other aspects of the program. The fitting options use the model parameters exactly as they are shown here and should not be entered in any other sequence. Additional models will be added – note that some models have been removed as these are currently being sorted out.

Model	Type and parameter sequence	Number of Parameters	With starting Estimates
1	Two exponentials (oral)	4	Yes
	$(\mathbf{B}, \mathbf{k}_{a}, \mathbf{A}, \lambda_{1})$		
2	Three exponentials (oral)	6	Yes
	$(C, k_a, \overline{A}, \lambda_1, B, \lambda_2)$		
3	Four exponentials (oral)	8	No
	$(D, k_a, A, \lambda_1, B, \lambda_2, C, \lambda_3)$		
4	One exponential i.v.	2	Yes
	(A, λ)		
5	Two exponentials i.v.	4	Yes
	$(A, \lambda_1, B, \lambda_2)$		
6	Three exponentials i.v.	6	Yes
	$(\mathbf{A}, \lambda_1, \mathbf{B}, \lambda_2, \mathbf{C}, \lambda_3)$		
7	One compartment oral (with lag time)	4	Yes
	(V, k_a, k_{10}, t_l)		
8	One compartment oral	3	Yes
	(V, k_a, k_{10})		
9	Two compartment oral (with lag time)	6	Yes
	$(V, k_a, k_{12}, k_{21}, k_{10}, t_l)$		
10	Two compartment oral	5	Yes
	$(V, k_a, k_{12}, k_{21}, k_{10})$		
11	One compartment i.v. bolus	2	Yes
	(V, k_{10})		
12	Two compartment i.v. bolus	4	Yes
	$(V, k_{12}, k_{21}, k_{10})$		
13	Three compartment i.v. bolus	6	Yes
	$(V, k_{12}, k_{21}, k_{13}, k_{31}, k_{10})$		
14	One compartment infusion with bolus	2	Yes
	(V, k_{10})		
15	One compartment infusion	2	Yes
	(V, k_{10})		
16	Two compartment infusion with bolus	4	Yes
	$(V, k_{12}, k_{21}, k_{10})$		
17	Two compartment infusion	4	Yes
	$(V, k_{12}, k_{21}, k_{10})$		
18	Three compartment infusion with bolus	6	Yes
	$(V, k_{12}, k_{21}, k_{13}, k_{31}, k_{10})$		
19	Three compartment infusion	6	Yes
	$(V, k_{12}, k_{21}, k_{13}, k_{31}, k_{10})$		
20	Weibull function (with lag time)	4	No
	(F, t_1, t_d, λ)		
21	Weibull function	3	No
	(F, t_d, λ)		

23	Zero order input one compartment oral	3	No
	(V, k_{10}, T)		
24	Zero order input two compartment oral (with lag time)	6	No
	$(V, k_{12}, k_{21}, k_{10}, T, t_l)$		
38	One compartment infusion (with bolus coefficients)	2	Yes
	(A, λ_1)		
39	Two compartment infusion (with bolus coefficients)	4	Yes
	$(A, \lambda_1, B, \lambda_2)$		
40	Three compartment infusion (with bolus coefficients)	6	Yes
	$(\mathbf{A}, \lambda_1, \mathbf{B}, \lambda_2, \mathbf{C}, \lambda_3)$		
42	Three compartment oral (with lag time)	8	No
	$(V, k_a, k_{12}, k_{21}, k_{13}, k_{31}, k_{10}, t_l)$		
43	Three compartment oral	7	No
	$(V, k_a, k_{12}, k_{21}, k_{13}, k_{31}, k_{10})$		
45	Power function $(p_1 t^{-p_2})$	2	No
46	Gamma function $(p_1t^{-p}2e^{-p_3}t)$	3	No
54	One compartment oral (equal rate constant, with lag time)	3	No
	$(\mathbf{V},\mathbf{k},\mathbf{t}_{l})$		
55	One compartment oral (equal rate constant)	2	No
	(V, k)		
60	$y = p_1 (1 - e^{-p_2(t-t_1)})$	3	No
68	Polynomial (degree 1)	2	No
	$(\mathbf{p}_1 + \mathbf{p}_2 \mathbf{x})$		
69	Polynomial (degree 2)	3	No
	$(p_1 + p_2 x + p_3 x^2)$		
70	Polynomial (degree 3)	4	No
	$(p_1 + p_2 x + p_3 x^2 + p_4 x^3)$		
71	Polynomial (degree 4)	5	No
	$(p_1 + p_2 x + p_3 x^2 + p_4 x^3 + p_5 x^4)$		

Summary of Symbols Used

Parameter	Interpretation
AUC	Area under concentration-time data
C_1, C_2	Coefficients of appropriate exponentials
$\lambda_1, \lambda_2\lambda_n$	Eigenvalues of model (or alpha, beta, gamma phases)
k _{i,j}	Microrate constants from compartment i to j
k ₀	Infusion rate
ke or k ₁₀	Elimination rate constants from compartment 1 (not necessarily λ)
ka	Absorption rate constant (oral models)
V_{iv} or V_{po}	Vol. of distribution (central compartment 1) for i.v. or oral models
V_1, V_2, V_3	Vols. of compartments 1, 2 and 3 i.e., $V_2 = k_{12} / k_{21} \times V_1$ and $V_3 = k_{13} / k_{31} \times V_1$
t ₁ or t _{1ag}	Lag time (absorption delay)
t _d	Mean dissolution time
β	Shape parameter (equals 1 for 1st order)
Т	Infusion time
p_1, p_2, \dots, p_n	Parameters used in fitting
CL	Clearance (Dose/AUC _{0-∞})

6 Appendix 1 (Modelling Approaches)

The pharmacokinetic program 'PCModfit', primarily written in Fortran for speed, is used for the mathematical analysis of drug concentration-time data. Drug data may be numerically fitted using a variety of explicit models with relative ease. The program will automatically generate parameter-starting estimates for many of the models prior to the data fitting (manually, a time-consuming task). There is an option for user estimates if required, with or without parameter constraints. If a satisfactory fit of the model to the data is achieved then PCModfit will generate text files and high-quality graphics. Regarding the graphics, the program will generate linear and logarithmic plots of the experimental data with the computed line to help the user to visually assess the result in addition to numerical output. There are two mathematical approaches for minimising functions which are briefly explained in this Appendix.

One of the mathematical algorithms for the iterative function minimisation is a modified version of the one developed by Davidon-Fletcher-Powell. This routine was coded by the author of PCModfit and incorporates numerical differentiation with options for parameter constraints. An additional algorithm, Marquardt, has been incorporated in this version for iteratively reweighted least squares. Again, numerical differentiation with constraints are available. Additionally, on using this method, if the lower and upper constraints are equal for a parameter then this parameter will be dropped from the iteration process. Function derivatives, gradients, sum of squares and parameter errors etc. at the final solution are automatically computed.

This section of the document deals with the general background to the computer fitting of pharmacokinetic data. The concept of 'least squares' is described and how this may be used in determining a satisfactory line. The mathematical algorithms used in PCModfit are explained briefly with an additional section on how parameter errors are calculated. The final part deals with acceptance of fit criteria that may be of assistance to the user. This is important for deciding which model is correct, when two are chosen, for a particular set of data and whether the results are both meaningful and acceptable.

The method of least squares is an established technique for the regression analysis of linear and non-linear functions. To explain the principle of least squares, a simple function such as a straight line is a good starting point. The equation of a straight line is y = ax + b and this may be formulated into a sum of squares function S.

$$S = \sum_{i=1}^{n} (y_i - (ax_i + b))^2$$
 Eqn. 1

The y_i and x_i represent the n experimental y-values and x-values respectively. The parameters 'a' and 'b' represent the slope and the intercept, respectively, of the line through the data. The equation of a straight line can be pictorially represented as shown.



The usual approach to obtain the 'best line' through the data is to adjust the line such that the sum of the squares of the deviations (d_i) are minimised i.e.

$$S = d_1^2 + d_2^2 + \dots + d_n^2 = \sum_{i=1}^n d_i^2$$
 Eqn. 2

which is equivalent to equation 1. The straight-line problem is relatively simple because the parameters 'a' and 'b' are linear and their explicit solutions are relatively simple. Given a fixed value of one parameter and allowing the other to vary for a set of data, a plot of the sum of squares versus the variable parameter will yield graphs of the form:



For the line of 'best fit', the minimum sum of squares will probably be smaller than either S_1 or S_2 . The sum of squares surface is actually 3-dimensional and can be represented thus;



Where p_1 and p_2 (or a and b) are the 2parameters and S is the sum of squares function (SOS). For the line of 'best fit', the minimum SOS is shown.

The values of parameters 'a' and 'b' can be determined by the solution of equation 3, shown below:

$$S = \sum_{i=1}^{n} (y_i - (ax_i + b))^2$$
 Eqn. 3

taking partial differentials,

$$\left(\frac{\partial S}{\partial a}\right)_{b} = -2\sum_{i=1}^{n} (y_{i} - (ax_{i} + b))x_{i}$$
 Eqn. 4

$$\left(\frac{\partial S}{\partial b}\right)_{a} = -2\sum_{i=1}^{n} (y_{i} - (ax_{i} + b))$$
 Eqn. 5

at the true minimum, both gradients (Eqns. 4 and 5) and both approximate to zero. Thus equations 4 and 5 can be solved simultaneously:

from equation 4;

$$a = \frac{(\sum xy - b\sum x)}{\sum x^2}$$
 Eqn. 6

and from equation 5:

$$b = \frac{(\sum y - a \sum x)}{n}$$
 Eqn. 7

Substitution for b in equation 6 yields the familiar equation for the slope 'a':

$$a = \frac{\sum xy - \frac{\sum x \sum y}{n}}{\sum x^2 - \frac{(\sum x)^2}{n}}$$
Eqn. 8

and 'b' can be calculated from equation 7, given 'a'.

This straight-line solution demonstrates that equations with linear parameters, such as 'a' and 'b', may be solved exactly. In pharmacokinetics, however, the majority of the equations usually contain non-linear parameters and these cannot be solved using simple conventional methods, as just described.

As an example, consider a drug concentration-time profile that exhibits a bi-exponential decline. The sum of squares function for this model can be formulated into equation 8.

$$S = \sum_{i=1}^{n} \left(C_i - \left(A e^{-\lambda_1 t_i} + B e^{-\lambda_2 t_i} \right) \right)^2$$
 Eqn. 9

where C_i represents the experimental concentrations at times t_i , A and B are the linear coefficients and λ_1 and λ_2 are the initial and terminal rate constants respectively. These poly-exponential, or other such transcendental functions, are linear in their coefficients A and B and non-linear in λ_1 and λ_2 . The approaches to solving these types of problems are usually iterative in nature. A schematic to demonstrate a simple approach to iteration theory is shown.

Initially, the four parameters have to be estimated and the sum of squares function calculated using equation 9. The parameters are then modified and the sum of squares recalculated until a final minimum value of S is achieved.

The following simplified flow diagram to illustrate an iterative process for finding the best line through a set of data (S is the sum of squares of deviations of the experimental data from the fitted equation).



The solution to this problem appears superficially straightforward, however there are several issues that need addressing. Parameters require a constraint of some sort to avoid numerical overflow; computers can only deal with numbers of a limited size. An additional very common problem arises when object-functions exhibit more than one minimum. In these situations, where the object function surface becomes distorted, it is not always easy to determine the desired global minimum.

Representation of a 3-D sum of squares surface, exhibiting two minima.



The problem becomes more complex when models containing n>8 parameters are involved and a (n+1) dimensional space exhibits multiple minima. The mathematics of minimising functions is very complex and is a disciplined subject in its' own right. An example of three such powerful algorithms is described in this manual and these are the ones used in PCModfit. A very important point to note in minimising functions is that however good the algorithm, very poor data will almost invariably produce a meaningless set of parameters with errors significantly larger than the parameters themselves.

WLS with DFP or Simplex algorithms

There are many examples of algorithms in the literature used for minimising a multiparameter function like those encountered in pharmacokinetics. The program PCModfit uses three algorithms. One of these is a modified Davidon-Fletcher-Powell (DFP) algorithm is one of several quasi-Newton or Variable-Metric methods that build up an approximation to the inverse of the second derivative, or Hessian, matrix. They are analytically complex and represent the culmination of years of research into the detailed analysis of functions. A brief summary of the DFP method is given here to help the reader to appreciate the elegance of the strategy devised by Davidon for solving functions by iterative methods. The three-dimensional surface can be projected into two dimensions as a contour diagram for a two-parameter function with a minimum sum of squares at M (the contours represent positions of equal sum of squares).



Assume that the starting estimates have p_1 and p_2 corresponding to a sum of squares value represented by point A. The first direction is along the line AB using a method devised by Powell, where a new sum of squares value is computed at point B. Along the line AB there is a minimum sum of squares in the valley at point C. Parameters at the starting point A are modified to generate a new sum of squares at B. Between these points the valley at C may be found by cubic interpolation.



The method used to find the local minimum at C, along the line AB, is the one suggested by Davidon, which utilises cubic polynomial interpolation. From the point C, a new search is established in the direction CD, where the final sum of squares at M can be found, again using cubic interpolation.

The extrapolation from A to B is often achieved using a simple linear method but this often causes numerical problems, especially for poorly defined data. A better method, which is used in PCModfit, is a quadratic extrapolation, which roughly approximates to the cubic used in the interpolation process and ensures that a reasonable sum of squares will be determined at B.

The pictorial method, above, may be translated into mathematical terms in a simpler form than that used by Fletcher and Powell, where Dirac Bra-ket notation was used (often seen in quantum mechanics).

The direction of search corresponding to AB, can be estimated in normalised form:

$$D_{i}^{k} = -\sum_{j=1}^{n} \left(H_{i,j} \left(\frac{\partial S}{\partial p_{j}} \right) \right) / \left[\sum_{L=1}^{n} \left(\sum_{j=1}^{n} H_{L,j} \left(\frac{\partial S}{\partial p_{j}} \right) \right) \right]^{1/2}$$
Eqn. 10

where k is the iteration number. The partial derivatives of the sum of squares function S with respect to the n parameters p_j . $H_{i,j}$ are the elements of a symmetric and positive matrix, initially chosen using the method of Powell.

Once the search direction has been established a line search is performed using quadratic extrapolation and subsequent cubic interpolation, to find the desired direction minimum sum of squares. For multiple parameter models' new directions of search and line minima are found.

The sum of squares and function gradients etc., are checked, to establish if a minimum has been reached. During the iteration procedure the Hessian matrix, used for parameter corrections, is updated by the method of Fletcher and Powell. The equations used in the algorithm are included for completeness. Briefly, the parameter corrections are made using equation 11.

$$p_{k+1} = p_k - c_k H_k g_k$$
, $H_{k+1} = H_k + A_k$ Eqn. 11

where H_k is an approximation to the inverse Hessian matrix, g_k is the gradient of S (sum of squares) at p_k . c_k is a chosen scalar and A_k is chosen to ensure that H_{k+1} satisfies the quasi-Newton equation:

 $H_{k+1}B_k=E_k \quad , \quad B_k=g_{k+1}-g_k \quad , \quad E_k=p_{k+1}-p_k \qquad \quad Eqn. \ 12$

The DFP update to the Hessian can be defined as:

$$H(new) = H + \frac{EE'}{E'B} - \frac{HBB'H}{B'HE}$$
 Eqn. 13

The formal proof of this algorithm is provided by Fletcher and Powell. It is very elegant but somewhat difficult to follow for anyone not conversant with such detailed mathematics. Users of PCModfit, fortunately, do not have to be concerned with the mathematics of the method.

It should be appreciated that any algorithm may fail under certain conditions. If reasonable parameter starting estimates are found, then any good algorithm should find a minimum sum of squares with however, varying degrees of efficiency. DFP has been tested extensively and when compared with other algorithms; notably the Marquardt, Newton and Gauss-Newton, it was found to be at least comparable. It has been tested on thousands of data sets by many users over years of use and no major problems have been encountered to date.

IRWLS with Marquardt or Simplex algorithms

The Iteratively Reweighted Nonlinear Least Squares (IRWLS) algorithm used in PCModfit is one by Marquardt or a Simplex approach and was incorporated into PCModfit to allow iterative reweighting to be used for nonlinear least squares regression analysis. Conventional weighted least squares (WLS) use the actual data for weighting schemes whereas IRWLS uses the predicted values calculated at each iteration. For the most part the results are similar and it is left to the user to decide which is preferable. It is quite permissible to try both and then choose the most appropriate one. The strategy for minimising functions using the Marquardt method is quite different from that used in DFP. At the time the Marquardt approach was devised, there was no way to directly evaluate the Hessian matrix, which is required for parameter corrections and for error calculations at the end of the fitting process. Therefore, iterative methods had to be used, not just because of function non-linearity but also to build up Hessian information from the starting unit matrix of steepest descent. A brief description of the Marquardt algorithm is given here to demonstrate to the reader the elegance of how it changes, very smoothly, between inverse Hessians and steepest descent approaches - very clever at the time! The following equations can be used to develop the strategy:

$$\beta_{i} \equiv -1/2 \frac{\partial S}{\partial p_{i}} \qquad \qquad \propto_{ij} \equiv 1/2 \frac{\partial^{2} S}{\partial p_{i} \partial p_{j}}$$

where p_n are model parameters and S is the sum of squares function. A set of linear equations can be set up:

$$\sum_{k=1}^{n} \propto_{ik} \delta p_k = \beta_k , i = 1, n$$

where the δp_k are increments of parameters p_k .

In practical terms, matrix α is equal to one half times the Hessian matrix and the steepest descent method translates to:

$\delta p_k \varpropto \beta_k$

Components of α_{ij} are dependent on both first and second derivatives of the object function (S). However, the second derivatives are often tiny and can sometimes destabilise the modelling process and it is common to use a first derivative approximation to the actual second derivative. Altering the correction vector to an approximate value does not affect the final estimates of parameters but only the iterative route that is taken in getting there; β_k should still be zero at the minimum. Marquardt's approach, in part, makes use of the steepest descent method by realising that

$$\delta p_{k} = \frac{1}{\lambda \alpha_{kk}} \beta_{k}$$

Where λ is a constant that may change during the iterations proceed. The next mathematical development was to generate a new matrix α ':

$$\alpha'_{jj} \equiv \alpha_{jj}(1+\lambda)$$

$$\alpha'_{jk} \equiv \alpha_{jk} \quad (j \neq k)$$

and finally:

$$\sum_{i=1}^m \alpha'_{ik} \, \partial p_i = \beta_k$$

Therefore, as λ becomes large, matrix α' is forced to diagonally dominate and tend to steepest descent and as λ becomes small, the inverse Hessian method is approached. Further details are available in Marquardt's original paper. The algorithm coded into PCModfit performs well; it is robust, fast and lends itself very easily to iteratively reweighted least squares. It has been tested on numerous data sets with no major problems to date.

Simplex

The Simplex algorithm, based on the one by Nelder-Mead, was added to PCModfit recently and has the option of WLS or IRWLS for modelling. It differs from the DFP and Marquardt methods in that, during the minimisation process only the model function is used without the need to calculate numerical derivatives. All three algorithms have their advantages and disadvantages and it is worth trying out all of these to assess the validity of the results from modelling.

As for the other algorithms, the theory can be complicated and for all three of these the reader is referred to the original publications. Very briefly, the Simplex approach can be explained (below).

The Nelder–Mead method (also downhill simplex method, amoeba method etc.) is a commonly used approach to find the minimum or maximum of an object function in a multidimensional space. It is a direct search method and is often applied to nonlinear optimisation problems. The Nelder–Mead technique is a heuristic search method that can converge to non-stationary points on problems that can sometimes be solved by alternative methods; but not always. The version coded into the Simplex in PCModfit contains an extra step which includes quadratic extrapolation and interpolation which can help with avoiding function local minima; but again, not in all cases.

In geometry, a simplex is a general term to describe of the notion of a triangle or tetrahedron to arbitrary dimensions. On the surface of a plot where parameters *vs.* a sum of squares (SOS) can be generated, the topology can be 'Himalayan' or 'Andes' in its appearance and the exercise to try and find the true global minimum for 'best fit' can sometimes be troublesome. The Nelder–Mead approach is to set up a triangle on the SOS surface and allow it to expand, contract and reflect itself and, at each point, recalculate the sum of squares function until a minimum value is achieved. Clever stuff! For a detailed description, please refer to the original publication (Nelder & Mead, The Computer Journal, January 1965).

Modelling data sets has proven quite challenging over history and even now, new numerical methods are being created or changed from earlier ones to try and achieve an efficient conclusion. However; if the data are garbage to start with, no algorithm will produce a valid set of results! The author personally finds that pragmatism and common-sense rules the day in the world of PK modelling.

Estimation of parameter errors

The estimation of parameter errors, for a given mathematical model, is important for quantifying the confidence of a given parameter. The calculation of standard errors is often considered a difficult procedure, especially for functions that contain both linear and non-linear parameters. This is mainly due to sparse or complicated explanations found in the literature. The following logical arguments may help the reader to appreciate some of the background to error estimation, utilising maximum likelihood theory.

For a normal distribution the familiar probability 'bell-shaped' curve is shown. It is clear that at the top of the curve there is a maximum value where the probability is highest, and this is often referred to as the maximum likelihood. The mathematical equation describing the curve is the normal density function, equation 1.

Pr (x_i) =
$$\frac{1}{\sqrt{(2\pi\sigma^2)}} e^{-(x_i - \mu)/2\sigma^2}$$
 Eqn. 1

where $Pr(x_i)$ is the probability of a given x_i - μ is the true centre of the distribution and σ^2 is the variance of the distribution. A Normal distribution probability curve described by the above equation is shown.



From the Pr equation the probability for a set of x_i's may be written as:

$$\Pr(x_1) \cdot \Pr(x_2) \dots \Pr(x_n) = \prod_{i=1}^n \left(\frac{1}{\sqrt{(2\pi\sigma^2)}} e^{-(x_i - \mu)/2\sigma^2}\right)$$
 Eqn. 2

taking logarithms,

$$\ln(\Pr) = \ln\left(\frac{1}{\sqrt{(2\pi\sigma^2)}}\right)^n - \sum_{i=1}^n \frac{(x_i - \mu)^2}{2\sigma^2}$$
 Eqn. 3

and rearranging,

$$-\ln(\Pr) = \frac{n}{2}\ln(2\pi\sigma^{2}) + \sum_{i=1}^{n} \frac{(x_{i} - \mu)^{2}}{2\sigma^{2}}$$
 Eqn. 4

The maximum likelihood probability may be found by the partial differentiation of equation 4 with respect to variables μ and σ^2 .

$$\frac{\partial(-\ln(\Pr))}{\partial\sigma^2} = \frac{n}{\sigma^2} - \frac{n}{2\sigma^4} \sum_{i=1}^n (x_i - \mu)^2$$
 Eqn. 5

For the maximum of a function, with a single turning point, the gradient equals zero therefore the partial derivative, equation 22, may be equated to zero and rearranged into equation 6

$$\sigma^2 = \frac{1}{n} \sum_{i=1}^n (\mathbf{x}_i - \boldsymbol{\mu})^2$$

Eqn. 6

Equation 6 is the common biased estimator for the variance of a normal distribution. Differentiating equation 4 with respect to parameter μ , yields equation 7, which may be solved for maximum likelihood by equating to zero,

$$\frac{\partial(-\ln(\Pr))}{\partial\mu} = -\frac{1}{\sigma^2} \sum_{i=1}^{n} (x_i - \mu) = 0 \qquad \text{Eqn. 7}$$

and rearranging,

$$\mu = \frac{1}{n} \sum_{i=1}^{n} (x_i) = \bar{x}$$
 Eqn. 8

Equation 8 may be recognised as the equation for the arithmetic mean \bar{x} for a set of x_i values. Equation 8 is a biased estimator of the variance. Transforming the true centre μ to the mean \bar{x} , thus reducing the degrees of freedom by one, an equation for the common unbiased variance can be formulated:

$$\sigma^{2} = \sum_{i=1}^{n} \frac{(x_{i} - \bar{x})^{2}}{n - 1}$$
 Eqn. 9

Differentiating equation 7 to yield the following equation can extend the theory further:

$$\frac{\partial^2(-\ln(\Pr))}{\partial\mu^2} = \frac{n}{\sigma^2}$$
 Eqn. 10

The inverse of this equation 10 can be combined with equation 9 to form an expression for the standard error of the mean (SEM).

SEM =
$$\sqrt{\sum_{i=1}^{n} ((x_i - \bar{x})^2 / n(n-1))}$$
 Eqn. 11

This approach can be used for the estimation of parameter errors, utilising the method of least squares, for the types of functions that are encountered in pharmacokinetics.

As a specific example, consider a mono-exponential model containing two parameters A and k. Assume that the 'best' values of A and k have been estimated for a set of data by an iterative procedure and that the parameter errors are required. For a mono-exponential model the sum of squares object function is:

$$S = \sum_{i=1}^{n} (C_i - Ae^{-kt_i})^2$$
 Eqn. 12

where S is the sum of squares and C_i the n concentration values at times t_i . Differentiating equation 12 with respect to A and k,

$$\frac{\partial S}{\partial A} = -2 \sum_{i=1}^{n} (C_i - A e^{-kt_i}) e^{-kt_i}$$
 Eqn. 13

$$\frac{\partial S}{\partial k} = 2 \sum_{i=1}^{n} (C_i - Ae^{-kt_i}) t_i Ae^{-kt_i}$$
 Eqn. 14

and differentiating equations 13 and 14 to form

$$\frac{\partial^2 S}{\partial A^2} = 2 \sum_{i=1}^{n} e^{-2kt_i}$$
Eqn. 15
$$\frac{\partial^2 S}{\partial k^2} = 2 \sum_{i=1}^{n} (2t_i^2 A^2 e^{-2kt_i} - C_i t_i^2 A e^{-kt_i})$$
Eqn. 16

and the cross-term

~

نے `` i=1

$$\frac{\partial^2 S}{\partial A \partial k} = 2 \sum_{i=1}^{n} (C_i t_i e^{-kt_i} - 2t_i A e^{-2kt_i})$$
 Eqn. 17

these second derivatives may be set up in matrix form:

$$\begin{pmatrix} \frac{\partial^2 S}{\partial A^2} & \frac{\partial^2 S}{\partial A \partial k} \\ \frac{\partial^2 S}{\partial A \partial k} & \frac{\partial^2 S}{\partial k^2} \end{pmatrix}$$
Eqn. 18

The inverse of this Hessian matrix provides the necessary information for the parameter errors to be calculated. For example, assume that the following matrix represents the inverse of equation 18:

 $\begin{pmatrix} a & b \\ c & d \end{pmatrix}$ Eqn. 19

The parameter errors (SE) can be calculated from the diagonal elements a and d thus:

SE of a =
$$\sqrt{\frac{a \times S}{(n-2)}}$$
 Eqn. 20

and

SE of d =
$$\sqrt{\frac{d \times S}{(n-2)}}$$
 Eqn. 21

where S is the residual sum of squares, n is the number of experimental points and (n-2) represents a loss of two degrees of freedom due to the number of parameters. A similar argument may be applied to more complex models containing many more parameters. The program PCModfit will allow models containing up to twenty parameters, but fortunately for the user, the errors are automatically calculated by the program, thus precluding the lengthy and almost impossible task of calculating them manually!

7 Appendix 2 (creating differential equations from models)

This short section has been added to help with setting up differential equations from proposed models that can be used in the simulation part of the program. Those users conversant with these types of techniques, may want to skip this Appendix.

Infusion

Consider an example of a 2-compartment intravenous infusion model, pictorially represented below.



The symbols indicate:

c1, c2	Compartment number
	(c1 is commonly assigned blood, c2 is highly perfused tissue)
p_1, p_2, p_3	Parameter
	(transfer rate of drug from one compartment to another. Traditionally, p ₁ , p ₂ and p ₃
	would be called k_{12} , k_{21} and k_{10})
\mathbf{k}_0	Infusion rate into compartment 1 (Rate = Dose / T, where T is infusion time)
Waste	Usually urine or other excreta

Practically, the model transfer rates are linked to the compartments simply to show the amounts of drug moving from one compartment to another e.g. c1 to c2 etc. – it is a dynamic process.

To setup a series of differential equations that can be used in PCModfit (and possibly other software) for solving such problems, consideration of the rate of change of drug amount with respect to time (dA_n/dt) comes into play. Without going into more complex mathematics e.g. Laplace transforms etc. the differential equations can be arrived at by the general simplified expression for each compartment:

 $\frac{dA_n}{dt} = Input rate - Output rate$

where A_n is the amount in compartment n, Input and Output are the rates of drug gain and loss into a particular compartment n. Consider the drug input and output for compartment 2 (c2) to start with:

Input $c^2 = A_1 \times p_1$ and $Output c^2 = -A_2 \times p_2$

Note that the input to c2 is coming from c1 (amount A_1) and the output (denoted by a minus to show loss of drug) from c2 (amount A_2) is going to c1. Combining these yields the differential equation for compartment 2.

$$\frac{\mathrm{dA}_2}{\mathrm{dt}} = \mathrm{A}_1 \times \mathrm{p}_1 - (\mathrm{A}_2 \times \mathrm{p}_2)$$

For compartment 1 (c1) the situation is slightly more complicated due to more inputs and outputs than for c2 but the same principle holds.

Input $c1 = k_0 + (A_2 \times p_2)$ and $Output c1 = -(A_1 \times p_1) - (A_1 \times p_3)$

Combining these yields the differential equation for compartment 1.

Compartment 1	Compartment 2
$\frac{dA_1}{dt} = k_0 + (A_2 \times p_2) - (A_1 \times p_1) - (A_1 \times p_3)$	$\frac{\mathrm{d}A_2}{\mathrm{d}t} = A_1 \times p_1 - (A_2 \times p_2)$

These would be the equations used by the Diff. Eqn. Simulator to solve this infusion model. PCModfit would actually use the equations as shown below (where cn is the amount in compartment n and pn is the appropriate parameter). After running the program, the amounts in compartments 1 and 2 are generated and if Volumes are supplied, then the output will be concentration values.

Eqn. 1	D/T-c1*p1-c1*p3+p2*c2	(Note addition of infusion rate, D/T in the equation)
Eqn. 2	(p1*c1-p2*c2)	(D is the dose and T is infusion time).

Amounts of drug at time zero have not been taken into account as all compartments will be zero at time zero. For other models such as oral and intravenous bolus, the dose at zero time will need to be taken into account. There are a few examples in the 'Diff. Eqn. Simulator (SD)' spreadsheet to help the user set up their own models for simulations.

8 Brief history updates

This short section has been added to help with Version updates should the user wish to see these.

Version 7.8 (1st September 2023)

The Non-Compartmental module (NCA) has been further updated in V7.8. There was a minor anomaly in earlier versions, which was noticed by a very astute user, in the NCA graphs (Dr Tony Jarman from Category 1 Pharma Consulting Pty Ltd Australia) wherein; the λ_z value was shown as a minus value when it should have been positive. None of the numerical results were affected but just the sign of λ_z values on the graphs! The numerical examples in all sections (including NCA) of the manual have been re-analysed using V7.8 and yield the correct results.

Version 7.7 (1st March 2023)

Compartmental modelling has been further updated. Using option 'Mixed models', profiles containing no i.v. models but oral models only (mixing with and without lag-time dosing) can now be analysed. This may be useful when for example, when oral doses are administered alternately, with and without a lag-time. There are example data sets on p. 105 and p. 108 to demonstrate that this option is working and yields the correct answer. As long as the number of compartments remain the same, this will work for 1, 2 and 3-compartment oral models. The λ_n values are also calculated as for the other possible Mixed models.

The subtitles for each profile can now contain spaces as previous versions sometimes got muddled with these. They have also been expanded to 30 characters/profile whereas previous versions only allowed for 20. All of the examples in the Modelling sections of the manual have been re-analysed using V7.7 and yield the correct results.

Version 7.6 (1st February 2023)

Compartmental modelling has been further upgraded. In the results summary Excel file, the lambda values (λ_1 , λ_2 and λ_3 for relevant compartmental models) are now calculated, being generated from the rate constants k_{12} , k_{21} etc., as this was requested by several users (example on p.102). This applies to Single, Repeat and Mixed model dosing. Further testing for all fitting options (Single, Repeat and Mixed) has been expedited and some minor bugs when clicking the 'Keywords' button have been corrected. A couple of users experienced an 'out of memory' message when the Modelling summary file was generated in V7.5. In the 'Fitting Options Selected' details, which was added as a helpful reminder for the settings used in a particular run, the size of picture was apparently the culprit. This has now been fixed by using a different and more efficient method. It has been tested on several computers with no further warning or error messages.

The Modelling Summary output file now has the file names of the pictures generated from a run which are detailed at the top of the Excel file at the request of several users. The same addition is also added to the NCA module as a complete record.

The 'Stats' spreadsheet for CI's etc. has been expanded to allow for up to 100 values (previous versions only allowed for 50).

Version 7.5 (1st December 2023)

PCModfit V7.5 with updates from previous versions is now released. A further update to modelling now has more information added to the Excel summary results file including the 'Fitting Options' choices used, and the cells where Doses, Parameters, Titles etc. are added as a complete record should the user wish to access these as a reminder. Also, after completion of a Fitting run (when the 'Next' button is clicked) the names of the Plot files are sent to the Summary file as well, for completeness. When these Doses and Parameters etc. are highlighted in the 'Modelling' spreadsheet and 'Activated', the parameter labels were previously erased (when 'User estimates' was selected) but now they are retained in the Sheet and sent to the Summary file, at the request of some users.

Version 7.4 (1st October 2022)

PCModfit V7.4 with updates from previous versions is now released (still runs on 32 or 64-bit PC computers). The NCA module has been upgraded so the user can now have up to 100 profiles with 1000 points in each (previously 100) as some users requested this update. There is now a red 'Cancel' button in the NCA

spreadsheet to stop a run at any point during analysis (also a request from a couple of users) which is useful if there are many profiles, and the user decides to abort the run for whatever the reason.

Modelling has been updated so that the Summary Excel file that now opens automatically after a completed run now specifies the parameter names instead of just numbers e.g., Parameters 1, 2, 3, 4 etc. becomes Parameters V_1 , k_{12} , k_{21} , k_{10} etc. In addition, the Summary file now contains individual profile data and the fitted data at the same time points with %Differences so users don't have to manipulate text files (this was often bothersome for some users). The fitted parameters and errors together with brief statistics, if more than one profile is analysed, are still displayed.

The summary file is often used as a tracking mechanism as it shows the date, time and records the fitting information (algorithm, weighting etc.) used for a particular run.

Version 7.3 (1st June 2022)

PCModfit V7.3 with updates from previous versions is now released (runs on 32 or 64-bit PC computers). The modelling option has been modified to allow models 1 to 6 (polyexponentials i.v. and oral) to be used in repeat dosing regimens as this was suggested by a few users. The models worked fine for single dose regimens but not coded for repeated doses with different doses and intervals. This option is now available and has been tested. If the user prefers the compartmental models (recommended) with micro-rates e.g., k_{12} , k_{21} etc. these models can still be used for single and repeat dose scenarios as before. In most of the spreadsheets there is now a facility (updated in V7.3) to calculate micro-rate values from λ values and vice-versa as these can be tricky to calculate with multiple compartments.

Version 7.2 (30th April 2022)

PCModfit V7.2 with updates from previous versions is now released (runs on 32 or 64-bit PC computers). The modelling module has been modified to show a progress bar after a fitting run is finished to let the user know how far the creation of the graphics in the spreadsheet and .png files has been completed. The fitting part is generally very fast but the data transfer from files into Excel can take a little while and is usually slower than the actual modelling. Useful to the user when numerous profiles are run within the same batch.

An intermittent runtime error was found for modelling data using model no. 2 (3-exponential oral). This is now fixed and updated in V7.2.

The Superposition module in V7.2 is now at least twice as fast when compared to previous versions and yields the same results as V7.1 (tested with several different regimens). This can be very useful for longer profile times with numerous doses. The increase in speed is primarily due to modifying Font changes in the spreadsheet.

Time above module has been modified to add a Profile reference to each result and Graph labels (axes, legends and title for completeness). The number of profiles maximum is 100 and each profile can now have up to 1000 data points (100 previously).

Version 7.1 (31st Mar 2022)

PCModfit V7.1, with minor updates from previous versions, is now released which runs on 32 or 64-bit computers. This can be downloaded from the website and includes an updated manual.

There is now a PCModfit Forum; web address <u>https://www.pcmodfit.co.uk/forum/index.php</u> and a link to it is also shown on the front page of the website; <u>https://www.pcmodfit.co.uk/</u>.

Version 7.0 (1st May 2021)

PCModfit V7.0 with major updates from previous versions is now released. When PCModfit is opened there is now a check to 'clean up' the numerous graphics and results files in the Results directory if desired (only if >100 is found). It is worth doing this regularly to save space and tidying up the Results directory to maintain a reasonable number of files.

The Non-Compartmental Analysis module (NCA) has been extensively modified to calculate CL, V_{ss} , V_d and MRT parameters in addition to the usual AUC values and $t\frac{1}{2}$ etc., with options for the user to define the concentration units, the dose and infusion time if relevant (the latter for calculation of MRT, CL etc.). The results are still shown in the NCA spreadsheet but now, they are also output to a detailed Excel file with descriptive stats. as well (timed and dated for a paper trail record) together with the points selected for $t\frac{1}{2}$ determination of each profile. At the end of a 'Run', the Excel file containing the results will be automatically saved (Results directory) and the user can open the file and inspect the values immediately. Pictures of the

NCA plots with points selected for $t\frac{1}{2}$ estimates are still stored in the Results directory as NCA*.png files which can be copied or imported in to Microsoft[®] Word etc.

The modelling option has been extensively updated (Sections 3.8 and 3.9. The setting up and the graphics (fitted line and data) are now all displayed in the '<u>Modelling</u>' Excel[®] spreadsheet. For setting up the 'Control' parameters, which was often a bit tricky, there is now a 'Keywords' button which helps with the required layout based on the Fitting Options selected in the spreadsheet (models, algorithm, weighting etc.). The graphics are of high quality (both linear and logarithmic plots are now on separate Charts within Excel[®]) and the number of points for the computed line can now be selected to ensure a representative line over extended time periods - useful for repeat dose fitting where the overall time can be quite long (up to 10000 points maximum).

There is additional help describing the models and parameters which are also shown in the spreadsheet (drop down boxes containing model numbers and what the models actually are and if user parameter starting estimates are required). The graphics files produced within Excel[®], are now stored as *.png and <u>not</u> *.wmf files to improve the whole appearance (Fitplotlin*.png for Linear and Fitplotlog*.png for Logarithmic Charts). Users can now analyse up to 1000 data points per profile and up to 100 profiles in a single run (should the user be so lucky!).

When modelling is completed, all of the graphs can be viewed within the spreadsheet to aid the user in deciding if it was acceptable or otherwise.

Mainly due to popular usage, the <u>Superposition</u> module (<u>Section 3.5</u>) has again been further updated by the author (now re-written in Fortran for speed) and also verified by two independent users in addition to many who have tested it for accuracy and validity. In addition to being able to vary the dosing interval, users can still change each dose across the entire regimen as well (thanks to suggestions by Angus McLean, Ph.D., in the USA and Dr med. Christian de Mey from ACPS in Germany).

There are still various plots of the Superposition results together with a selection for accuracy/time increments to dictate the number of points required for each run. Using the highest accuracy (0.001) which can take some time (transferring so many numbers into Excel[®]) although the Fortran module is much quicker for longer repeat dose regimens wherein; up to 100 doses can now be defined) there can be up to 1,000,000 points generated which is getting close to the number that Excel[®] can handle without messing around too much. The author recommends a value of either 0.1 or 0.01 which is a very good compromise.

Summary Superposition plots and values for parameters such as C_{min} , C_{max} and AUC are still output for each dose. There is also a Summary table within the spreadsheet indicating the accumulation values by comparing parameters from Dose 1 to the last Dose for a quick assessment. In addition (new to V7.0) the user can now manually override the estimated t¹/₂ value when required (sometimes useful for very sparse data but when the t¹/₂ is known) and can now add their own data points to the repeat dose plots very easily, if required, which is particularly good for showing pre-dose values at later time points within a repeat dosing regimen.

The '<u>Time above</u>' a MIC has been extensively modified with more precision and parameters. There is now an option for different time values (often useful in Phase II studies) for each profile, whereas previous versions only allowed the same sampling times for all data sets. This version now allows up to 100 data points per profile and up to 100 data sets to be analysed in a single run. The graphics have also been improved with an increase in speed and visual appearance with all data lines now having the same thickness.

Version 6.9 (1st Oct 2020)

PCModfit V6.9 onwards will check the internet automatically to see if there is a newer version available each time it is executed (notified to the user). The Website now uses a Secure Socket Layer URL for security assurance.

The Superposition module has been extensively updated and now verified by two independent users in addition to many who have tested it out for ease of use and sense. In addition to being able to vary the dosing interval, users can now change each dose across the entire Superposition regimen as well (thanks to suggestions by Angus McLean, Ph.D., in the USA and Dr med. Christian de Mey from ACPS in Germany). There are several further additions including various plots of the results together with selection of accuracy to dictate the number

of points required for each run. Using the highest accuracy, which can take some time, there can be up to 800,000 points generated which is getting close to the number that Excel[®] can handle.

The author recommends a value of 0.01 which is a very good compromise. Summary plots and values for parameters such as C_{min} , C_{max} and AUC are output for each dose, which may be useful for simple and complex regimens.

Version 6.8 (1st Dec 2019)

SD and RD simulations graphic display and legends have been tidied up. The SD and RD simulators will now allow user defined time values to be added in addition to the normal output (sometimes useful for modelling and for Tabular results for showing specific Conc-Time values).

A 3-compartment model (oral) was added for SD and RD simulations in V6.7 and is now available for modelling in V6.8, should the data be adequate, and shows a specific example in the manual (note that user parameter starting estimates are required). The model numbers are 42 and 43, with and without lag-time, respectively).

NCA intercept value is now displayed on the graph, in the Spreadsheet and txt results file. Useful for C_0 values with bolus i.v. data and in other calculations.

Manual updated for all additions/modifications and an extra section for NCA with examples explaining how zero time points are dealt with for AUC calculations.

Version 6.7 (21st June 2019)

PCModfit now has an option for conducting Superposition repeat dose profiles (Section 3.4) with varying dosing intervals (thanks to a suggestion by Angus McLean in the USA) and with more precision.

Also, slightly revamped, repeated dose simulations can be conducted with user defined Differential Equations allowing varying doses, intervals, and models in any sequence.

The Loo-Riegelman Deconvolution module has been rewritten with more accuracy throughout, using Wagner's exact equations (J. Pharm. Sci. 72, 7, July 1983) and has test profiles to show their validity (1, 2 and 3 compartment models) detailed in Section 3.5.

A three-compartment oral model has been added, by request, for single and repeat dose simulations. This has been checked against the Differential equation module and the results are identical. Check boxes have been added to NCA and Deconvolution to make selections quicker and easier (not having to enter an asterisk character).

There is now a 'Models' button on the Modelling sheet as a quick aide-memoir for available model numbers.

Version 6.6 (1st March 2019)

Repeated dose simulations can now be conducted with user defined Differential Equations with varying doses, intervals, and models. This is a new addition and seems pretty fast with the testing done so far. The spreadsheet has lots of help for the user with an additional section in the V6.6 manual (Section 3.3.2) with a detailed and specific example to demonstrate its use and how to set it up.

Version 6.5 (19th January 2019)

This version will allow single dose simulations using differential equations (user defined) and will be enhanced in future versions. A Simplex algorithm has now been added to help with data modelling as an additional option to DFP and Marquardt.

9 A few words about the author

The author of PCModfit (Graham Allen) since leaving 'Big Pharma' many years ago, has been a successful freelance Consultant in Pharmacokinetics for >30 years and has published in numerous Journals with *ca*. 50 papers to date. He initially graduated with the Royal Society of Chemistry and much later in Mathematics which he found very useful for sorting out some of the problems in PK. The original publication of Modfit, as it was then called back in 1990, has undergone countless updates and additions with most of the routines being completely re-written for correctness and versatility with its current name of **PCModfit**. There are currently >7000 users of the program and it has been referenced in over 100 publications in the literature and in countless drug submissions to regulatory bodies world-wide. The author hopes that it helps users in their study, work and/or research for furthering drug development and an understanding of the sometimes-complex field of Pharmacokinetics. The author is a Fellow of the Royal Society of Medicine (London, UK) which allows him to access thousands of books and Journals on-line to keep up with modern trends.

10 Brief list of publications referencing PCModfit

Although there are >100 publications referencing PCModfit, just for information, some of these are listed below (*ca*. 63).

1. Pharmacokinetics of N,N-dimethyltryptamine in Humans

Meghan Good, Zelah Joel, Tiffanie Benway, Carol Routledge, Chris Timmermann, David Erritzoe, Richard Weaver, Graham Allen, Charlotte Hughes, Helen Topping, Amy Bowman & Ellen James European Journal of Drug Metabolism and Pharmacokinetics, 48, 311-327 (Issue 3, May 2023).

2. Development of stabilized fuzapladib solution for injection: forced degradation study and pharmacokinetic evaluation Hideyuki Sato, Chika Yamane, Koji Higuchi, Takeshi Shindo, Hiroshi Shikama, Kohei Yamada, Satomi Onoue. Pharmaceutical Development and Technology, 09 Jun 2022

3. Neuropsychopharmacological profiling of scoparone in mice Joanna Kowalczyk, Barbara Budzynska, Lukasz Kurach, Daniele Pellegata, Nesrine S. El Sayed, Jurg Gertsch and Krystyna Skalicka-Wozniak Nature: Scientific Reports volume 12, Article number: 822 (2022)

4. Pharmacokinetics and milk extraction pattern of eprinomectin at different dose rates in dairy cattle Mariana Ballent, Candela Canton, Paula Dominguez, Laura Mate, Laura Ceballos, Carlos Lanusse, Adrian Lifschitz Veterinary Pharmacology and Therapeutics, Sept. 2021, 45, 92-98.

5. Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph-Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice Francesca Ferlenghi, Carmine Giorgio, Matteo Incerti, Lorenzo Guidetti, Paola Chiodelli, Marco Rusnati, Massimiliano Tognolini, Federica Vacondio, Marco Mor, Alessio Lodola Pharmaceuticals 2022, 15(1), 41

6. Stem-cell mobilization of healthy sibling donors with pegfilgrastim-A prospective open-label phase II trial (EudraCT no: 2005-004971-39)

Vladan Vucinic, Madlen Jentzsch, Sabine Leiblein, Enrica Bach, Yvonne Remane, Kai Schulze-Forster, Michael Cross, Wolfram Ponisch, Sebastian Schwind, Georg-Nikolaus Franke, Uwe Platzbecker, Dietger Niederwieser Transfusion. Dec. 2021, 1-8

7. Successive treatments with ivermectin (3.15%) to control the tick Rhipicephalus (Boophilus) microplus in cattle: Pharmacokinetic and efficacy assessment

Macarena Sarli, Maria Victoria Miro, Maria Victoria Rossner, Santiago Nava, Adrian Lifschitz Ticks and Tick-borne Diseases, Volume 13, Issue 1, January 2022, 101848

8. Pharmacokinetics of Meropenem in Critically Ill Patients with Acute Renal Failure Treated by Continuous Hemodiafiltration

W. A. Krueger, T. H. Schroeder, M. Hutchison, E. Hoffmann, H.-J. Dieterich, A. Heininger, C. Erley, A. Wehrle, K. Unertl

Antimicrobial Agents and Chemotherapy, Vol. 42, No. 9, Research Article, 17 December 2020

9. A Pharmacokinetic Study of Native E-coli Asparaginase for Acute Lymphoblastic Leukemia Treated with ThaiPOG Protocol

Phumin Chaweephisal, Trai Tharnpanich, Aphinya Suroengrit, Pattramon Aungbamnet, Panya Seksarn, Darintr Sosothikul, Supanun Lauhasurayotin, Kanhatai Chiengthong, Hansamon Poparn, Piti Techavichit Asian Pac J Cancer Prev. 22 (10), 3309-3315, Oct. 22, 2021

10. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer Hemant M. Kocher, Bristi Basu, Fieke E. M. Froeling, Debashis Sarker, Sarah Slater, Dominic Carlin, Nandita M. deSouza, Katja N. De Paepe, Michelle R. Goulart, Christine Hughes, Ahmet Imrali, Rhiannon Roberts, Maria Pawula, Richard Houghton, Cheryl Lawrence, Yathushan Yogeswaran, Kelly Mousa, Carike Coetzee, Peter Sasieni, Aaron Prendergast & David J. Propper

Nature Communications volume 11, Article number: 4841 (2020)

11. SARS-CoV-2 Neutralization in Commercial Lots of Plasma-derived Immunoglobulin Volk Andreas, Covini-Souris Caroline, Kuehnel Denis, De Mey Christian, Römisch Jürgen, Schmidt Torben COVID-19 SARS-CoV-2 preprint from bioRxiv, Aug. 13, 2021.

12. Self-emulsifying drug delivery system of (R)-alpha-lipoic acid to improve its stability and oral absorption Sujan Banik, Shimul Halder, Hideyuki Sato, Satomi Onoue Biopharmaceutics and Drug Disposition, Vol. 42, Issue 5, May 2021, p. 226-233.

The GABA(B) receptor positive allosteric modulator COR659: in vitro metabolism, in vivo pharmacokinetics in rats, synthesis and pharmacological characterization of metabolically protected derivatives.
 Francesca Ferlenghi, Paola Maccioni, Claudia Mugnaini, Antonella Brizzi, Federica Fara, Rafaela Mostallino, Maria Paola Castelli, Giancarlo Colombo, Marco Mor, Federica Vacondio, Federico Corelli.
 European J. of Pharm. Sci., Vol. 155, 1 Dec. 2020, 105544.

14. Effect of e-cigarette flavors on nicotine delivery and puffing topography: results from a randomized clinical trial of daily smokers.

Voos N, Smith D, Kaiser L, Mahoney MC, Bradizza CM, Kozlowski LT, Benowitz NL, O'Connor RJ, Goniewicz ML. Psychopharmacology (Berl). 2020 Feb;237(2):491-502. doi: 10.1007/s00213-019-05386-x. Epub 2019 Nov 26.

15. Taylor D.L. et al. (2019) Harnessing Human Microphysiology Systems as Key Experimental Models for Quantitative Systems Pharmacology. In: Barrett J., Page C., Michel M. (eds) Concepts and Principles of Pharmacology. Handbook of Experimental Pharmacology, Vol 260. Springer, Cham.

16. Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action. Chen Wang, Shuihong Cheng, Yuanyuan Zhang, Yibo Ding, Huihui Chong, Hui Xing, Shibo Jiang, Xuebing Li, and Liying Ma. Viruses, v.11(9); 2019 Sep, PMC6784077

17. Randomized within-subject trial to evaluate smokers initial perceptions, subjective effects and nicotine delivery across six vaporized nicotine products

Natalie Voos, Lisa Kaiser, Martin C. Mahoney, Clara M. Bradizza, Lynn T. Kozlowski, Neal L. Benowitz, Richard J. O'Connor, Maciej L. Goniewicz.

Addiction, 9-Mar-2019, Research Report, Society for the study of Addiction.

18. Safety and Pharmacokinetics of Multiple Doses of Aclidinium Bromide, a Novel Long-Acting Muscarinic Antagonist for the Treatment of Chronic Obstructive Pulmonary Disease, in Healthy Participants Journal of Clin. Pharm., Vol. 49, Issue 10, 2009, 1239-1246. Josep M. Jansat PhD, Dr Rosa Lamarca PhD, Dr Gonzalo de Miquel MD, Dr Andreas Schrodter MD, PhD, Dr Barbara Miletzki MD, Mr Matthias Gurniak MSc

19. Aluminium toxicokinetics after intramuscular, subcutaneous, and intravenous injection of Al citrate solution in rats. Weisser, K., Goen, T., Oduro, J.D. et al, Arch Toxicol. pp. 1-11 (2018)

20. A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life Shan Su, Giselle Rasquinha, Lanying Du, Qian Wang, Wei Xu, Weihua Li, Lu Lu and Shibo Jiang. Molecules 2019, 24, 1134 (13 pages). 21. Imperatorin exhibits anticancer activities in human colon cancer cells via the caspase cascade Yi Mei Zheng, Amy Xiaoxu Lu, James Zheng Shen, Amy Ho Yan Kwok, Wing Shing Ho Oncology Reports, Jan. 21st 2016, pp 1995-2002.

22. Nicotine Intake from Electronic Cigarettes on Initial Use and After 4 Weeks of Regular Use Peter Hajek, PhD Maciej L. Goniewicz, PharmD, PhD Anna Phillips, MSc Katie Myers Smith, PhD Oliver West, MSc Hayden McRobbie, PhD Nicotine Tob Res (2015) 17 (2): 175-179.

23. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate.
Philippe J Bareille; A. Allen; V.M Rousell
GlaxoSmithKline.
MedLine Citation: PMID: 23184737
Clinical pharmacokinetics, Volume: 52,2013 Jan, Clin Pharmacokinet.

24. Anti-oxidant and anti-cancer activities of Angelica dahurica extract via induction of apoptosis in colon cancer cells YiMeiZhenga, James Zheng Shenb, Yan Wangb, Amy Xiaoxu Lub, Wing Shing Ho Phytomedicine: international journal of phytotherapy and phytopharmacology 23(11) Dec.2015.

25. The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function D. Cockshott, E. A. Sotaniemi, K. J. Cooper and D. C. Jones, Zeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire and Department of Internal Medicine, University of Oulu, Oulu, Finland Br J Clin. Pharmacol. 1993; 36: 339-343

26. Lack of Pharmacologic Interaction Between Paroxetine and Alprazolam at Steady State in Healthy Volunteers Calvo, Gonzalo MD, PhD; Garcia-Gea, Consuelo BSc; Luque, Antonio MD; Morte, Adelaida MD; Dal-Re, Rafael MD, PhD; Barbanoj, Manel MD, PhD Journal of Clinical Psychopharmacology: June 2004 - Volume 24 - Issue 3 - pp 268-276

27. A pharmacoscintigraphic study of three time-delayed capsule formulations in healthy male volunteers McConville JT1, Hodges LA, Jones T, Band JP, O'Mahony B, Lindsay B, Ross AC, Florence, AJ, Stanley AJ, Humphrey MJ, Wilson CG, Stevens HN. J Pharm Sci. 2009 Nov;98(11):4251-63. doi: 10.1002/jps.21739.

28. Pharmacological characteristics and side effects of a new galenic formulation of propofol without soyabean oil M. Paul, M. Dueck, S. Kampe, H. Fruendt, S. M. Kasper First published: 20 October 2003 Full publication history, DOI: 10.1046/j.1365-2044.2003.03345

29. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation:C. Monchaud, P. Marquet.Part I. Clin. Pharmaco., Springer Verlag, 2009, 48 (7), pp.419-62.

30. Inflammation-Mediated Abrogation of Androgen Signaling: An In Vitro Model of Prostate Cell Inflammation Bilge Debelec-Butuner, Cansu Alapinar, Lokman Varisli, Burcu Erbaykent-Tepedelen, Syed Muhammad Hamid, Ceren Gonen-Korkmaz and Kemal Sami Korkmaz Molecular Carcinogenesis 53:85-97 (2014)

31. Single-Dose, Randomized, Crossover Bioequivalence Study of Amlodipine Maleate versus Amlodipine Besylate in Healthy Volunteers
Fiorenzo Mignini, Daniele Tomassoni, Enea Traini & Francesco Amenta
Pages 539-552 | Received 14 May 2007, Accepted 26 Jun 2007, Published online: 03 Jul 2009
Download citation http://dx.doi.org/10.1080/10641960701744046

32. The GPVI Fc Fusion Protein Revacept Reduces Thrombus Formation and Improves Vascular Dysfunction in Atherosclerosis without Any Impact on Bleeding Times
Martin Ungerer, Zhongmin Li, Christine Baumgartner, Silvia Goebel, Jasmin Vogelmann, Hans-Peter Holthoff, Meinrad Gawaz, Gotz Munch
Published: August 12, 2013
http://dx.doi.org/10.1371/journal.pone.0071193 33. Effects of Recombinant Human Insulin-Like Growth Factor I (IGF-I) Therapy on the Growth Hormone-IGF System of a Patient with a Partial IGF-I Gene Deletion
Cecilia Camacho-Hubner Katie A. Woods Farideh Miraki-Moud Peter C. Hindmarsh Adrian J. Clark Yngve Hansson Atholl Johnston Robert C. Baxter Martin O. Savage
The Journal of Clinical Endocrin. & Metab. Vol. 84, No. 5 1611-1616 (1999) 84 (5): 1611-1616.

34. A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment after First and Repeated Application to Children with Atopic Dermatitis
John Harper, Catherine Smith, Andris Rubins, Adrian Green, Karina Jackson, Sanita Zigure,
John Bourke, Augusti Alomar, Paul Stevenson, Claire Foster, and Nasrullah Undre
Great Ormond Street Hospital for Children, London, UK;
Skin Therapy Research Unit, University Hospital Lewisham and Kings College London, London, UK; Medical Academy of Latvia, Riga, Latvia; South Infirmary Victoria Hospital, Cork, Ireland;
Hospital de la Santa Creu i Sant Peu, Barcelona, Spain;Fujisawa GmbH, Munich, Germany
J Invest Dermatol 124:695-699, 2005

35. Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of One US-Marketed and Two European-Marketed Epoetin Alfas: A Randomized Prospective Study
Michael Lissy, Marite Ode, and Karsten Roth
Drugs R D. 2011 Mar; 11(1),61-75.
Published online 2012 Nov 27. doi: 10.2165/11588270-00000000-00000
PMCID: PMC3586119

36. Polyinosinic Acid and Polycationic Liposomes Attenuate the Hepatic Clearance of Circulating Plasmid DNA Rodney F. Minchin, Denise Carpenter and Rebecca J. Orr Journal of Pharmacology and Experimental Therapeutics March 2001, 296 (3) 1006-1012;

37. Absorption, Distribution, Metabolism and Excretion of 2,3-Dimethyl-2,3-Dinitrobutane.
John. Jenner, Christopher. H. Dalton, Haley. Bird and Stuart. G. Wood.
Biomedical Sciences Department, Dstl, Porton Down, Salisbury. SP4 0JQ, UK
Biodynamics Ltd, Pegasus Way, Rushden, Northants. NN10 6ER, UK, (C) Crown 2004

38. The pharmacokinetics, metabolism and urinary detection time of tramadol in camels M. Elghazali, I.M. Barezaik, A.A. Abdel Hadi, F.M. Eltayeb, J. Al Masri, I.A. Wase The Veterinary Journal 178 (2008) 272-27

39. Pharmacokinetic, metabolism and withdrawal time of orphenadrine in camels (Camelus dromedarius) after intravenous administrationM. ElghazaliThe Veterinary Journal Oct (2016)

40. Absorption, metabolism and excretion studies on clavulanic acid in the rat and dog. Allen G.D., Bolton G.C., Filer C.W. and Jeffery D.J. Xenobiotica, Vol. 14, No. 6, 483-490, 1984.

41. The disposition of clavulanic acid in man. Allen G.D., Bolton G.C., Davies B.E., Filer C.W. and Jeffery D.J. Xenobiotica, Vol. 16, No. 9, 853-863, 1986.

42. On the absorption of clavulanic acid. Allen G.D., Coates P.E. and Davies B.E. Biopharmaceutics and Drug Disposition, Vol. 9, 127-136, 1988.

43. Absorption, metabolism and excretion of C14 denbufylline in man after i.v. and oral administration. Allen G.D., Koester F.E., Langley P.F. and Palm M. British Journal of Clinical Pharmacology, 33, 236, 1992.

44. Investigation of the single and repeat dose oral pharmacokinetics of denbufylline in healthy young and elderly subjects.

Allen G.D., Brett M.A., Gulati R., Hoetzel L., Hollis F.J., Pfeiffer P. and Thawley A.R. British Journal of Clinical Pharmacology, 33, 235, 1992

45. Metabolic and PK studies following oral administration of C14 famciclovir to healthy subjects. Allen G.D., Brown T.A., Filer C.W., Fowles S.E., Mort E., Prince W.T. and Ramji J.V. Xenobiotica, 24(4), 357-368, 1994.

46. Disposition of famciclovir in healthy volunteers.

Filer C.W., Allen G.D., Mort E., Fowles S.E. and Ramji J.V.

6th International congress for infectious diseases, Prague, March, 1994.

47. Quantitative HPLC-MS-MS in support of a pharmacokinetic study involving simultaneous constant rate and accelerated infusions via the intravenous and intraportal routes.
Allen G.D., Griffiths R., Abbott R.W., Bartlett S., Brown T., Lewis V.A., Nash M. and Rontree J. GlaxoSmithKline.
Proceedings of 13th International MS Conference, Budapest, September, 1994.
International Biomedical Symposium, Life Sciences, California, Sept. 1994

48. Phase I double blind, placebo controlled, ascending single intravenous dose study with a synthetic direct thrombin inhibitor, TGN255.

Combe S, Allen G.D. and Kennedy T.

The 18th International Congress on Thrombosis (ICT), June 20-24, 2004, Ljubljana, Slovenia.

49. A Phase I double blind 24-hour i.v. infusion study with TGN255, a direct thrombin inhibitor. Combe S, Allen G.D. and Kennedy T., ASN (27 Sept.-1 Oct. 2004) Washington DC, USA.

50. Pharmacokinetics of TGN 255, a Novel Intravenous Low Molecular Weight Direct Thrombin Inhibitor, In Healthy Volunteers

Allen G.D., Combe S, Dupe R.and Kennedy T.

Poster P1714 at the XXth Congress of the International Society of Thrombosis and Haemostasis (ISTH), 6-12 August 2005, Sydney, Australia.

51. Comparative Pharmacodynamics of TGN 255, a Novel Direct Thrombin Inhibitor and Unfractionated Heparin in Healthy Volunteers

Combe S, Dupe R, Allen G. and Kennedy T.

Poster 1864 at the 47th Annual Meeting of the American Society of Hematology, 2-6 December 2005, Atlanta, Georgia, USA.

52. A Phase I Double-Blind, Ascending Dose Study of an Oral Synthetic Direct Thrombin Inhibitor, TGN167. Combe S, Kennedy T, Allen G Blood (ASH Annual Meeting Abstracts) 2005 106: Abstract 1863

53. A Phase I Interaction Study between TGN 255, a Direct Thrombin Inhibitor, and Aspirin plus Clopidogrel Combe S, Kennedy T, Allen G Poster Presentation at the World Congress of Cardiology, 2-6 September 2006, Barcelona, Spain.

54. Pharmacokinetics of F901318 in man from an Intravenous Single Ascending Dose Study. T. Kennedy, J. Steiner, G.D. Allen, J. Oliver, M. Birch, G. Sibley, D. Law Interscience Conf. Antimicrob. Agents and Chem. ICAAC 17-21 Sept. 2015. San Diego, California.

55. The relationship between paroxetine and the sparteine oxidation polymorphism. Sindrup SH, Brosen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TC, et al. Clin Pharmacol Ther. 1992 Mar;51(3):278-87.

56. A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment after First and Repeated Application to Children with Atopic Dermatitis Undre N et al

Journal of Investigative Dermatology (2005) 124, 695-699

57. Influence of albumin supplementation on tacrolimus and cyclosporine therapy early after liver transplantation Andrew Trull, PhD, Victoria Hughes, Dawn Cooper, Matthew Wilkins, Alexander Gimson, Peter Friend, Atholl Johnston, Linda Sharples, Gilbert Park Liver Transplantation Volume 8, Issue 3, Pages 224-232, Published Online: 30 Dec 2003 Copyright (C) 2002 by the American Association for the Study of Liver Diseases

58. Pharmacokinetics of S- and R-Enantiomers of Aminoglutethimide following Oral Administration of Racemic Drug in Breast Cancer Patients
Dr. Ibrahim A. Alshowaier PhD, Dr. Adnan El-Yazigi PhD, FCP, Dr. Adnan Ezzat MD, Dr. Ahmad Abd El-Warith MD, Dr. IP. J. Nicholls PhD
Pharmacokinetics Laboratory, Department of Biological and Medical Research, MBC-03, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia
J. Clin. Pharmacol. November 1999

59. Patent: Prodrugs of Substituted 1,3-Dioxanes and Their Uses, US 20150158838 A1

60. Patent: Thrombin inhibitor, CA 2691243 A1

61. Prediction of Plerixafor Pharmacokinetics in Mice Using PCModfit Software Sihana AHMETI LIKA Dorentina BEXHETI, Edita Alili IDRIZI 2018, 3rd International Scientific Conference of the Medical Sciences - University of Tetova

62. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I Caroline Monchaud and Pierre Marquet Clin Pharmacokinet. 2009; 48(7): 419-462.

63. IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies

Wenwen Bi, Wei Xu, Liang Cheng, Jing Xue, Qian Wang, Fei Yu, Shuai Xia, Qi Wang, Guangming Li, Chuan Qin, Lu Lu , Lishan Su , Shibo Jiang

2019 (5 Dec.) Research Article, PLOS Pathogens 15 (12) e1008082.https://doi.org/ 10.1371/journal.ppat.1008082

11 Symbols used throughout document

As an aide memoire for most of the acronyms used in the PCModfit manual, the following Table will hopefully be a useful guide.

Symbol	Interpretation
AUC	Area under the concentration-time curve
AUC _{t1-t2}	Area under the concentration-time curve from time t1 to t2 (commonly 0 to t, t_{last} or ∞)
AUMC _{t1-t2}	Area under the concentration x time vs. time 'moment' curve (commonly 0 to t, t_{last} or ∞)
Ci	Actual concentration at the i th data point (sometimes C _n)
\hat{C}_i	Predicted concentration at the i th data point (sometimes \hat{C}_n for the last point)
CL	Clearance (normally, Dose/ AUC _{0-∞})
C _{max}	Observed maximum concentration
D	Dose
F	Fraction of drug absorbed (normally ≤ 1)
IRWLS	Iteratively re-weighted least squares (the weighting factor at each time point changes throughout the minimisation process to try and eliminate bias)
k ₀	Infusion rate (normally, Dose/T where T is the infusion time)
ka	Absorption rate (conventionally from gut to liver/blood)
k _{i,j}	Transfer rate from compartment i to j in multi-compartment models (often used to estimate $k_{i,j}$ values)
LR	Loo-Riegelman deconvolution
MRT	Mean residence time (from moment analysis, <i>ca</i> . 62.4% of a process to complete). Defined as AUMC _{0-∞} /AUC _{0-∞} (- T/2 for infusions)
p_i	i th parameter
S (SS or SOS)	Sum of squares (used in modelling etc., see Modelling chapter)
SS	Steady state (an equilibrium situation, often used in repeat dosing regimens)
Т	Infusion time
t½	Conventionally, half-life (time for 50% of a process to complete)
t _i	Time at the i th data point
t _{max}	Time of observed maximum concentration (C _{max})
V	Volume of distribution e.g., V_1 or V_2 are normally volumes of compartments 1 and 2
WLS	Weighted least squares (weighting factor fixed, commonly defined as unweighted, $1/C$ or $1/C^2$)
λ_n	Conventionally, the nth elimination rate constant e.g. λ_z is the final rate often used for t ¹ / ₂ estimation. For modelling a 2-compartment i.v. model, as another example, it would often represent λ_1 and λ_2 as the 'fast' and 'slow' elimination rates of decline, respectively.